<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006624.pub2" GROUP_ID="SCHIZ" ID="208306090713073791" MERGED_FROM="" MODIFIED="2013-01-15 17:46:19 +0000" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;/p&gt;&lt;p&gt;Old title: Amisulpride versus other atypical antipsychotics for schizophrenia&lt;/p&gt;" NOTES_MODIFIED="2013-01-15 17:38:22 +0000" NOTES_MODIFIED_BY="Claire Irving" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.1 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2013-01-15 17:33:34 +0000" MODIFIED_BY="Claire Irving">
<TITLE>Amisulpride versus other atypical antipsychotics for schizophrenia</TITLE>
<CONTACT>
<PERSON ID="87F1AFC682E26AA20078D4E6A8FF088C" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Katja</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Komossa</LAST_NAME>
<SUFFIX/>
<POSITION>4th Year Resident (Dr. Med)</POSITION>
<EMAIL_1>k.komossa@lrz.tu-muenchen.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Klinik und Poliklinik für Psychosomatische und Medizin und Psychotherapie</DEPARTMENT>
<ORGANISATION>Technische Universität München, Klinikum rechts der Isar</ORGANISATION>
<ADDRESS_1>Moehlstrasse 26</ADDRESS_1>
<ADDRESS_2/>
<CITY>München</CITY>
<ZIP>81675</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>0049 (0) 89 4141/4247</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-01-15 17:32:58 +0000" MODIFIED_BY="Claire Irving">
<PERSON ID="87F1AFC682E26AA20078D4E6A8FF088C" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Katja</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Komossa</LAST_NAME>
<SUFFIX/>
<POSITION>4th Year Resident (Dr. Med)</POSITION>
<EMAIL_1>k.komossa@lrz.tu-muenchen.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Klinik und Poliklinik für Psychosomatische und Medizin und Psychotherapie</DEPARTMENT>
<ORGANISATION>Technische Universität München, Klinikum rechts der Isar</ORGANISATION>
<ADDRESS_1>Moehlstrasse 26</ADDRESS_1>
<ADDRESS_2/>
<CITY>München</CITY>
<ZIP>81675</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>0049 (0) 89 4141/4247</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11852B3682E26AA201DC7B3E1C938991" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Christine</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rummel-Kluge</LAST_NAME>
<SUFFIX/>
<POSITION>Fachärztin für Psychiatrie und Psychotherapie</POSITION>
<EMAIL_1>Christine.rummel-kluge@medizin.uni-leipzig.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Leipzig</DEPARTMENT>
<ORGANISATION/>
<ADDRESS_1>Semmelweisstr. 10</ADDRESS_1>
<ADDRESS_2/>
<CITY>04103 Leipzig</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49-34-1972-4493</PHONE_1>
<PHONE_2/>
<FAX_1>+49-34-1972-4599</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="2E84257C82E26AA201BA4B54250245B7" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Heike</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hunger</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>mailtoHeike@gmx.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT>
<ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION>
<ADDRESS_1>Möhlstr. 26</ADDRESS_1>
<ADDRESS_2/>
<CITY>München</CITY>
<ZIP>81675</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+498 941 404247</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="D99E43AC82E26AA201BA4B549DE5F4E8" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Franziska</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Schmid</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>supra.renin@web.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT>
<ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION>
<ADDRESS_1>Möhlstr. 26</ADDRESS_1>
<ADDRESS_2/>
<CITY>München</CITY>
<ZIP>81675</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>0049/89/4140/4247</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="90591E5482E26AA201AA8B42BEBB7D04" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sandra</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Schwarz</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>sandra.schwarz@khsweb.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT>
<ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION>
<ADDRESS_1>Möhlstr. 26</ADDRESS_1>
<ADDRESS_2/>
<CITY>München</CITY>
<ZIP>81675</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>0049/89/4140/4247</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="0DC6779782E26AA201CB12789C7D8B5E" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Joaquim</FIRST_NAME>
<MIDDLE_INITIALS>I</MIDDLE_INITIALS>
<LAST_NAME>Silveira da Mota Neto</LAST_NAME>
<SUFFIX/>
<POSITION>Research Worker</POSITION>
<EMAIL_1>motaneto@ufpel.tche.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Evidence Based Medicine Centre</DEPARTMENT>
<ORGANISATION>Universidade Federal de Pelotas</ORGANISATION>
<ADDRESS_1>Avenida Duque de Caxias, 250</ADDRESS_1>
<ADDRESS_2/>
<CITY>Pelotas</CITY>
<ZIP>96100</ZIP>
<REGION/>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 532 222018</PHONE_1>
<PHONE_2>+55 532 259690</PHONE_2>
<FAX_1>+55 532 213554</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11850D1F82E26AA201DC7B3E2041CA58" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Werner</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Kissling</LAST_NAME>
<SUFFIX/>
<POSITION>Leitender Oberarzt</POSITION>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT>
<ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION>
<ADDRESS_1>Möhlstr. 26</ADDRESS_1>
<ADDRESS_2/>
<CITY>München</CITY>
<ZIP>81675</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>49-89-4140-4207</PHONE_1>
<PHONE_2/>
<FAX_1>49-89-4140-4894</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Stefan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Leucht</LAST_NAME>
<SUFFIX/>
<POSITION>Oberarzt</POSITION>
<EMAIL_1>Stefan.Leucht@lrz.tu-muenchen.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT>
<ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION>
<ADDRESS_1>Ismaningerstrasse 22</ADDRESS_1>
<ADDRESS_2/>
<CITY>München</CITY>
<ZIP>81675</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49-89-4140 ext: 4249</PHONE_1>
<PHONE_2/>
<FAX_1>+49-89-4140-4888</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2013-01-15 17:33:34 +0000" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Minor update: 05/03/07&lt;/p&gt;" NOTES_MODIFIED="2013-01-15 17:33:34 +0000" NOTES_MODIFIED_BY="Claire Irving">
<UP_TO_DATE>
<DATE DAY="7" MONTH="5" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="4" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="6" MONTH="9" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2012-07-30 10:05:39 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-07-30 10:05:39 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="7" YEAR="2012"/>
<DESCRIPTION>
<P>Update search of Cochrane Schizophrenia Group's Trial Register (see <A HREF="http://archie.cochrane.org/sections/documents/view?version=44705070754671417758120516110605&amp;format=REVMAN#SEARCH_METHODS">Search methods for identification of studies</A>), 47 studies added to awaiting classification.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-11-02 11:01:09 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-02 11:01:09 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review<BR/>format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Psychiatrische Klinik, Klinikum rechts der Isar, TU München, Freistaat Bayern</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Bundesministerium für Bildung und Forschung, Nr FKZ: 01KG 0606, GZ: GFKG01100506</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-01-15 17:38:22 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-10-27 07:14:21 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-09-17 11:45:08 +0100" MODIFIED_BY="[Empty name]">Amisulpride versus other atypical antipsychotics for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2009-10-27 07:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>This review compared the effects of amisulpride with those of other so called second generation (atypical) antipsychotic drugs. For half of the possible comparisons not a single relevant study could be identified. Based on very limited data there was no difference in efficacy comparing amisulpride with olanzapine and risperidone, but a certain advantage compared with ziprasidone. Amisulpride was associated with less weight gain than risperidone and olanzapine.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-01-15 17:33:51 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-07-02 11:33:00 +0100" MODIFIED_BY="[Empty name]">
<P>In many countries of the industrialised world second generation (atypical) antipsychotics have become first line drug treatments for people with schizophrenia. The question as to whether, and if so how much, the effects of the various second generation antipsychotics differ is a matter of debate. In this review we examine how the efficacy and tolerability of amisulpride differs from that of other second generation antipsychotics.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the effects of amisulpride compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-01-15 17:33:51 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CINAHL, EMBASE, MEDLINE and PsycINFO.</P>
<P>We updated this search in July 2012 and added 47 new trials to the awaiting classification section.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-07-02 11:24:49 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised, at least single-blind, trials comparing oral amisulpride with oral forms of aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychoses.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-10-27 07:11:10 +0000" MODIFIED_BY="[Empty name]">
<P>We extracted data independently. For continuous data we calculated weighted mean differences (MD), for dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-09-11 13:27:58 +0100" MODIFIED_BY="[Empty name]">
<P>The review currently includes ten short to medium term trials with 1549 participants on three comparisons: amisulpride versus olanzapine, risperidone and ziprasidone. The overall attrition rate was considerable (34.7%) with no significant difference between groups. Amisulpride was similarly effective as olanzapine and risperidone and more effective than ziprasidone (leaving the study early due to inefficacy: n=123, 1 RCT, RR 0.21 CI 0.05 to 0.94, NNT 8 CI 5 to 50). Amisulpride induced less weight gain than risperidone (n=585, 3 RCTs, MD -0.99 CI -1.61 to -0.37) or olanzapine (n=671, 3 RCTs, MD -2.11 CI -2.94 to -1.29). Olanzapine was also associated with a higher increase of glucose (n=406, 2 RCTs, MD -7.30 CI -7.62 to -6.99). There was no difference in terms of cardiac effects and extra pyramidal symptoms (EPS) compared with olanzapine (akathisia: n= 587, 2 RCTs, RR 0.66 CI 0.36 to 1.21), compared with risperidone (akathisia: n=586, 3 RCTs, RR 0.80 CI 0.58 to 1.11) and compared with ziprasidone (akathisia: n=123, 1 RCT, RR 0.63, CI 0.11 to 3.67).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-01-14 12:09:46 +0000" MODIFIED_BY="[Empty name]">
<P>There is little randomised evidence comparing amisulpride with other second generation antipsychotic drugs. We could only find trials comparing amisulpride with olanzapine, risperidone and ziprasidone. We found amisulpride may be somewhat more effective than ziprasidone, and more tolerable in terms of weight gain and other associated problems than olanzapine and risperidone. These data, however, are based on only ten short to medium term studies and therefore too limited to allow for firm conclusions.</P>
<P>Note: the 47 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-01-15 17:36:30 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-07-30 10:35:01 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2009-10-27 07:15:58 +0000" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is usually a chronic and disabling psychiatric disorder which afflicts approximately one per cent of the population world-wide, with little gender differences. The annual incidence of schizophrenia averages 15 per 100,000, the point prevalence averages approximately 4.5 per population of 1000, and the risk of developing the illness over one's lifetime averages 0.7% (<LINK REF="REF-Tandon-2008" TYPE="REFERENCE">Tandon 2008</LINK>). Its typical manifestations are positive symptoms such as fixed, false beliefs (delusions) and perceptions without cause (hallucinations), negative symptoms such as apathy and lack of drive, disorganisation of behaviour and thought, and catatonic symptoms such as mannerisms and bizarre posturing (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>). The degree of suffering and disability is considerable with 80% - 90% not working (<LINK REF="REF-Marvaha-2004" TYPE="REFERENCE">Marvaha 2004</LINK>) and up to 10% dying (<LINK REF="REF-Tsuang-1978" TYPE="REFERENCE">Tsuang 1978</LINK>). In the age group of 15-44 years, schizophrenia is among the top ten leading causes of disease-related disability in the world (<LINK REF="REF-WHO-2001" TYPE="REFERENCE">WHO 2001</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-10-27 07:19:55 +0000" MODIFIED_BY="[Empty name]">
<P>Conventional antipsychotic drugs such as chlorpromazine and haloperidol have traditionally been used as first line antipsychotics<B> </B>for people with schizophrenia (<LINK REF="REF-Kane-1993" TYPE="REFERENCE">Kane 1993</LINK>). In the 1990's the introduction of clozapine, a new antipsychotic that was found to be more effective and associated with fewer movement disorders than chlorpromazine (<LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK>), boosted the development of a new/second generation of antipsychotics (NGA) also known as atypical antipsychotics. There is no absolute definition of what an "atypical" or "second generation" antipsychotic is. They were initially said to differ from typical antipsychotics in that they did not cause movement disorders (catalepsy) in rats at clinically effective doses (<LINK REF="REF-Arnt-1998" TYPE="REFERENCE">Arnt 1998</LINK>). The terms "new" or "second generation" antipsychotics are not much better, because clozapine itself is now a very old drug. According to treatment guidelines (<LINK REF="REF-APA-2004" TYPE="REFERENCE">APA 2004</LINK>, <LINK REF="REF-Gaebel-2006" TYPE="REFERENCE">Gaebel 2006</LINK>) second generation antipsychotics include drugs such as amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone sertindole, ziprasidone and zotepine, although it is unclear whether some old and cheap compounds such as sulpiride or perazine have similar properties (<LINK REF="REF-M_x00f6_ller-2000" TYPE="REFERENCE">Möller 2000</LINK>). The second generation antipsychotics raised major hopes of superior effects in a number of areas such as compliance, cognitive functioning, negative symptoms, movement disorders, quality of life, and treatment of people whose illness had been resistant to treatment.</P>
</INTERVENTION>
<THEORY MODIFIED="2008-09-04 10:30:42 +0100" MODIFIED_BY="[Empty name]">
<P>Amisulpride, a substituted benzamide, has a selective and high affinity for dopamine (D3/D2) receptors and presents an interesting pharmacological profile. The profile is said to enable a dose-dependent modulation of dopamine activity. Amisulpride increases dopaminergic transmission at low doses via presynaptic receptor blockade, preferentially in limbic structures, as opposed to the striatum (<LINK REF="REF-Freeman-1997" TYPE="REFERENCE">Freeman 1997</LINK>, <LINK REF="REF-Rein-1997" TYPE="REFERENCE">Rein 1997</LINK>). It has no affinity for other receptor or transporter systems. This unusual property could theoretically make amisulpride different from other atypical antipsychotic drugs in its ability to treat positive and negative symptoms, and its side-effect profile (<LINK REF="REF-Mota-Neto-2002" TYPE="REFERENCE">Mota Neto 2002</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-07-30 10:35:01 +0100" MODIFIED_BY="[Empty name]">
<P>The debate as to how far NGA improve these outcomes compared with conventional antipsychotics continues (<LINK REF="REF-Duggan-2005" TYPE="REFERENCE">Duggan 2005</LINK>, <LINK REF="REF-El_x002d_Sayeh-2006" TYPE="REFERENCE">El-Sayeh 2006</LINK>) and the results from recent studies were sobering (<LINK REF="REF-Liebermann-2005" TYPE="REFERENCE">Liebermann 2005</LINK>, <LINK REF="REF-Jones-2006-a" TYPE="REFERENCE">Jones 2006 a</LINK>). Nevertheless, in some parts of the world, especially in the highly industrialised countries, second generation antipsychotics have become the mainstay of treatment. The second generation antipsychotics also differ in terms of their costs; while amisulpride and risperidone are already generic, aripiprazole and olanzapine for example are still not. Therefore the question as to whether they differ from each other in their clinical effects becomes increasingly important. In this review we aim to summarise evidence from randomised controlled trials comparing amisulpride with other second generation antipsychotics.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-02-08 10:08:45 +0000" MODIFIED_BY="[Empty name]">
<P>To review the effects of amisulpride compared with other second generation antipsychotics for people with schizophrenia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-01-15 17:36:30 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-10-27 07:23:49 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-10-27 07:23:49 +0000" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials which were at least single-blind (i.e. at least blind raters). Where a trial was described as 'double-blind', but it was only implied that the study was randomised, we included these trials in a sensitivity analysis. If there was no substantive difference within primary outcomes (see <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>) when these 'implied randomisation' studies were added, then we included these in the final analysis. If there was a substantive difference, we only used clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week.</P>
<P>Randomised cross-over studies will be eligible but only data up to the point of first cross-over because of the instability of the problem behaviours and the likely carry-over effects of all treatments.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-07-21 10:50:44 +0100" MODIFIED_BY="[Empty name]">
<P>We included people with schizophrenia and other types of schizophrenia-like psychoses (e.g. schizophreniform and schizoaffective disorders), irrespective of the diagnostic criteria used. There is no clear evidence that the schizophrenia-like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-07-14 15:28:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: any oral form of application, any dose<BR/>2. Other "atypical" antipsychotic drugs: aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, zotepine: any oral form of application, any dose.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-07-14 15:32:05 +0100" MODIFIED_BY="[Empty name]">
<P>We grouped outcomes into the short term (up to 12 weeks), medium term (13-26 weeks) and long term (over 26 weeks).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-07-14 15:32:05 +0100" MODIFIED_BY="[Empty name]">
<P>1. No clinically important response as defined by the individual studies (e.g. global impression 'less than much improved' or 'less than 50% reduction on a rating scale')<B> </B>
</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-07-02 12:04:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Leaving the studies early (any reason, adverse events, inefficacy of treatment)</P>
<P>2. Global state<BR/>2.1 No clinically important change in global state (as defined by individual studies)<BR/>2.2 Relapse (as defined by the individual studies)</P>
<P>3. Mental state (with particular reference to the positive and negative symptoms of schizophrenia)<BR/>3.1 No clinically important change in general mental state score<BR/>3.2 Average endpoint general mental state score<BR/>3.3 Average change in general mental state score<BR/>3.4 No clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia)<BR/>3.5 Average endpoint specific symptom score<BR/>3.6 Average change in specific symptom score</P>
<P>4. General functioning<BR/>4.1 No clinically important change in general functioning<BR/>4.2 Average endpoint general functioning score<BR/>4.3 Average change in general functioning score</P>
<P>5. Quality of life/satisfaction with treatment<BR/>5.1 No clinically important change in general quality of life<BR/>5.2 Average endpoint general quality of life score<BR/>5.3 Average change in general quality of life score</P>
<P>6. Cognitive functioning<BR/>6.1 No clinically important change in overall cognitive functioning<BR/>6.2 Average endpoint of overall cognitive functioning score<BR/>6.3 Average change of overall cognitive functioning score</P>
<P>7. Service use<BR/>7.1 Number of participants hospitalised</P>
<P>8. Adverse effects<BR/>8.1 Number of participants with at least one adverse effect<BR/>8.2 Clinically important specific adverse effects (cardiac effects, death, movement disorders, prolactin increase and associated effects, seizures, sedation, weight gain, effects on white blood cell count)<BR/>8.3 Average endpoint in specific adverse effects<BR/>8.4 Average change in specific adverse effects</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-01-15 17:36:30 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-01-15 17:36:30 +0000" MODIFIED_BY="[Empty name]">
<P>1. The Cochrane Schizophrenia Group Trials Register was searched (April 2007) using the phrase:<BR/>[((amisulprid* AND (aripiprazol* OR clozapin* OR olanzapin* OR quetiapin* OR risperidon* OR sertindol* OR ziprasidon* OR zotepin*)) in title, abstract or index terms of REFERENCE) or ((amisulprid* AND (aripiprazol* OR clozapin* OR olanzapin* OR quetiapin* OR risperidon* OR sertindol* OR ziprasidon* OR zotepin*)) in interventions of STUDY)]<BR/>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see <A HREF="http://mrw.interscience.wiley.com/cochrane/cochrane_clsysrev_crglist_fs.html">Group Module</A>). The Cochrane Schizophrenia Group Trials Register is maintained on Meerkat 1.5.1. This version of Meerkat stores references as studies. When an individual reference is selected through a search, all references which have been identified as the same study are also selected.</P>
<P>2. Cochrane Schizophrenia Group Trials Register</P>
<P>The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group&#8217;s Trials Register (July 2012) using the phrase:</P>
<P>[((*amisulprid* AND (*aripiprazol* OR *clozapin* OR *olanzapin* OR *quetiapin* OR *risperidon* OR *sertindol* OR *ziprasidon* OR *zotepin*)) in title, abstract or index terms of REFERENCE) or ((*amisulprid* AND (*aripiprazol* OR *clozapin* OR *olanzapin* OR *quetiapin* OR *risperidon* OR *sertindol* OR *ziprasidon* OR *zotepin*)) in interventions of STUDY)]</P>
<P>The Cochrane Schizophrenia Group&#8217;s Trials Register is compiled by systematic searches of major databases, handsearches of relevant journals and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>). Incoming trials are assigned to existing or new review titles.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-09-04 10:36:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Reference searching<BR/>We inspected the references of all identified studies for more trials.</P>
<P>2. Personal contact<BR/>We contacted the first author of each included study for missing information.</P>
<P>3. Drug companies<BR/>We contacted the manufacturers of all atypical antipsychotics included for additional data.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-11-03 11:05:59 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-11-03 11:05:59 +0000" MODIFIED_BY="[Empty name]">
<P>KK and SL independently inspected all reports. We resolved any disagreement by discussion, and where there was still doubt, we acquired the full article for further inspection. Once the full articles were obtained, we independently decided whether the studies met the review criteria. If disagreement could not be resolved by discussion, we sought further information and these trials were added to the list of those awaiting assessment.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-11-02 11:23:45 +0000" MODIFIED_BY="[Empty name]">
<P>1. Data extraction<BR/>KK and CRK independently extracted data from selected trials. When disputes arose we attempted to resolve these by discussion. When this was not possible and further information was necessary to resolve the dilemma, we did not enter data and added the trial to the list of those awaiting assessment.</P>
<P>2. Management<BR/>KK and CRK extracted the data onto standard simple forms. Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for ziprasidone.</P>
<P>3. Rating scales<BR/>A wide range of instruments are available to measure outcomes in mental health studies. These instruments vary in quality and many are not validated, or are even ad hoc. It is accepted generally that measuring instruments should have the properties of reliability (the extent to which a test effectively measures anything at all) and validity (the extent to which a test measures that which it is supposed to measure) (<LINK REF="REF-Rust-1989" TYPE="REFERENCE">Rust 1989</LINK>). Unpublished scales are known to be subject to bias in trials of treatments for schizophrenia (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>). Therefore continuous data from rating scales were included only if the measuring instrument had been described in a peer-reviewed journal.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-11-02 11:04:45 +0000" MODIFIED_BY="[Empty name]">
<P>Again working independently, authors KK and SL assessed risk of bias using the tool described in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases.</P>
<P>The risk of bias in each domain and overall were assessed and categorised into:</P>
<P>A. Low risk of bias: plausible bias unlikely to seriously alter the results (categorised as 'Yes' in Risk of Bias table)<BR/>B. High risk of bias: plausible bias that seriously weakens confidence in the results (categorised as 'No' in Risk of Bias table)<BR/>C. Unclear risk of bias: plausible bias that raises some doubt about the results (categorised as 'Unclear' in Risk of Bias table)</P>
<P>Trials with high risk of bias (defined as at least four out of seven domains were categorised as 'No') or where allocation was clearly not concealed, were not included in the review. If the raters disagreed, the final rating was made by consensus with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials are provided, authors of the studies were contacted in order to obtain further information. Non-concurrence in quality assessment was reported.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-10-27 07:31:25 +0000" MODIFIED_BY="[Empty name]">
<P>1. Data types<BR/>We assessed outcomes using continuous (for example changes on a behaviour scale), categorical (for example, one of three categories on a behaviour scale, such as "little change", "moderate change" or "much change") or dichotomous (for example, either "no important changes or "important change" in a person's behaviour) measures. Currently RevMan does not support categorical data so we were unable to analyse this.</P>
<P>2. Dichotomous- yes/no- data<BR/>We carried out an intention to treat analysis. Everyone allocated to the intervention were counted, whether they completed the follow up or not. It was assumed that those who left the study early had no change in their outcome. This rule is conservative concerning response to treatment, because it assumes that those discontinuing the studies would not have responded. It is not conservative concerning adverse effects, but we felt that assuming that all those leaving early would have developed side-effects would overestimate risk. Where possible, efforts were made to convert outcome measures to dichotomous data. This can be done by identifying cut off points on rating scales and dividing participants accordingly into "clinically improved" or "not clinically improved". It was generally assumed that if there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>, <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
<P>We calculated the relative risk (RR) and its 95% confidence interval (CI) based on the random effects model, as this takes into account any differences between studies even if there is no statistically significant heterogeneity. It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimate of the impression of the effect. When the overall results were significant we calculated the number needed to treat (NNT) and the number needed to harm (NNH) as the inverse of the risk difference.</P>
<P>3. Continuous data<BR/>3.1 Normal distribution of the data<BR/>The meta-analytic formulas applied by RevMan Analyses (the statistical programme included in Rev Man) require a normal distribution of data. The software is robust towards some skew, but to which degree of skewness meta-analytic calculations can still be reliably carried out is unclear. On the other hand, excluding all studies on the basis of estimates of the normal distribution of the data also leads to a bias, because a considerable amount of data may be lost leading to a selection bias. Therefore, we included all studies in the primary analysis. In a sensitivity analysis we excluded potentially skewed data applying the following rules:<BR/>a) When a scale started from the finite number zero the standard deviation, when multiplied by two, was more than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>).<BR/>b) If a scale started from a positive value (such as PANSS which can have values from 30 to 210) the calculation described above was modified to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score<BR/>c) In large studies (as a cut-off we used 200 participants) skewed data pose less of a problem. In these cases we entered the data in a synthesis.<BR/>d) The rules explained in a) and b) do not apply to change data. The reasons is that when continuous data are presented on a scale which includes a possibility of negative values, it is difficult to tell whether data are non-normally distributed (skewed) or not. This is also the case for change data (endpoint minus baseline). In the absence of individual patient data it is impossible to know if data are skewed, though this is likely. After consulting the ALLSTAT electronic statistics mailing list, we presented change data in RevMan Analyses in order to summarise available information. In doing this, it was assumed either that data were not skewed or that the analysis could cope with the unknown degree of skew. Without individual patient data it is impossible to test this assumption. Change data were therefore included and a sensitivity analysis was not applied. For continuous outcomes we estimated a weighted mean difference (MD) between groups. We combined both endpoint data and change data in the analysis, because there is no principal statistical reason why endpoint and change data should measure different effects (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). When standard errors instead of standard deviations (SD) were presented, we converted the former to standard deviations. If both were missing we estimated SDs from p-values or used the average SD of the other studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2009-11-02 11:29:13 +0000" MODIFIED_BY="[Empty name]">
<P>1. Cluster trials<BR/>Studies increasingly employ "cluster randomisation" (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a "unit of analysis" error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes Type 1 errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intraclass correlation coefficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a "design effect". This is calculated using the mean number of participants per cluster (m) and the intraclass correlation coefficient (ICC) [Design effect=1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).<BR/>
<BR/>If cluster studies had been appropriately analysed taking into account intraclass correlation coefficients and relevant data documented in the report, we synthesised these with other studies using the generic inverse variance technique.</P>
<P>2. Cross-over trials<BR/>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in schizophrenia, we will only use data of the first phase of cross-over studies.</P>
<P>3. Studies with multiple treatment groups<BR/>Where a study involved more than two treatment groups, if relevant, the additional treatment groups were presented in additional relevant comparisons. Data were not double counted. Where the additional treatment groups were not relevant, these data were not reproduced.<BR/>
</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2009-10-27 07:36:28 +0000" MODIFIED_BY="[Empty name]">
<P>At some degree of loss of follow-up data must lose credibility (<LINK REF="REF-Xia-2007" TYPE="REFERENCE">Xia 2007</LINK>). Although high rates of premature discontinuation are a major problem in this field, we felt that it is unclear which degree of attrition leads to a high degree of bias. We, therefore, did not exclude trials on the basis of the percentage of participants completing them. However we addressed the problem of participants leaving the study early in all parts of the review, including the abstract. For this purpose we calculated, presented and commented on frequency statistics (overall rates of leaving the studies early in all studies and comparators pooled).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-08-20 15:40:32 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical heterogeneity<BR/>We considered all the included studies within any comparison to judge for clinical heterogeneity.</P>
<P>2. Statistical<BR/>2.1 Visual inspection<BR/>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
<P>2.2 Employing the I<SUP>2</SUP> statistic<BR/>Visual inspection was supplemented using, primarily, the I<SUP>2</SUP>statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I<SUP>2</SUP> estimate was greater than or equal to 50% we interpreted this as indicating the presence of considerable levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-09-04 12:02:43 +0100" MODIFIED_BY="[Empty name]">
<P>We entered data from all identified and selected trials into a funnel graph (trial effect versus trial size) in an attempt to investigate the likelihood of overt publication bias. A formal test for funnel-plot asymmetry was not undertaken.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-10-27 07:38:01 +0000" MODIFIED_BY="[Empty name]">
<P>Where possible, for both dichotomous and continuous data we used the random-effects model for data synthesis as this takes into account any differences between studies even if there is no statistically significant heterogeneity. We understand that there is no closed argument for preference for use of fixed or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us, however, random-effects does put added weight onto the smaller of the studies - those trials that are most vulnerable to bias.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-08-20 15:44:40 +0100" MODIFIED_BY="[Empty name]">
<P>If data are clearly heterogeneous we checked that data were correctly extracted and entered and that we had made no unit of analysis errors. If inconsistency was high and clear reasons explaining the heterogeneity were found, we presented the data separately. If not, we commented on the heterogeneity of the data.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-09-04 12:03:42 +0100" MODIFIED_BY="[Empty name]">
<P>In sensitivity analyses we excluded studies with potentially skewed data. A recent report showed that some of the comparisons of atypical antipsychotics may have been biased by using inappropriate comparator doses (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>). We, therefore, also analysed whether the exclusion of studies with inappropriate comparator doses changed the results of the primary outcome and the general mental state.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-01-14 12:11:29 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-01-14 12:11:29 +0000" MODIFIED_BY="[Empty name]">
<P>For substantive description of studies please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.</P>
<SEARCH_RESULTS MODIFIED="2009-07-24 12:43:35 +0100" MODIFIED_BY="[Empty name]">
<P>The search strategy yielded 3620 reports of which 23 were closely inspected. After excluding ten studies,16 publications on ten trials and three comparisons met the inclusion criteria: amisulpride versus olanzapine (N=5), amisulpride versus risperidone (N=4) and amisulpride versus ziprasidone (N=1).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-11-02 11:05:13 +0000" MODIFIED_BY="[Empty name]">
<P>For details of the included studies please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.<BR/>The ten included studies randomised 1549 people, all ten studies were double blind. Six studies were sponsored by pharmaceutical companies producing amisulpride. Three studies were sponsored by pharmaceutical companies marketing the comparator antipsychotic drug. The sponsoring of the remaining trial was unclear.</P>
<P>1. Length of studies<BR/>Six of the included studies fell in the short term category with a duration of 6-12 weeks. The remaining four studies fell in the medium term categories and had a duration of 24-26 weeks. There were no long term studies.</P>
<P>2. Setting<BR/>
<LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK> was conducted only in hospitals and <LINK REF="STD-Olie-2006" TYPE="STUDY">Olie 2006</LINK> only in outpatient departments. Five studies reported the setting as in- and outpatient, while the setting of three remaining studies setting was not reported.</P>
<P>3. Participants<BR/>All participants were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders (Version III-R or Version IV). One study group additionally used the International Classification of Disease Version 10 (<LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK>). Two studies explicitly included only people with chronic schizophrenia (<LINK REF="STD-Olie-2006" TYPE="STUDY">Olie 2006</LINK>, <LINK REF="STD-Sechter-2002" TYPE="STUDY">Sechter 2002</LINK>), but the participants of the other studies were also relatively chronic, with a mean illness duration of over eight years. <LINK REF="STD-M_x00f6_ller-2005" TYPE="STUDY">Möller 2005</LINK> restricted its inclusion criteria to elderly people over the age of 65 years. <LINK REF="STD-Vanelle-2006" TYPE="STUDY">Vanelle 2006</LINK> examined those with schizophrenia and comorbid depression, <LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK> included only participants with predominant negative symptoms. There were no studies randomising acutely ill people or people with a first episode of schizophrenia.</P>
<P>4. Study size<BR/>The largest study was <LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK> and included 377 participants, the smallest study was <LINK REF="STD-M_x00f6_ller-2005" TYPE="STUDY">Möller 2005</LINK> which included 36 participants. Five studies included more and five studies included less than 100 people.</P>
<P>5. Interventions<BR/>5.1 Amisulpride<BR/>In seven studies amisulpride was given in flexible doses with varying dose ranges between 100-1000 mg per day. Two studies used fixed doses of 150 mg per day (<LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK>) and 800 mg per day (<LINK REF="STD-Peuskens-1999" TYPE="STUDY">Peuskens 1999</LINK>).<BR/>
<BR/>5.2 Comparator<BR/>Comparators were olanzapine (dose range: 5-20mg/day), risperidone (1 to 10mg/day) and ziprasidone (80 -160mg/day).</P>
<P>6. Outcomes<BR/>6.1 General remarks<BR/>Most reports described the number of participants leaving the studies early due to any reason, adverse events and lack of efficacy. We prespecified 50% PANSS/BPRS reduction from baseline as a clinically relevant measure of response, but not all studies reported data on this cutoff. <LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK> indicated the criterion at least 50% BPRS reduction from baseline, <LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK> used at least 50 % PANSS total score reduction from baseline, <LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK> combined at least 20% SANS total score reduction and 10% PANSS total score reduction and <LINK REF="STD-Vanelle-2006" TYPE="STUDY">Vanelle 2006</LINK> used the criterion CGI "at least very much" or "much improved". Data on relapse were only provided by <LINK REF="STD-Sechter-2002" TYPE="STUDY">Sechter 2002</LINK> and <LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK>.</P>
<P>6.2 Outcome scales<BR/>Details of scales that provided usable data are shown below. Reasons for exclusion of data from other instruments are given under 'Outcomes' in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>6.2.1 Global state<BR/>6.2.1.1 Clinical Global Impression Scale - CGI Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This scale is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardised against other people with the same diagnosis. A seven-point scoring system is usually used with low scores showing decreased severity and/or overall improvement.</P>
<P>6.2.2 Mental state<BR/>6.2.2.1 Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>)<BR/>This schizophrenia scale has 30 items, each of which can be defined on a seven-point scoring system varying from 1 - absent to 7 - extreme. It can be divided into three sub-scales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates lesser severity.</P>
<P>6.2.2.2 Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>This scale is used to assess the severity of abnormal mental state. The original scale has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale varying from 'not present' to 'extremely severe', scoring from 0-6 or 1-7. Scores can range from 0-126, with high scores indicating more severe symptoms. Some studies extracted the BPRS scores from the PANSS.</P>
<P>6.2.2.3 Scale for the Assessment of Negative Symptoms - SANS (<LINK REF="REF-Andreasen-1984" TYPE="REFERENCE">Andreasen 1984</LINK>)<BR/>This six-point scale gives a global rating of the following negative symptoms; alogia, affective blunting, avolition-apathy, anhedonia-asociality and attention impairment. Higher scores indicate more symptoms.</P>
<P>6.2.2.4 Global cognitive index - GCI (<LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK>)<BR/>For cognitive assessment <LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK> used a global cognitive index that was constructed by summing and averaging the z-scored variables of various cognitive tests.</P>
<P>6.2.3 Adverse effects<BR/>6.2.3.1 Abnormal Involuntary Movement Scale - AIMS (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This scale has been used to assess tardive dyskinesia, a long-term, drug-induced movement disorder and short-term movement disorders such as tremor.</P>
<P>6.2.3.2 Simpson Angus Scale - SAS (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This ten-item scale, with a scoring system of 0-4 for each item, measures drug-induced parkinsonism, a short-term drug-induced movement disorder. A low score indicates low levels of parkinsonism.</P>
<P>6.2.4 Social functioning<BR/>6.2.4.1 Social and Occupational Functioning Assessment scale- SOFAS (<LINK REF="REF-Goldman-1992" TYPE="REFERENCE">Goldman 1992</LINK>)<BR/>The SOFAS focuses on the different levels of social and occupational functioning. Higher scores indicate a higher level of functioning.</P>
<P>6.2.4.2 Quality of Life Scale - QLS (<LINK REF="REF-Carpenter-1984" TYPE="REFERENCE">Carpenter 1984</LINK>)<BR/>This semi-structured interview is administered and rated by trained clinicians. It contains 21 items rated on a seven-point scale based on the interviewers judgement of patient functioning. A total QLS and four sub-scale scores are calculated, with higher scores indicating better quality.</P>
<P>6.3 Missing outcomes<BR/>We identified no useable data on service use.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-01-14 12:11:29 +0000" MODIFIED_BY="[Empty name]">
<P>For details of the excluded studies please see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>
<BR/>The search strategy yielded 3620 reports. From these we requested 23 studies for closer inspection. Twelve of these studies had to be excluded for the following reasons: six were not randomised, three were open label, two studies pooled analysis and the intervention of one study did not fit our protocol criteria.</P>
<P>2. Awaiting assessment<BR/>Forty seven studies are awaiting assessment.<BR/>
</P>
<P>3. Ongoing studies<BR/>No studies are ongoing.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-10-27 07:47:20 +0000" MODIFIED_BY="[Empty name]">
<P>Judgements of risk are summarised in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2009-07-21 11:02:27 +0100" MODIFIED_BY="[Empty name]">
<P>All of the included studies were randomised controlled trials, but details about the randomisation procedure were provided by only two studies. <LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK> used a computer generated randomisation sequence and provided additional information on allocation concealment. <LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK> used medication containers according to a pseudo-random computer, but information on allocation concealment was not provided. Therefore whether randomisation procedure was adequate remained unclear for nine of the ten included studies.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-07-21 11:01:13 +0100" MODIFIED_BY="[Empty name]">
<P>All but one study were described as double-blind but only two provided further information, <LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK> and <LINK REF="STD-Peuskens-1999" TYPE="STUDY">Peuskens 1999</LINK> described using identical capsules for blinding. Whether blinding was effective is unclear, because none of the studies examined this. The side-effect profiles of the compounds may differ which may have made blinding difficult. Therefore, the risk of bias for objective outcomes (e.g. death or laboratory values) may have been low, but there was a risk of bias for subjective outcomes.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-10-27 07:47:20 +0000" MODIFIED_BY="[Empty name]">
<P>The overall rate of leaving the study early was considerable (34.7%). In five studies (<LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK>, <LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK>, <LINK REF="STD-Peuskens-1999" TYPE="STUDY">Peuskens 1999</LINK>, <LINK REF="STD-Sechter-2002" TYPE="STUDY">Sechter 2002</LINK>, <LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK>) the rate of leaving the study early was above 30%, and one study did not provide data on overall attrition rates (<LINK REF="STD-M_x00f6_ller-2005" TYPE="STUDY">Möller 2005</LINK>). We considered the risk of bias in these six studies to be high. <LINK REF="STD-Olie-2006" TYPE="STUDY">Olie 2006</LINK> reported an intermediate degree of attrition 25%. In <LINK REF="STD-Bai-2005" TYPE="STUDY">Bai 2005</LINK> and <LINK REF="STD-Hwang-2003" TYPE="STUDY">Hwang 2003</LINK> the risk of bias was low, because the rates of leaving the study early was below 10% and reasons were reported. In <LINK REF="STD-Vanelle-2006" TYPE="STUDY">Vanelle 2006</LINK> the overall attrition was probably acceptable (14.7%), but there was a high number of major protocol deviations. Most studies applied the last-observation-carried-forward method to account for participants leaving the study early which is an imperfect method. It assumes that a participant who left the study prematurely would not have had a change of his condition if they had stayed in the study. This assumption can often be wrong. This may be less of a problem in the studies with low attrition, but clearly problematic in studies with high attrition.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-07-21 11:05:46 +0100" MODIFIED_BY="[Empty name]">
<P>In all included studies this risk of bias was high, either because they did not report on certain outcomes (<LINK REF="STD-Bai-2005" TYPE="STUDY">Bai 2005</LINK>, <LINK REF="STD-Hwang-2003" TYPE="STUDY">Hwang 2003</LINK>, <LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK>, <LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK>, <LINK REF="STD-M_x00f6_ller-2005" TYPE="STUDY">Möller 2005</LINK>, <LINK REF="STD-Olie-2006" TYPE="STUDY">Olie 2006</LINK>, <LINK REF="STD-Peuskens-1999" TYPE="STUDY">Peuskens 1999</LINK>, <LINK REF="STD-Vanelle-2006" TYPE="STUDY">Vanelle 2006</LINK>, <LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK>) or because they only reported those side effects with an incidence of at least 5% or 10% (<LINK REF="STD-Hwang-2003" TYPE="STUDY">Hwang 2003</LINK>, <LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK>, <LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK>, <LINK REF="STD-Olie-2006" TYPE="STUDY">Olie 2006</LINK>, <LINK REF="STD-Peuskens-1999" TYPE="STUDY">Peuskens 1999</LINK>, <LINK REF="STD-Sechter-2002" TYPE="STUDY">Sechter 2002</LINK>). This procedure is problematic because rare but potentially serious side-effects may be missed.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-02-08 10:59:10 +0000" MODIFIED_BY="[Empty name]">
<P>Nine of the included studies were industry sponsored, for one study (<LINK REF="STD-Bai-2005" TYPE="STUDY">Bai 2005</LINK>) sponsoring remained unclear. There is evidence that pharmaceutical companies sometimes highlight the benefits of their compounds and tend to suppress their disadvantages (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>). The study sponsored by ziprasidone's manufacturer (<LINK REF="STD-Olie-2006" TYPE="STUDY">Olie 2006</LINK>) used an amisulpride dose (maximum 200mg/day) that may have been too low, because ziprasidone was used in the full dose (maximum 160mg/day).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-10-28 07:43:38 +0000" MODIFIED_BY="[Empty name]">
<P>COMPARISON 1. AMISULPRIDE versus OLANZAPINE<BR/>Five studies provided data for the comparison amisulpride versus olanzapine.</P>
<P>1.1 Global state<BR/>1.1.1 No clinically significant response (as defined by original studies)<BR/>There was no significant difference in terms of response to treatment as defined by various criteria (n=724, 4 RCTs, RR 1.03 CI 0.87 to 1.22).</P>
<P>1.1.2 No clinically important change (as defined by original studies)<BR/>There was no significant difference (n=314, 3 RCTs, RR 0.91 CI 0.70 to 1.19).</P>
<P>1.1.3 Relapse - medium term (as defined by original studies)<BR/>Only <LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK> reported on relapse but did not find a significant difference (n=210, 1 RCT, RR 0.93 CI 0.40 to 2.18).</P>
<P>1.2 Leaving the study early<BR/>There was no significant difference in terms of leaving the study early due to any reason (n=804, 5<B> </B>RCTs, RR 1.07 CI 0.9 to 1.26), due to adverse events (n=724, 4 RCTs, RR 1.19 CI 0.74 to 1.92), or due to inefficacy of treatment (n= 724, 4 RCTs, RR 1.19 CI 0.71 to 1.99).</P>
<P>1.3 Mental state<BR/>1.3.1 General - no clinically important change - short term - less than 50% PANSS total reduction<BR/>A single study revealed no significant difference (n=52, 1 RCT, RR 0.69 CI 0.40 to 1.18).</P>
<P>1.3.2 General - average score at endpoint - PANSS total score<BR/>Four studies did not show a significant difference overall (n=701, 4 RCTs, MD 1.57 CI -2.94 to 6.09), short term (n=119, 2 RCTs, MD -2.86 CI -17.08 to 11.36), medium term (n=582, 2 RCTs, MD 2.53 CI -2.48 to 7.54).<BR/>
</P>
<P>1.3.3 General - no clinically important change - medium term - less than 50% BPRS total reduction<BR/>Only one study provided data for this outcome and found no significant difference (n=377, 1 RCT, RR 1.09 CI 0.88 to 1.36).</P>
<P>1.3.4 General - average score at endpoint - BPRS total score<BR/>There was no significant difference in the overall analysis (n=665, 3 RCTs, MD 1.26 CI -0.82 to 3.34), short term (n=83, 1 RCT, MD 1.40 CI -2.18 to 4.98) and medium term (n=582, 2 RCTs, MD 1.39 CI -2.04 to 4.83).</P>
<P>1.3.5 Positive symptoms - no clinically important change - short term - less than 50% PANSS positive symptom reduction<BR/>The results are based on only one study that revealed no significant difference (n=52, 1 RCT, RR 0.69 CI 0.36 to 1.33).</P>
<P>1.3.6 Positive symptoms - average score at endpoint - PANSS positive subscore<BR/>Four studies reported on the PANSS positive subscore. There was no significant difference between groups in the overall analysis (n=701, 4 RCTs, MD 0.66 CI -0.56 to 1.88), short term (n=119, 2 RCTs, MD 0.15 CI -2.27 to 2.57) and medium term (n=582, 2 RCTs, MD 0.98 CI -1.16 to 3.12).</P>
<P>1.3.7 Negative symptoms: no clinically important change -medium term - less than 20% SANS total plus 10% PANSS total reduction<BR/>One study found was no significant difference (n=210, 1 RCT, RR 1.13 CI 0.80 to 1.60).</P>
<P>1.3.8 Negative symptoms - average score at endpoint - PANSS negative subscore<BR/>Four studies reported on the PANSS negative subscore. Again, there was no significant difference between groups in the overall analysis (n= 701, 4 RCTs, MD 0.21 CI -0.69 to 1.10), short term (n=119, 2 RCTs, MD -0.49 CI -3.02 to 2.05) and medium term (n=582, 2 RCTs, MD 0.38 CI -0.80 to 1.56).<BR/>
</P>
<P>1.3.9 Negative symptoms - average score at endpoint - SANS total score<BR/>There was no significant difference (n=243, 2 RCT, MD 0.00 CI -1.43 to1.43) in the overall analysis, short term (n=33, 1 RCT, MD -8.62 CI -27.69 to 10.45) and medium term (n=210, 1 RCT, MD 0.05 CI -1.39 to 1.49).</P>
<P>1.4 General functioning - average score at endpoint - SOFAS total score - percent change<BR/>There was no significant difference (n=359, 1 RCT, MD 0.20 CI -10.54 to10.94).</P>
<P>1.5 Quality of life - average score at endpoint - medium term - QLS total score<BR/>Data on quality of life did not show a significant difference (n=510, 2 RCTs, MD 0.00 CI -0.22 to 0.22).</P>
<P>1.6 Cognitive functioning<BR/>1.6.1 Cognitive functioning: no clinically important change - short term - less than 50 % Global cognitive index reduction.<BR/>There was no significant difference (n=52 ,1 RCT, RR 1.00 CI 0.74 to 1.35).</P>
<P>1.6.2 Cognitive functioning - average score at endpoint - short term - Global Cognitive Index<BR/>There was no significant difference (n=36, 1 RCT, MD -0.13, CI -0.35 to 0.09).</P>
<P>1.7 Adverse effects<BR/>1.7.1 General - at least one adverse effect<BR/>There was no significant difference (n=462, 2 RCTs, RR 1.03, CI 0.87 to 1.21).</P>
<P>1.7.2 Death<BR/>Two studies reported on death with no significant difference between treatment and control groups, neither for natural causes (n=377, 1 RCT, RR 2.98 CI 0.12 to 72.79) nor for suicide (n=210, 1 RCT, RR 0.33, CI 0.01 to 8.09). Suicide attempts did also not occur in significantly different frequency (n=210, 1 RCT, RR 0.67 CI 0.07 to 6.29).</P>
<P>1.7.3 Cardiac effects - number of participants with QTc prolongation<BR/>In <LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK> there was no occurrence of QTc prolongation in either group, the other studies did not provide any data on this outcome.</P>
<P>1.7.4 Cardiac effects - change of QTc interval from baseline in ms<BR/>There was no significant difference in the mean prolongation of the QTc interval (n=303, 2 RCTs, MD 5.25 CI -0.57 to 11.07).</P>
<P>1.7.5 Central nervous system - sedation<BR/>There was no significant difference (n=587, 2 RCTs, RR 1.22 CI 0.64 to 2.34).</P>
<P>1.7.6 Central nervous system - seizures<BR/>There was no significant difference (n=210, 1 RCT, RR 0.66 CI 0.03 to 16.04).</P>
<P>1.7.7 Extrapyramidal effects<BR/>Extrapyramidal side effects were reported as akathisia (n= 587, 2 RCTs, RR 0.66 CI 0.36 to 1.21), dyskinesia (n= 210, 1 RCT, RR 0.66 CI 0.03 to 16.04), dystonia (n=377, 1 RCT, RR 4.97 CI 0.24 to 102.91), extrapyramidal symptoms (n=210, 1 RCT, RR 1.2 CI 0.72 to 2.00), parkinsonism (n=587, 2 RCTs, RR 3.60 CI 0.42 to 31.12), tremor (n= 210, 1 RCT, RR 0.57 CI 0.12 to 2.68) and use of antiparkinson medication (n=377, 1 RCT, RR 1.52 CI 0.85 to 2.71). There was no statistically significant difference in these side effects between amisulpride and olanzapine.</P>
<P>1.7.8 Extrapyramidal effects - scale measured<BR/>Scale derived data on extrapyramidal side-effects using the Aquired Involuntary Movement Scale (AIMS, n=356, 1 RCT, MD -0.40 CI-1.13 to 0.33) or the Simpson Angus Scale (SAS, n=206, 2 RCTs, MD 0.00 CI -0.08 to 0.08) indicated no significant difference between amisulpride and olanzapine.</P>
<P>1.7.9 Haematological - white blood cell count - leukopenia<BR/>There was no significant difference (n=210, 1 RCT, RR 0.40 CI 0.02 to 8.16).</P>
<P>1.7.10 Prolactin associated side effects<BR/>There was no significant difference in prolactin associated side effects reported as sexual dysfunction (n=521, 2 RCTs, RR 1.36 CI 0.14 to12.94), amenorrhea (n=66, 1 RCT, RR 1.53 CI 0.28 to 8.48) and galactorrhea (n=66, 1 RCT, RR 6.71 CI 0.29 to 158.10).</P>
<P>1.7.11 Metabolic - cholesterol - change from baseline in mg/dl<BR/>There was no significant difference in the mean change of total cholesterol from baseline (n=85, 1 RCT, MD -3.42 CI -12.32 to 5.48).</P>
<P>1.7.12 Metabolic - glucose - number of participants with diabetes mellitus<BR/>There was no significant difference in the number of participants with elevated glucose levels (n=377, 1 RCT, RR 0.33 CI 0.01 to 8.09).</P>
<P>1.7.13 Metabolic - glucose - change from baseline in mg/dl<BR/>Amisulpride was associated with significantly less increase of glucose levels from baseline than olanzapine (n=406, 2 RCTs, MD -7.30 CI -7.62 to -6.99).</P>
<P>1.7.14 Metabolic - weight - number of participants with weight gain<BR/>Weight gain was reported by three studies, either as weight gain reported adverse event or as weight gain of 7% or more of total body weight. Overall there was a significant difference favouring amisulpride (n=672, 3 RCTs, RR 0.55 CI 0.40 to 0.75, NNT 9, CI 6 to 20).</P>
<P>1.7.15 Metabolic - weight - change from baseline in kg<BR/>When weight gain was analysed as a mean change from baseline in kg the results also showed a significant superiority of amisulpride (n=671, 3 RCTs, MD -2.11 CI -2.94 to -1.29).</P>
<P>1.8 Publication bias<BR/>Due to small number of included studies a funnel plot analysis was not performed.</P>
<P>1.9 Investigation for heterogeneity and sensitivity analysis<BR/>The reasons for the preplanned sensitivity analysis did not apply and were therefore not performed.<BR/>
<BR/>COMPARISON 2. AMISULPRIDE versus RISPERIDONE<B> </B>
<BR/>Four studies provided data for the comparison amisulpride versus risperidone.<BR/>
<BR/>2.1Global state<BR/>2.1.1 No clinically significant response - as defined by original studies<BR/>The results of three studies were slightly heterogeneous (I<SUP>2 </SUP>54%). The combined analysis did not indicate a difference (n=586, 3 RCTs, RR 0.89 CI 0.67 to 1.20), but when (<LINK REF="STD-Hwang-2003" TYPE="STUDY">Hwang 2003</LINK>) was excluded there was a significant superiority of amisulpride (n=541, 2 RCTs, RR 0.80 CI 0.67 to 0.95, NNT 9 CI 5 to 50).</P>
<P>2.1.2 No clinically important change - as defined by original studies<BR/>Overall there was no significant difference (n=586, 3 RCTs, RR 0.89 CI 0.67 to 1.20), but some degree of heterogeneity (I<SUP>2 </SUP>54%). The short term study <LINK REF="STD-Peuskens-1999" TYPE="STUDY">Peuskens 1999</LINK> (n=86, RR 0.78 CI =0.56 to 1.09) and the medium term study <LINK REF="STD-Sechter-2002" TYPE="STUDY">Sechter 2002</LINK> (n=310, 1 RCT, RR 0.79 CI 0.61 to 1.01) indicated a slight but not significant benefit for the treatment group, which was not seen in the other short term study <LINK REF="STD-Hwang-2003" TYPE="STUDY">Hwang 2003</LINK> (n=24, RR 1.52, CI 0.85 to 2.72).<BR/>
</P>
<P>2.1.3 Relapse - medium term - as defined by original studies<BR/>There was no significant difference (n=173, 1 RCT, RR 0.67 CI 0.42 to 1.07).</P>
<P>2.2 Leaving the study early<BR/>There was no significant difference in terms of leaving the study early due to any reason (n= 586, 3 RCTs, RR 0.98 CI 0.65 to 1.47), due to adverse events (n=622, 4 RCTs, RR 1.08 CI 0.70- 1.65) or due to inefficacy of treatment (n=586, 3 RCTs, RR 0.69 CI 0.39 to 1.21).</P>
<P>2.3 Mental state<BR/>2.3.1 General - no clinically important change - less than 50% PANSS reduction<BR/>There was a trend in favour of amisulpride which did not reach conventional levels of statistical significance (n=310, 1 RCT, RR 0.81 CI 0.65 to 1.00).<BR/>
<BR/>2.3.2 General - no clinically important change - short term - less than 20% PANSS reduction<BR/>When this cutoff was applied there was no significant difference (n=48, 1 RCT, RR 1.45 CI 0.59 to 3.54).</P>
<P>2.3.3 General - average score at endpoint - PANSS total<BR/>There was no significant difference (n=291, 2 RCTs, MD 0.38 CI -4.57 to 5.33).</P>
<P>2.3.4 General - no clinically important change - less than 50% BPRS reduction<BR/>There was a significant difference favouring amisulpride (n=310, 1 RCT, RR 0.78 CI 0.62 to 0.98, NNT 8 CI 4 to 100).</P>
<P>2.3.5 General - no clinically important change - short term - less than 40% BPRS reduction<BR/>There was no significant difference (n=228, 1 RCT, RR 0.78, CI 0.56 to 1.09).<BR/>
<BR/>2.3.6 General - average score at endpoint - BPRS total<BR/>There was no significant difference (n=519, 3 RCTs, MD -0.68 CI -3.14 to 1.79) in the overall analysis, short term (n=275, 2 RCTs, MD -0.50 CI -5.53 to 4.54) and medium term (n=244, 1 RCT, MD -0.20 CI -3.68 to 3.28).</P>
<P>2.3.7 Positive symptoms - average score at endpoint - PANSS positive subscore<BR/>There was no significant difference (n=519, 3 RCTs, MD -0.03 CI -1.29 to 1.24) in the overall analysis, short term (n=275, 2 RCTs, MD -0.15 CI -2.47 to 2.17) and medium term (n=244, 1 RCT, MD 0.30 CI -1.51 to 2.11).<BR/>
<BR/>2.3.8 Positive symptoms - average score at endpoint - short term- BPRS positive subscore<BR/>There was no significant difference (n=228, 1 RCT, MD -0.50 CI -1.89 to 0.89).<BR/>
<BR/>2.3.9 Negative symptoms - average score at endpoint - PANSS negative subscore<BR/>There was no significant difference (n= 519, 3 RCTs, MD -1.00 CI -2.11 to 0.11) in the overall analysis, short term (n=275, 2 RCTs, MD -0.60 CI -2.92 to 1.72) and medium term (n=244, 1 RCT, MD -1.20 CI -2.61 to 0.21).<BR/>
<BR/>2.3.10 Negative Symptoms: SANS total score<BR/>There was no significant difference (n=244, 1 RCT, MD -2.70 CI -7.73 to 2.33).<BR/>
<BR/>2.4 General functioning<BR/>2.4.1 No clinically important change - less than 50% SOFAS total score reduction<BR/>There was a trend in favour of amisulpride which did not reach conventional levels of statistical significance (n=310, 1 RCT, RR 0.90 CI 0.80 to 1.01).<BR/>
<BR/>2.4.2 Average score at endpoint - SOFAS total score<BR/>There was no significant difference in the overall analysis (n=291, 2 RCTs, MD -2.31 CI -5.90 to 1.28), short term (n=47, 1 RCT, MD -1.10 CI -9.23 to 7.03) and medium term (n=244, 1 RCT, MD -2.60 CI -6.60 to 1.40).<BR/>
<BR/>2.5 Adverse effects<BR/>2.5.1 General - at least one adverse effect<BR/>There was no significant difference (n=622, 4 RCTs, RR 1.00 CI 0.91 to 1.11).</P>
<P>2.5.2 Death<BR/>Only one study provided data on death. There was no significant difference in terms of natural causes (n=310, RR 3.12 CI 0.13 to 75.94) or suicide (n=310, RR 2.08 CI 0.19 to 22.69).</P>
<P>2.5.3 Cardiac effects - QTc prolongation<BR/>Two studies (<LINK REF="STD-Hwang-2003" TYPE="STUDY">Hwang 2003</LINK>, <LINK REF="STD-Peuskens-1999" TYPE="STUDY">Peuskens 1999</LINK>) described no incidence of QTc prolongation.<BR/>
<BR/>2.5.4 Central nervous system - sedation<BR/>There was no significant difference between amisulpride and risperidone (n=310, 1 RCT, RR 0.69 CI 0.29 to 1.65).<BR/>
<BR/>2.5.5 Central nervous system - seizures<BR/>There were no seizures neither in the treatment nor in the control group.<BR/>
</P>
<P>2.5.6 Extrapyramidal effects<BR/>Extrapyramidal symptoms were reported as akathisia (n=586, 3 RCTs, RR 0.80 CI 0.58 to 1.11), extrapyramidal symptoms (n=228, 1 RCT, RR 1.13 CI 0.77 to 1.67), hyperkinesia (n=538, 2 RCTs, RR 1.33 CI 0.88 to 2.03), parkinsonism (n=538, 2 RCTs, RR 0.88 CI 0.51 to 1.51), rigor (n=276, 2 RCTs, RR 0.93 CI 0.23 to 3.77), tremor (n=586, 3 RCTs, RR 0.69 CI 0.31 to 1.51) and use of antiparkinson medication (n=586, 3 RCTs, RR 0.94 CI 0.64 to 1.38). There was no significant difference between amisulpride and risperidone.</P>
<P>2.5.7 Extrapyramidal side effects - scale measured<BR/>Continuous data on extrapyramidal side effects were examined with the AIMS (n=538, 2 RCTs, MD 0.08 CI -0.55 to 0.72) and the SAS scale ( n=538, 2 RCTs, MD -0.03 CI -0.13 to 0.06).There was no significant difference between amisulpride and risperidone.<BR/>
<BR/>2.5.8 Prolactin associated side effects<BR/>Prolactin associated side effects were reported as amenorrhoea (n=140, 1 RCT, RR 1.03 CI 0.07 to 16.13) and galactorrhoea (n=231, 2 RCTs, RR 1.45 CI 0.33 to 6.32). There was no significant difference. Fewer participants in the amisulpride group than in the risperidone group suffered from sexual dysfunction (n=307, 1 RCT, RR 0.08 CI 0.01 to 0.57, NNT 13 CI 8 to 33).</P>
<P>
<BR/>2.5.9 Metabolic - weight - number of participants with significant weight gain<BR/>Fewer participants in the amisulpride groups than in the risperidone groups gained weight (n=538, 2 RCTs, RR 0.57 CI 0.35 to 0.95, NNT 20 CI 9 to 50).</P>
<P>2.5.10 Metabolic - weight - change from baseline in kg<BR/>The mean weight gain in the amisulpride groups was smaller than in the risperidone groups (n=585, 3 RCTs, MD -0.99 CI -1.61 to -0.37).</P>
<P>2.6 Publication bias:<BR/>Due to small number of included studies a funnel plot analysis was not performed.</P>
<P>2.7 Investigation for heterogeneity and sensitivity analysis:<BR/>The reasons for the preplanned sensitivity analysis did not apply and were therefore not performed.</P>
<P>COMPARISON 3. AMISULPRIDE versus ZIPRASIDONE - all data short term<BR/>Only one study (<LINK REF="STD-Olie-2006" TYPE="STUDY">Olie 2006</LINK>) provided data for the comparison amisulpride versus ziprasidone.</P>
<P>3.1 Global state<BR/>3.1.1 No clinically significant response - as defined by the original studies<BR/>There was no significant difference (n=123, 1 RCT, RR 0.95 CI 0.84 to 1.08).</P>
<P>3.1.2. No clinically important change - as defined by the original studies<BR/>There was no significant difference (n=123, 1 RCT, RR 0.90 CI 0.66 to 1.22).</P>
<P>3.2 Leaving the study early<BR/>There was no significant difference in the number of participants leaving the study early due to any reason (n=123, 1 RCT, RR 0.69 CI 0.37 to 1.28) or adverse effects (n= 123, 1 RCT, RR 1.27 CI 0.30 to 5.44). However, significantly more participants in the ziprasidone group left the study early due to inefficacy of treatment (n=123, 1 RCT, RR 0.21 CI 0.05 to 0.94, NNT 8 CI 5 to 50).<BR/>
<BR/>3.3 Mental State:<BR/>3.3.1 General - average score at endpoint - PANSS total<BR/>There was no significant difference (n=123, 1 RCT, MD - 2.70 CI -9.04 to 3.64).<BR/>
<BR/>3.3.2 General - average score at endpoint - BPRS total<BR/>There was no significant difference (n=123, 1 RCT, MD - 2.10 CI -5.72 to 1.52).<BR/>
<BR/>3.3.3 Negative symptoms - no clinically important change - less than 50% PANSS negative reduction<BR/>There was no significant difference (n=123, 1 RCT, RR 0.95 CI 0.84 to 1.08).<BR/>
<BR/>3.3.4 Negative symptoms - average score at endpoint - PANSS negative subscore<BR/>There was no significant difference (n=123, 1 RCT, MD -0.80 CI -3.00 to 1.40).<BR/>
<BR/>3.4 Adverse effects<BR/>3.4.1 General - at least one adverse effect<BR/>There was no significant difference (n=123, 1 RCT, RR 0.90 CI 0.66 to 1.22).</P>
<P>3.4.2 Cardiac effects - QTc prolongation<BR/>There was no occurrence of QTC prolongation in either group.</P>
<P>3.4.3 Central nervous system - sedation<BR/>There was no significant difference (n=123, 1 RCT, RR 2.86 CI 0.60 to 13.61).<BR/>
</P>
<P>3.4.4 Extrapyramidal effects<BR/>Extrapyramidal side effects were described as akathisia (n=123, 1 RCT, RR 0.63, CI 0.11 to 3.67), parkinsonism (n=123, RR 0.16 CI 0.02 to 1.28) and use of antiparkinson medication (n=123, 1 RCT, RR 0.59, CI 0.33 to 1.07). There was no significant difference between amisulpride and ziprasidone.</P>
<P>3.4.6 Metabolic - weight - gain of 7% or more of total body weight<BR/>There was no significant difference (n=123, 1 RCT, RR 2.10 CI 0.77 to 5.67)</P>
<P>3.5 Publication bias<BR/>Due to small number of included studies a funnel plot analysis was not performed.</P>
<P>3.6 Investigation of heterogeneity and sensitivity analysis<BR/>Whether the amisulpride dose (maximum 200mg/day) in the single study available (<LINK REF="STD-Olie-2006" TYPE="STUDY">Olie 2006</LINK>) was appropriate can be questioned. The study was conducted in participants with predominant negative symptoms in which amisulpride doses between 50 and 300mg/day have been shown to be effective (<LINK REF="REF-Leucht-2002" TYPE="REFERENCE">Leucht 2002</LINK>). Nevertheless, ziprasidone was given in full dose (maximum 160mg/day) and the degree of positive symptoms of the participants is unclear because it has not been reported. If this sensitivity analysis were performed, not a single study would be available.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-11-02 13:59:02 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2009-11-02 13:59:02 +0000" MODIFIED_BY="[Empty name]">
<P>We only identified 10 studies on three out of eight possible comparisons of amisulpride with other second generation antipsychotic drugs. The interpretation of the comparison of amisulpride with ziprasidone is especially difficult, because it is based on a single study. A considerable overall premature discontinuation rate of 35% calls the validity of the results into question. Furthermore, the longest studies lasted only six months. Long term data are not available which is far from ideal for judging the relative tolerability and efficacy of these compounds in a chronic disease like schizophrenia. Another aspect is the high proportion of industry sponsored trials. Nine out of ten studies were industry sponsored, and in the remaining one the sponsor is unclear. It has been shown in a blinded analysis of abstracts, that pharmaceutical companies emphasise the positive aspects of their compounds (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>). Systematic reviews can in part account for this effect by objectively summarising the data, but they can not cope with intentional omission of outcomes. Indeed, reporting was incomplete. For example, usable data on increase in prolactin levels, a frequent problem of amisulpride, were not available.</P>
<P>1.<B> </B>COMPARISON 1: AMISULPRIDE versus OLANZAPINE<BR/>Most of the studies identified were included in this comparison (N=5, n=804). The number of participants leaving the studies early was considerable (37.2%), questioning the validity of the findings. One study provided hardly any data (<LINK REF="STD-Bai-2005" TYPE="STUDY">Bai 2005</LINK>). In our opinion five studies with 800 participants is not sufficient considering the high numbers of people with schizophrenia using either medication world-wide.</P>
<P>1.1 Global state, general and specific mental state<BR/>There were no statistically significant differences in any efficacy related outcome. The use of complex and difficult to understand rating scales such as the PANSS or the BPRS in addition to the small number of trials and participants limit the interpretation. Nevertheless, the available data do not support an obvious preference for either substance.<BR/>
<BR/>1.2 Leaving the study early<BR/>All studies reported on 'leaving the study early due to any reason' which can be considered as a composite measure of acceptability of treatment. The acceptability of both compounds seems to be similar, at least in the context of clinical trials.<BR/>
<BR/>1.3 Quality of life, general functioning<BR/>Only two studies provided data on this important outcome using the SOFAS and QLS scales. There was no apparent difference between amisulpride and olanzapine.</P>
<P>1.4 Cognition<BR/>Only one study reported on cognitive functioning and found no significant difference (<LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK>). The lack of more data is unfortunate because cognitive functioning may be very important for a person's general overall functioning including the ability to work.</P>
<P>1.5 Adverse effects<BR/>Reporting on adverse effects was incomplete. Only two studies <LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK> and <LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK> reported on extrapyramidal symptoms, cardiac effects, effects on cholesterol, glucose levels and prolactin associated side effects, weight gain, white blood cell count, sedation or seizures and death. Among the analysed side effects only the difference of glucose change from baseline and weight change (2.1 kg more in the olanzapine groups) reached statistical significance favouring amisulpride. These metabolic effects are very serious issues. They may make amisulpride more recommendable than olanzapine for those at risk of developing a metabolic syndrome.</P>
<P>2. COMPARISON 2: AMISULPRIDE versus RISPERIDONE<BR/>Four studies with 622 people randomised and a leaving the study rate of 33.2% could be included in this comparison. Again, more data are needed for firm conclusions.<BR/>
<BR/>2.1 Global state, general and specific mental state:<BR/>Overall there was no clear efficacy difference between amisulpride and risperidone. There was a significant superiority of amisulpride in terms of 50% BPRS reduction. However, this result was based on only one trial and may have well occurred by chance alone given the high number of statistical tests applied (<LINK REF="STD-Sechter-2002" TYPE="STUDY">Sechter 2002</LINK>).</P>
<P>2.2 Leaving the study early<BR/>There was no significant difference in premature study discontinuations.<BR/>The acceptability of both compounds seems to be similar, at least in the context of clinical trials.</P>
<P>2.3 General functioning<BR/>A single study using the SOFAS scale reported on social functioning and found no difference between amisulpride and risperidone. Pragmatic studies that are conducted in situations that are more similar to routine care are needed to address this important outcome.</P>
<P>2.4 Adverse effects<BR/>There were some data on extrapyramidal side effects, cardiac effects, prolactin associated side effects, sedation, seizures and death. Besides the reporting on sexual dysfunction which indicated a benefit for amisulpride, the only adverse event showing a significant difference was weight gain which was 1kg more in the risperidone group. This difference was found in short to medium term studies. It may well be that the difference would be more pronounced in the long term, but longer studies are needed to verify this assumption. Nevertheless, if metabolic issues are a concern, amisulpride may be a better choice than risperidone.</P>
<P>3. COMAPRISON 3: AMISULPRIDE versus ZIPRASIDONE<BR/>Only one study (<LINK REF="STD-Olie-2006" TYPE="STUDY">Olie 2006</LINK>) with 123 randomised people and a drop out rate of 25% fell in this category. This number of randomised participants is even lower than in the other two comparisons. The study was conducted in participants with predominant negative symptoms, which may explain that only low doses of amisulpride (100-200mg/day) were used. Indeed, it has been shown that low amisulpride doses are effective in such people (<LINK REF="REF-Leucht-2002" TYPE="REFERENCE">Leucht 2002</LINK>). Nevertheless, it can be questioned whether the use of the full dose range of ziprasidone (80-160 mg/day) is a fair comparison. We highlight that the degree of positive symptoms at baseline has not been indicated making it impossible to judge whether the low amisulpride doses were really appropriate.</P>
<P>3.1 Global state, general and specific mental state<BR/>There was no difference in global state, general mental state and negative symptoms. However, results on positive symptoms have not been reported which is surprising because the participants were rated with PANSS scale which contains a subscale for positive symptoms. This may be a typical example of reporting bias in industry sponsored antipsychotic drug trials (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>).<BR/>
</P>
<P>3.2 Leaving the study early<BR/>There was no difference in premature study discontinuations due to any reason. Therefore, in the short term both agents may be similarly acceptable for people with schizophrenia, at least in the context of a clinical trial. On the other hand significantly more participants in the ziprasidone group left the study early due to inefficacy of treatment. Amisulpride may thus be more effective than ziprasidone for people with chronic schizophrenia and predominant negative symptoms. As there was no difference in the number of participants leaving the studies early due to adverse events, the overall tolerability of amisulpride and ziprasidone may be similar.</P>
<P>3.3 Adverse effects<BR/>Adverse effects reporting on at least one adverse effect, extrapyramidal side effects, QTc prolongation, sedation and weight gain revealed no statistically significant differences between groups suggesting that the tolerability of both compounds may be similar. Nevertheless, these results are based on a small, short term study which was underpowered to detect rare but serious effects such as seizures, agranulocytosis or sudden death.<BR/>
</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-10-28 07:53:33 +0000" MODIFIED_BY="[Empty name]">
<P>There is only randomised evidence for only three out of eight possible comparisons of amisulpride with other second generation antipsychotic drugs. For most comparisons eg. amisulpride versus aripiprazole, clozapine, quetiapine, sertindole and zotepine not a single study was identified and overall evidence of amisulpiride's effectiveness compared with other newer antipsychotics is very incomplete. In the available studies the side effect reporting was especially incomplete. In particular, prolactin increase, a typical side effect of amisulpride, has not been reported. In terms of applicability of the evidence we highlight that all of the included studies were "efficacy" studies. Large and simple, pragmatic, effectiveness studies are not available, limiting external validity.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-07-24 13:09:48 +0100" MODIFIED_BY="[Empty name]">
<P>Except for one (<LINK REF="STD-Bai-2005" TYPE="STUDY">Bai 2005</LINK>), all studies were randomised and double-blind, but details rarely presented. Therefore in most of the studies it is unclear whether randomisation and blinding were really appropriately done. Furthermore often high rates of participants leaving the studies prematurely (five studies reported rates of more than 30%) and the lack of long term studies limit the overall quality. Additionally nine of the ten included trials were industry sponsored and in one a potential dose related bias could not be excluded. These factors limit the overall quality of the evidence.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-07-24 13:09:25 +0100" MODIFIED_BY="[Empty name]">
<P>We are not aware of obvious flaws in our review process. Due to small number of included studies we did not perform a funnel plot<BR/>analysis.<BR/>
</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2008-12-12 13:09:38 +0000" MODIFIED_BY="[Empty name]">
<P>A previous Cochrane review compared the effects of amisulpride with those of any other antipsychotic drug in schizophrenia (<LINK REF="REF-Mota-Neto-2002" TYPE="REFERENCE">Mota Neto 2002</LINK>). The authors found no difference between amisulpride and risperidone, but at the time when the review was conducted only one study was available.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-01-14 12:12:33 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-09-11 13:28:59 +0100" MODIFIED_BY="[Empty name]">
<P>1. For people with schizophrenia and clinicians<BR/>For people with schizophrenia it is important to know that amisulpride may be similarly effective as olanzapine or risperidone, and possibly somewhat more effective than ziprasidone. In terms of tolerability it seems to cause less weight gain than olanzapine and risperidone, and less glucose increase than olanzapine. Nevertheless, people with schizophrenia should also be aware that the available evidence is limited, and that the studies have not reported on other important side effects of amisulpride such as prolactin increase.</P>
<P>2. For clinicians<BR/>Clinicians should know that randomised evidence of the effects of amisulpride compared with other second generation antipsychotic drugs is only available for olanzapine, risperidone and ziprasidone. Even this evidence is limited and more studies are needed to clarify the role of amisulpride compared with other second generation antipsychotic drugs.</P>
<P>3. For managers/policy makers<BR/>Hardly any data are available that are relevant for policy makers such as service utilisation or functioning in society. We are thus unable to make any recommendations for managers or policy makers. Nevertheless, it may be important to know for them that amisulpride has lost its patent and is therefore available as a generic in many countries which may be cheaper than other second generation antipsychotic drugs.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-01-14 12:12:33 +0000" MODIFIED_BY="[Empty name]">
<P>1. General<BR/>Outcome reporting remains insufficient in antipsychotic drug trials. Strict adherence to the CONSORT statement (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>) would make such studies much more informative.</P>
<P>2. Specific<BR/>There is a lot of room for further randomised controlled trials comparing amisulpride with other second generation antipsychotics. Comparisons with ariprazole, clozapine, quetiapine, sertindole and zotepine are currently missing. <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> we make a suggestion as to how such a study may look like.</P>
<P>3. Note: the 47 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-01-15 17:38:22 +0000" MODIFIED_BY="[Empty name]">
<P>We thank the editorial base of the Cochrane Schizophrenia Group for its assistance. We also thank the following authors for providing additional information on their studies: T.Hwang, A.Mortimer, J.Peuskens, B.Quednow, D.Sechter and M.Wagner.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-10-28 07:57:03 +0000" MODIFIED_BY="[Empty name]">
<P>Katja Komossa: none.<BR/>Stefan Leucht: received speaker/consultancy honoria from Sanofi-Aventis, BMS, Eli Lilly, Janssen, Lundbeck and Pfizer. He received research support from Sanofi-Aventis and Eli Lilly. <BR/>Werner Kissling: received speaker or consultancy honoraria from SanofiAventis, BMS, Lilly, Janssen, Lundbeck, Bayer and Pfizer.<BR/>Christine Rummel: received lecture honoraria and travel grants to attend scientific meetings from AstraZeneca, Janssen-Cilag, Eli Lilly and Pfizer.<BR/>Heike Hunger: none.<BR/>Franziska Schmid: none.<BR/>Sandra Schwarz: none.<BR/>Joaquim Silveira da Mota Neto: none.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-08-19 13:27:12 +0100" MODIFIED_BY="[Empty name]">
<P>Katja Komossa: protocol development, searching, study selection, data extraction, report writing.<BR/>Christine Rummel: protocol development, searching, study selection, data extraction.<BR/>Stefan Leucht: protocol development, searching, study selection, data extraction, report writing.<BR/>Werner Kissling: protocol development.<BR/>Heike Hunger: helped with data extraction and writing.<BR/>Franziska Schmid: helped with data extraction and writing.<BR/>Sandra Schwarz: helped with data extraction and writing.<BR/>Joaquim Silveira da Mota Neto: protocol development.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-12-12 13:29:41 +0000" MODIFIED_BY="[Empty name]">
<P>The review was slightly adapted to new functions available in Review Manager 5, namely the risk of bias table.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-07-30 10:35:01 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-07-30 10:34:41 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-08-20 14:39:08 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bai-2005" MODIFIED="2009-07-24 14:36:49 +0100" MODIFIED_BY="[Empty name]" NAME="Bai 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-24 14:36:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bai YM, Ping LY, Lin CC, Wang YC, Liou YJ, Wu BJ, Chen TT, Chen JY, Lin CY, Chou P</AU>
<TI>Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24-week randomized, single-blind, controlled study</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>S473</PG>
<IDENTIFIERS MODIFIED="2008-12-16 16:27:00 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hwang-2003" MODIFIED="2008-12-12 15:11:47 +0000" MODIFIED_BY="[Empty name]" NAME="Hwang 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-12-12 15:11:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hwang TJ, Lee S-M, Sun HJ, Lin H-N, Tsai S-J, Lee Y-C, Chen Y-S</AU>
<TI>Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan</TI>
<SO>Journal of the Formosan Medical Association</SO>
<YR>2003</YR>
<VL>102</VL>
<NO>1</NO>
<PG>30-6</PG>
<CY>Taiwan</CY>
<IDENTIFIERS MODIFIED="2008-12-12 15:11:47 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lecrubier-2006" MODIFIED="2009-07-24 14:38:41 +0100" MODIFIED_BY="[Empty name]" NAME="Lecrubier 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-24 14:38:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S</AU>
<TI>The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2006</YR>
<VL>114</VL>
<PG>319-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00f6_ller-2005" MODIFIED="2009-07-24 14:37:56 +0100" MODIFIED_BY="[Empty name]" NAME="Möller 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-24 14:37:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Möller HJ, Riedel M, Eich FX</AU>
<TI>A randomised, double-blind clinical trial comparing treatment with amisulpride or risperidone for six weeks in elderly patients with schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>S511</PG>
<IDENTIFIERS MODIFIED="2008-12-16 16:28:53 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mortimer-2004" MODIFIED="2009-02-05 17:21:08 +0000" MODIFIED_BY="[Empty name]" NAME="Mortimer 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-16 16:28:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mortimer A, Martin S, Loo H, Peuskens J, SOLIANOL Sudy Group</AU>
<TI>A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>2</NO>
<PG>63-9</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2008-12-16 16:28:11 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-05 17:20:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mortimer A</AU>
<TI>The European First Episode Schizophrenia Trial: comparison of outcome in first episode schizophrenia with different low dose antipsychotic regimens (EUFEST)</TI>
<SO>National Research Register</SO>
<YR>2003</YR>
<VL>1</VL>
<IDENTIFIERS MODIFIED="2009-02-05 17:20:53 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-05 17:21:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Singh V</AU>
<TI>A six month international controlled trial of the therapeutic activity of amisulpride 200 to 800 mg/day verses olanzapine 5 to 20 mg/day in patients with schizophrenic disorders</TI>
<SO>National Research Register</SO>
<YR>2001</YR>
<VL>1</VL>
<IDENTIFIERS MODIFIED="2009-02-05 17:21:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olie-2006" MODIFIED="2008-12-16 16:30:27 +0000" MODIFIED_BY="[Empty name]" NAME="Olie 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-16 16:29:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Olie J-P, Spina E, Murray S, Yang R</AU>
<TI>Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>3</NO>
<PG>143-51</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2008-12-16 16:29:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-16 16:30:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olie JP, Spina E, Benattia I</AU>
<TI>Ziprasidone vs amisulpride for negative symptoms of schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>Suppl 3</NO>
<PG>S313</PG>
<IDENTIFIERS MODIFIED="2008-12-16 16:30:27 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peuskens-1999" MODIFIED="2009-07-24 14:38:30 +0100" MODIFIED_BY="[Empty name]" NAME="Peuskens 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-07-24 14:38:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peuskens J, Bech P, Möller H-J, Bale R, Fleurot O, Rein W</AU>
<TI>Amisulpride vs. risperidone in the treatment of acute exacerations of schizophrenia</TI>
<SO>Psychiatry Research</SO>
<YR>1999</YR>
<VL>88</VL>
<PG>107-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sechter-2002" MODIFIED="2009-08-20 14:39:08 +0100" MODIFIED_BY="[Empty name]" NAME="Sechter 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-24 21:57:19 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;check&lt;/p&gt;" NOTES_MODIFIED="2009-07-24 21:57:19 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nicholls CJ, Hale AS, Freemantle N</AU>
<TI>Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia</TI>
<SO>Journal of Drug Assessment</SO>
<YR>2003</YR>
<VL>6</VL>
<NO>2</NO>
<PG>79-89</PG>
<IDENTIFIERS MODIFIED="2008-12-16 16:30:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-24 14:50:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y</AU>
<TI>Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>27</VL>
<PG>1071-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanelle-2006" MODIFIED="2009-07-24 14:50:46 +0100" MODIFIED_BY="[Empty name]" NAME="Vanelle 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-24 14:50:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vanelle JM, Douki S</AU>
<TI>A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression</TI>
<SO>European Psychiatry</SO>
<YR>2006</YR>
<VL>21</VL>
<PG>523-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-24 14:50:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanelle JM, Douki S</AU>
<TI>Metabolic control in patients with comorbid schizophrenia and depression treated with amisulpride or olanzapine</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>S284</PG>
<IDENTIFIERS MODIFIED="2008-12-16 16:29:59 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wagner-2005" MODIFIED="2008-12-16 16:30:16 +0000" MODIFIED_BY="[Empty name]" NAME="Wagner 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-16 16:30:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quednow BB, Wagner M, Westheide J, Beckmann K, Bliesener N, Maier W, Kuhn KU</AU>
<TI>Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine</TI>
<SO>Biological Psychiatry</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>6</NO>
<PG>536-45</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-16 16:30:16 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-16 16:30:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kuhn K-U</AU>
<TI>Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>2</NO>
<PG>381-90</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-16 16:30:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-08-20 14:28:48 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Baloescu-2006" MODIFIED="2008-12-16 16:31:15 +0000" MODIFIED_BY="[Empty name]" NAME="Baloescu 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-16 16:31:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baloescu A, Vasile D, Gheorghe MD, Grigorescu G</AU>
<TI>Side effects of atypical antipsychotics - prediction factor for compliance</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S403</PG>
<IDENTIFIERS MODIFIED="2008-12-16 16:31:15 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beuzen-2005" MODIFIED="2009-07-24 14:58:32 +0100" MODIFIED_BY="[Empty name]" NAME="Beuzen 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-24 14:58:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Beuzen JN, Pans M, Modell S, Hagens P, McQuade R, Iwamoto T, Carson W</AU>
<TI>Naturalistic study of aripiprazole treatment</TI>
<SO>Proceedings of the XIII World Congress of Psychiatry; 2005 Sept 10-15th; Cairo, Egypt</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2008-12-16 16:31:24 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fleischhacker-2005" MODIFIED="2008-12-16 16:31:33 +0000" MODIFIED_BY="[Empty name]" NAME="Fleischhacker 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-16 16:31:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fleischhacker WW, Keet IPM, Kahn RS</AU>
<TI>The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>78</VL>
<NO>2-3</NO>
<PG>147-56</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2008-12-16 16:31:33 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giudicelli-1999" MODIFIED="2008-12-16 16:31:40 +0000" MODIFIED_BY="[Empty name]" NAME="Giudicelli 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-12-16 16:31:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giudicelli A, Rein W</AU>
<TI>Social adaptation in schizophrenic patients: experience with amisulpride</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>S275</PG>
<IDENTIFIERS MODIFIED="2008-12-16 16:31:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelemen-2006" MODIFIED="2008-12-16 16:31:47 +0000" MODIFIED_BY="[Empty name]" NAME="Kelemen 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-16 16:31:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelemen O, Nagy O, Máttyássy A, Kiss I, Janka Z, Kéri S</AU>
<TI>Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia?</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S430</PG>
<IDENTIFIERS MODIFIED="2008-12-16 16:31:47 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00f6_ller-1997" MODIFIED="2009-07-24 15:01:10 +0100" MODIFIED_BY="[Empty name]" NAME="Möller 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-07-24 15:01:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Möller HJ</AU>
<TI>Amisulpride A non conventional antipsychotic</TI>
<SO>Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22-27; Nice, France</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moritz-2002" MODIFIED="2008-09-18 09:24:22 +0100" MODIFIED_BY="[Empty name]" NAME="Moritz 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-09-18 09:24:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moritz S, Andresen B, Perro C, PERSIST Study Group, Schickel M, Krausz M, Naber D</AU>
<TI>Neurocognitive performance in first-episode and chronic schizophrenic patients</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>2002</YR>
<VL>252</VL>
<PG>33-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oli_x00e9_-2001" MODIFIED="2008-12-16 16:32:31 +0000" MODIFIED_BY="[Empty name]" NAME="Olié 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-12-16 16:32:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olié JP, Stalla-Bourdillon A</AU>
<TI>Social functioning and quality of life in schizophrenia: experience with amisulpride</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>3</NO>
<PG>261</PG>
<IDENTIFIERS MODIFIED="2008-12-16 16:32:31 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oliveira_x002d_Castro-1991" MODIFIED="2008-12-16 16:32:24 +0000" MODIFIED_BY="[Empty name]" NAME="Oliveira-Castro 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-12-16 16:32:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oliveira-Castro J, Duval F, Makrani MC, Crocq M, Macher JP</AU>
<TI>Neuroendocrine effects of typical and atypical antipsychotic agents in schizophrenic patients</TI>
<TO>Effets neuroendocriniens d'agents antipsychotiques typiques et atypiques chez des patients schizophrenes</TO>
<SO>Encephale</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>2</NO>
<PG>100</PG>
<IDENTIFIERS MODIFIED="2008-12-16 16:32:24 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rettenbacher-2004" MODIFIED="2008-12-16 16:32:40 +0000" MODIFIED_BY="[Empty name]" NAME="Rettenbacher 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-16 16:32:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rettenbacher Ma, Baumgartner S, Ebenbichler C, Edlinger M, Hofer a, Hummer M, Kemmler G, Lechleitner M, Fleischhacker W</AU>
<TI>Alterations of glucose metabolism under treatment with clozapine vs. amisulpride</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>191</PG>
<CY>Po Box 211, 1000 Ae Amsterdam, Netherlands</CY>
<IDENTIFIERS MODIFIED="2008-12-16 16:32:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ryu-2006" MODIFIED="2008-12-16 16:32:47 +0000" MODIFIED_BY="[Empty name]" NAME="Ryu 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-16 16:32:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ryu SH, Jang WS, Cho EY, Kim SK, Lee DS, Hong KS</AU>
<TI>Association of leptin gene polymorphism with antipsychotic drug-induced weight gain</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S419</PG>
<IDENTIFIERS MODIFIED="2008-12-16 16:32:47 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yagdiran-2000" MODIFIED="2008-12-16 16:32:57 +0000" MODIFIED_BY="[Empty name]" NAME="Yagdiran 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-12-16 16:32:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yagdiran O, Krausz M, =PERSIST</AU>
<TI>Depressive symptoms under atypical neuroleptic treatment in schizophrenia</TI>
<SO>Nervenarzt</SO>
<YR>2000</YR>
<VL>71</VL>
<NO>Suppl 1</NO>
<PG>S135-S136</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2008-12-16 16:32:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-07-30 10:34:41 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anon-2005" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="Anon 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Anon</AU>
<TI>Risperdal consta clinical protocol RIS-SCH-4055</TI>
<SO>Clinical Trial Agreement For Pharmaceutical Industry Sponsored Research In NHS Trust</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Assion-2008" MODIFIED="2012-07-30 10:11:21 +0100" MODIFIED_BY="[Empty name]" NAME="Assion 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-07-30 10:11:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G</AU>
<TI>Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2008</YR>
<VL>41</VL>
<NO>1</NO>
<PG>24-8</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2012-07-26 12:49:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18203048"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beuzen-2005a" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="Beuzen 2005a" YEAR="2005">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Beuzen J-N, Pans M, Modell S, Hagens P, McQuade R, Iwamato T, et al</AU>
<TI>Broad effectiveness trial with aripiprazole in Europe Eu-Beta</TI>
<SO>Proceedings of the 13th Congress of the Association of European Psychiatrists; 2005 Apr 2-6; Munich, Germany</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beuzen-2006" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="Beuzen 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Beuzen J-N, Schirr K, Pans M, Hagens P, Kostic D, Carson W, et al</AU>
<TI>Effectiveness of aripiprazole in a naturalistic setting: a European multicenter study</TI>
<SO>Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bhowmick-2010" MODIFIED="2012-07-30 10:08:58 +0100" MODIFIED_BY="[Empty name]" NAME="Bhowmick 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-07-30 10:08:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bhowmick S, Hazra A, Ghosh M</AU>
<TI>Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>2010</YR>
<VL>44</VL>
<NO>3</NO>
<PG>237-42</PG>
<IDENTIFIERS MODIFIED="2012-07-26 12:49:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="20050717"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Birchwood-2005" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="Birchwood 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Birchwood M</AU>
<TI>Untitled</TI>
<SO>Psychological Medicine</SO>
<YR>2005</YR>
<VL>35</VL>
<NO>1</NO>
<PG>152</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dazzan-2011" MODIFIED="2012-07-30 10:11:51 +0100" MODIFIED_BY="[Empty name]" NAME="Dazzan 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-07-30 10:11:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Dazzan P</AU>
<TI>Optimization of treatment and management of schizophrenia in europe study - double blind (amisulpride or olanzapine) - optimise2</TI>
<SO>http://public.ukcrn.org.uk/</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DRKS00003603" MODIFIED="2012-07-26 13:42:51 +0100" MODIFIED_BY="[Empty name]" NAME="DRKS00003603" YEAR="2012">
<REFERENCE MODIFIED="2012-07-26 13:42:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>DRKS00003603</AU>
<TI>A randomized double-blind controlled trial to assess the benefits of olanzapine and amisulpride combination treatment in acutely ill schizophrenia patients.-combine</TI>
<SO>http://apps.who.int/</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eufest-2005" MODIFIED="2012-07-30 10:24:33 +0100" MODIFIED_BY="[Empty name]" NAME="Eufest 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-26 13:01:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boter H, Derks EM, Fleischhacker WW, Davidson M, Kahn RS, Grp ES</AU>
<TI>Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST)</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2010</YR>
<VL>71</VL>
<NO>1</NO>
<PG>58-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19852905"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-30 10:08:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, et al</AU>
<TI>Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST)</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>115</VL>
<NO>2-3</NO>
<PG>97-103</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19819114"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 12:52:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Boter H</AU>
<TI>The European First Episode Schizophrenia Trial (EUFEST): comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens</TI>
<SO>http://www.controlled-trials.com</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-30 10:08:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, et al</AU>
<TI>"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)": correction</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>166</VL>
<NO>6</NO>
<PG>731</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-30 10:08:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, et al</AU>
<TI>Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>166</VL>
<NO>6</NO>
<PG>675-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19369319"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-30 10:08:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaebel W, Riesbeck M, von Wilmsdorff M, Burns T, Derks EM, Kahn RS, et al</AU>
<TI>Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST)</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>5</NO>
<PG>310-6</PG>
<CY>Netherlands</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 13:05:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galderisi S, Davidson M, Kahn RS, Mucci A, Boter H, Gheorghe MD, et al</AU>
<TI>Correlates of cognitive impairment in first episode schizophrenia: The eufest study</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>115</VL>
<NO>2-3</NO>
<PG>104-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19822407"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-30 10:08:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahn R, Boter H</AU>
<TI>EUFEST: A randomized pragmatic long-term trial in first episode schizophrenia</TI>
<SO>European Psychiatry</SO>
<YR>2005</YR>
<VL>20</VL>
<PG>S56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 12:57:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kahn R, Fleischhacker WW, Karayal O, Siu C, Pappadopulos E</AU>
<TI>EUFEST: the effects of first and second generation antipsychotics on metabolic and cardiovascular risk factors</TI>
<SO>Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-30 10:12:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahn R</AU>
<TI>Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial</TI>
<SO>Early Intervention in Psychiatry</SO>
<YR>2008</YR>
<VL>2</VL>
<NO>Suppl 1</NO>
<PG>A24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-30 10:12:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al</AU>
<TI>Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>371</VL>
<NO>9618</NO>
<PG>1085-97</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18374841"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-30 10:16:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kahn RS</AU>
<TI>Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial</TI>
<SO>Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-30 10:17:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kahn RS</AU>
<TI>Effectiveness of second-generation antipsychotics in first episode schizophrenia: the EUFEST study</TI>
<SO>Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 13:04:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malik P, Kemmler G, Hummer M, Riecher-Roessler A, Kahn RS, Fleischhacker WW, et al</AU>
<TI>Sexual dysfunction in first-episode schizophrenia patients results from european first episode schizophrenia trial</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>3</NO>
<PG>274-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="BIOSIS:PREV201100315033"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-30 10:17:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NTR25</AU>
<TI>The european first episode schizophrenia trial (eufest): Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens</TI>
<SO>http://www.trialregister.nl/trialreg/index.asp</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 13:03:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>No authorshipindicated</AU>
<TI>Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder</TI>
<SO>African Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>1</NO>
<PG>82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-30 10:19:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabe-Jablonska J, Pawelczyk T, Jarema M, Olajossy M, Rybakowski J</AU>
<TI>Polish patients of the eufest study after 1 year antipsychotic treatment: Drug discontinuation and metabolic syndrome parameters</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2010</YR>
<VL>1</VL>
<PG>467</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-30 10:24:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Rybakowski JK, Vansteelandt K, Szafranski T, Thys E, Jarema M, Wolfgang Fleischhacker W, et al</AU>
<TI>Treatment of depression in first episode of schizophrenia: Results from eufest</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2012 May 22 [Epub ahead of print]</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 13:03:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szafranski T, Jarema M, Olajossy M, Rabe-Jablons J, Rybakowski JK</AU>
<TI>Depressive symptoms in the first episode of schizophrenia - analysis of polish results of the eufest study</TI>
<SO>Schizophrenia Research</SO>
<YR>2010</YR>
<VL>117</VL>
<NO>2-3</NO>
<PG>503</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="ISI:000276936801329"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 13:05:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, et al</AU>
<TI>Efficacy of antipsychotic drugs against hostility in the european first-episode schizophrenia trial (eufest)</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2011</YR>
<VL>72</VL>
<NO>7</NO>
<PG>955-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21824456"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fleischhacker-2009" MODIFIED="2012-07-30 10:25:31 +0100" MODIFIED_BY="[Empty name]" NAME="Fleischhacker 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-07-30 10:25:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fleischhacker WW</AU>
<TI>Safety and tolerability of first and second generation antipsychotics</TI>
<SO>Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Genc-2007" MODIFIED="2012-07-30 10:08:58 +0100" MODIFIED_BY="[Empty name]" NAME="Genc 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-07-30 10:08:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Genc Y, Taner E, Candansayar S</AU>
<TI>Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study</TI>
<SO>Advances in Therapy</SO>
<YR>2007</YR>
<VL>24</VL>
<NO>1</NO>
<PG>1-13</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2012-07-26 12:49:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17526456"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goder-2008" MODIFIED="2012-07-30 10:25:50 +0100" MODIFIED_BY="[Empty name]" NAME="Goder 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-07-30 10:25:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goder R, Fritzer G, Gottwald B, Lippmann B, Seeck-Hirschner M, Serafin I, et al</AU>
<TI>Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2008</YR>
<VL>3</VL>
<PG>92-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haro-2009" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="Haro 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Haro J</AU>
<TI>Amisulpride and quetiapine for schizophrenia</TI>
<SO>Stanley Foundation Research Programs</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN68824876" MODIFIED="2012-07-27 14:23:42 +0100" MODIFIED_BY="[Empty name]" NAME="ISRCTN68824876" YEAR="2010">
<REFERENCE MODIFIED="2012-07-27 14:23:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN68824876</AU>
<TI>Amisulpride augmentation in clozapine-unresponsive schizophrenia</TI>
<SO>http://www.controlled-trials.com</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-2006" MODIFIED="2012-07-30 10:08:58 +0100" MODIFIED_BY="[Empty name]" NAME="Jones 2006" YEAR="2010">
<REFERENCE MODIFIED="2012-07-30 10:08:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barnes T, Jones P, Dunn G, Hayhurst K, Drake R, Lewis S</AU>
<TI>Large effect of baseline treatment with long acting antipsychotic drugs on randomized treatment outcomes</TI>
<SO>Schizophrenia Research</SO>
<YR>2010</YR>
<VL>117</VL>
<NO>2-3</NO>
<PG>380</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 13:34:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peluso MJ, Lewis SW, Barnes TRE, Jones PB</AU>
<TI>Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2012</YR>
<VL>200</VL>
<NO>5</NO>
<PG>387-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="BIOSIS:PREV201200441780"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joyce-2004" MODIFIED="2012-07-30 10:10:45 +0100" MODIFIED_BY="[Empty name]" NAME="Joyce 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-07-30 10:10:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joyce E, Rein W, Fleurot O</AU>
<TI>Effect of amisulpride and olanzapine on neuropsychological performance in schizophrenic patients: a sub-analysis of a double-blind, randomized clinical trial</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>7</VL>
<NO>Suppl 2</NO>
<PG>S244</PG>
<IDENTIFIERS MODIFIED="2012-07-26 12:49:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="200510188191"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2007" MODIFIED="2012-07-30 10:08:58 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-07-30 10:08:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim S-W, Shin I-S, Kim J-M, Lee S-H, Lee J-H, Yoon B-H, et al</AU>
<TI>Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>2007</YR>
<VL>31</VL>
<NO>7</NO>
<PG>1504-9</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2012-07-26 12:49:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17692448"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2007a" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 2007a" YEAR="2007">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim SW, Yoon JS, Lee SH, Yang DS, Lee JH, Kim WJ, et al</AU>
<TI>Effectiveness of switching from risperidone to amisulpride in stabilized schizophrenic patients with depression</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>Suppl 4</NO>
<PG>S440</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lecrubier-2004" MODIFIED="2012-07-30 10:10:45 +0100" MODIFIED_BY="[Empty name]" NAME="Lecrubier 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-07-30 10:10:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lecrubier Y, Rein W, Ponsard C</AU>
<TI>A double-blind, randomized clinical trial of amisulpride and olanzapine in acute schizophrenia: patient responder profile</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>7</VL>
<NO>Suppl 2</NO>
<PG>S409-S10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-2005" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="Lewis 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis S, Barnes T, Murray R, Davies L, Kerwin R, Taylor D, et al</AU>
<TI>First generation versus second generation (non-clozapine) antipsychotic drugs versus clozapine in schizophrenia: the Cutlass trials</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>Suppl 1</NO>
<PG>S31-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahmoud-2011" MODIFIED="2012-07-30 10:30:32 +0100" MODIFIED_BY="[Empty name]" NAME="Mahmoud 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-07-30 10:30:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mahmoud A, Hayhurst KP, Drake RJ, Lewis SW</AU>
<TI>Second generation antipsychotics improve sexual dysfunction in schizophrenia: A randomised controlled trial</TI>
<SO>http://www.hindawi.com/journals/sprt/2011/596898/</SO>
<YR>(accessed 14 April 2012)</YR>
<IDENTIFIERS MODIFIED="2012-07-30 10:27:51 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-30 10:27:51 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1155/2011/596898"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martins-2002" MODIFIED="2012-07-30 10:10:45 +0100" MODIFIED_BY="[Empty name]" NAME="Martins 2002" YEAR="2003">
<REFERENCE MODIFIED="2012-07-26 13:36:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peuskens J, De Hert M, Mortimer A, SOLIANOL SG</AU>
<TI>Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>3</NO>
<PG>145-52</PG>
<CY>England</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17414740"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-30 10:10:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Peuskens J</AU>
<TI>Less weight gain with amisulpride: results from double-blind studies vs. risperidone and olanzapine</TI>
<SO>Proceedings of the 16th European College of Neuropsychopharmacology Congress; 2003 Sep 20-24; Prague, Czech Republic</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCue-2007" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="McCue 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCue RE</AU>
<TI>Clozapine improves symptoms but not quality of life compared with other second-generation antipsychotics in people with treatment resistant schizophrenia</TI>
<SO>Evidence-Based Mental Health</SO>
<YR>2007</YR>
<VL>10</VL>
<NO>2</NO>
<PG>57</PG>
<IDENTIFIERS MODIFIED="2012-07-26 12:49:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17459988"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moore-2006" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Moore N</AU>
<TI>Switching to aripiprazole from other second-generation antipsychotics</TI>
<SO>Australian New Zealand Clinical Trials Registry</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mortimer-2007" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="Mortimer 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mortimer AM, Joyce E, Balasubramaniam K, Choudhary PC, Saleem PT</AU>
<TI>Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia</TI>
<SO>Human Psychopharmacology</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>7</NO>
<PG>445-54</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2012-07-26 12:49:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17691076"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00419653" MODIFIED="2012-07-26 13:41:19 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00419653" YEAR="2007">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00419653</AU>
<TI>Modulation of regional brain activation in schizophrenic patients by pharmacological therapy with amisulpride, olanzapine or haloperidol a study with functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI)</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00761670" MODIFIED="2012-07-26 13:41:34 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00761670" YEAR="2008">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00761670</AU>
<TI>Efficacy study on cognitive functions in schizophrenic patients</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00926965" MODIFIED="2012-07-26 13:41:39 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00926965" YEAR="2008">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00926965</AU>
<TI>Tardive dyskinesia and cognitive function</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00956189" MODIFIED="2012-07-26 13:41:44 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00956189" YEAR="2009">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00956189</AU>
<TI>Identification and treatment response prediction of antipsychotic-related metabolic syndrome</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01029769" MODIFIED="2012-07-26 13:41:50 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01029769" YEAR="2009">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01029769</AU>
<TI>The switch study - efficacy of an early antipsychotic switch in case of poor initial response to the treatment of schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01246232" MODIFIED="2012-07-27 14:23:56 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01246232" YEAR="2010">
<REFERENCE MODIFIED="2012-07-26 13:39:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Barnes T</AU>
<TI>Amisulpride augmentation in clozapine-unresponsive schizophrenia - AMICUS</TI>
<SO>http://public.ukcrn.org.uk</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-27 14:23:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01246232</AU>
<TI>Amisulpride augmentation in clozapine-unresponsive schizophrenia</TI>
<SO>http://ClinicalTrials.gov/show/NCT01246232</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01446328" MODIFIED="2012-07-26 13:41:57 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01446328" YEAR="2011">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01446328</AU>
<TI>Bergen psychosis project 2</TI>
<SO>http://ClinicalTrials.gov/show/NCT01446328</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01448499" MODIFIED="2012-07-26 13:42:01 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01448499" YEAR="2011">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01448499</AU>
<TI>Clozapine versus amisulpride in treatment-resistant schizophrenia patients</TI>
<SO>http://ClinicalTrials.gov/show/NCT01448499</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01609153" MODIFIED="2012-07-27 14:24:03 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01609153" YEAR="2012">
<REFERENCE MODIFIED="2012-07-27 14:24:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01609153</AU>
<TI>Is an antipsychotic combination treatment of olanzapine and amisulpride more effective than monotherapy</TI>
<SO>http://ClinicalTrials.gov/show/NCT01609153</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nicholls-2002" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="Nicholls 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nicholls CJ, Hale AS, Freemantle N</AU>
<TI>Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia</TI>
<SO>Journal of Medical Economics</SO>
<YR>2002</YR>
<VL>6</VL>
<PG>31-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pfizer-2006" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="Pfizer 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pfizer</AU>
<TI>Down-titration schedules of amisulpride in patients suffering from schizophrenia or schizoaffective disorders when initiating therapy with ziprasidone: an open-label, three-months study</TI>
<SO>http://www.clinicalstudyresults.org/</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rettenbacher-2007" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="Rettenbacher 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rettenbacher MA, Hummer M, Hofer A, Baumgartner S, Ebenbichler C, Edlinger M, et al</AU>
<TI>Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>4</NO>
<PG>400-4</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2012-07-26 12:49:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17050656"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riedel-2009" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="Riedel 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riedel M, Eich FX, Moller HJ</AU>
<TI>A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients</TI>
<SO>European Psychiatry</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>3</NO>
<PG>149-53</PG>
<CY>France</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruiz_x002d_Doblado-2010" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="Ruiz-Doblado 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruiz-Doblado S, Baena-Baldomero A, Esparrago-Llorca G</AU>
<TI>Pharmacological augmentation strategies in clozapine-resistant schizophrenia: Overcoming the resistance</TI>
<SO>Psiquiatria Biologica</SO>
<YR>2010</YR>
<VL>17</VL>
<NO>3</NO>
<PG>96-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schimmelmann-2005" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="Schimmelmann 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schimmelmann BG, Moritz S, Karow A, Schafer I, Bussopulos A, Golks D, et al</AU>
<TI>Correlates of subjective well-being in schizophrenic patients treated with atypical antipsychotics</TI>
<SO>International Journal of Psychiatry in Clinical Practice</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>2</NO>
<PG>94-8</PG>
<PB>Informa Healthcare; US</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmechtig-2010" MODIFIED="2012-07-30 10:32:58 +0100" MODIFIED_BY="[Empty name]" NAME="Schmechtig 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-07-30 10:32:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmechtig A, Dourish C, Craig K, Dawson GR, Williams S, Deakin W, et al</AU>
<TI>Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by high schizotypy</TI>
<SO>Society for Neuroscience Abstract Viewer and Itinerary Planner</SO>
<YR>2011</YR>
<VL>21</VL>
<PG>A99</PG>
<IDENTIFIERS MODIFIED="2012-07-30 10:30:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmechtig-2010a" MODIFIED="2012-07-30 10:33:25 +0100" MODIFIED_BY="[Empty name]" NAME="Schmechtig 2010a" YEAR="2010">
<REFERENCE MODIFIED="2012-07-30 10:33:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schmechtig A, Lees J, Dawson G, Dourish C, Craig K, Deakin B, et al</AU>
<TI>Effects of high schizotypy on control of eye movements: Modulation by antipsychotic drugs and nicotine</TI>
<SO>Proceedings of the 49th Annual meeting of the Americam College of Neuropsychopharmacology; 2010 Dec 5-9; Miami, Florida</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmechtig-2011" MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" NAME="Schmechtig 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-07-26 12:49:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schmechtig A, Lees J, Dawson GR, Dourish CT, Craig KJ, Deakin JFW, et al</AU>
<TI>Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2011</YR>
<PG>306</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sechter-2003" MODIFIED="2012-07-30 10:10:45 +0100" MODIFIED_BY="[Empty name]" NAME="Sechter 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-07-30 10:10:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y</AU>
<TI>Amisulpride vs risperidone in chronic schizophrenia: results of a 6-month, double-blind study: correction</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>3</NO>
<PG>611</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shim-2012" MODIFIED="2012-07-30 10:11:21 +0100" MODIFIED_BY="[Empty name]" NAME="Shim 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-07-30 10:11:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, et al</AU>
<TI>Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: A randomized double-blind placebo-controlled trial</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2012</YR>
<VL>37</VL>
<NO>3</NO>
<PG>660-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Somers-2011" MODIFIED="2012-07-30 10:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Somers 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-07-30 10:34:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Somers M, Sommer IEC, Kahn RS</AU>
<TI>Optimization of treatment and management of schizophrenia in europe: The optimise trial</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2011</YR>
<VL>1</VL>
<PG>321</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanelle-2004" MODIFIED="2012-07-30 10:11:51 +0100" MODIFIED_BY="[Empty name]" NAME="Vanelle 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-07-30 10:11:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanelle J, Douki S</AU>
<TI>An 8-week double blind, randomized trial comparing amisulpride and olanzapine in schizophrenic patients with depression</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>7</VL>
<NO>Suppl 2</NO>
<PG>S243</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-07-30 10:35:01 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-07-30 10:35:01 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" MODIFIED="2009-02-05 17:22:04 +0000" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecing skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS MODIFIED="2009-02-05 17:22:04 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1984" MODIFIED="2009-07-24 21:48:38 +0100" MODIFIED_BY="[Empty name]" NAME="Andreasen 1984" TYPE="BOOK">
<AU>Andreasen NC</AU>
<SO>Scale for the assessment of negative symptoms</SO>
<YR>1984</YR>
<PB>University of Iowa</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-2004" MODIFIED="2009-07-24 15:11:20 +0100" MODIFIED_BY="[Empty name]" NAME="APA 2004" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Practice guidelines for the treatment of patients with schizophrenia</SO>
<YR>2004</YR>
<PG>1-114</PG>
<EN>2nd</EN>
<PB>American Psychiatric Publishing, Inc</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arnt-1998" NAME="Arnt 1998" TYPE="JOURNAL_ARTICLE">
<AU>Arnt J, Skarsfeldt T</AU>
<TI>Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>63-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1984" NAME="Carpenter 1984" TYPE="JOURNAL_ARTICLE">
<AU>Heinrichs DW, Hanlon ET, Carpenter WT</AU>
<TI>The quality of life scale: an instrument for rating the schizophrenic deficit syndrome</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1984</YR>
<VL>10</VL>
<PG>388-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2009-07-24 15:12:34 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2005" MODIFIED="2012-07-26 12:50:03 +0100" MODIFIED_BY="[Empty name]" NAME="Duggan 2005" TYPE="COCHRANE_REVIEW">
<AU>Duggan L, Dardennes R, El-Dosoky A, Fenton M, Indran S, Rathbone J</AU>
<TI>Olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<PB>Wiley and Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2012-07-26 12:50:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-26 12:50:03 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001359.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-El_x002d_Sayeh-2006" MODIFIED="2012-07-26 12:51:21 +0100" MODIFIED_BY="[Empty name]" NAME="El-Sayeh 2006" TYPE="COCHRANE_REVIEW">
<AU>El-Sayeh HG, Morganti C</AU>
<TI>Aripiprazole for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<PB>Wiley and Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2012-07-26 12:51:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-26 12:51:21 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004578.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2009-11-02 11:28:11 +0000" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="11914310"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Freeman-1997" NAME="Freeman 1997" TYPE="JOURNAL_ARTICLE">
<AU>Freeman HL</AU>
<TI>Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies</TI>
<SO>International clinical psychopharmacology</SO>
<YR>1997</YR>
<VL>12</VL>
<PG>11-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gaebel-2006" MODIFIED="2009-07-24 21:45:30 +0100" MODIFIED_BY="[Empty name]" NAME="Gaebel 2006" TYPE="BOOK">
<AU>Gaebel W, Falkai P, Weinmann S, Wobrock T</AU>
<TO>Behandlungsleitlinie Schizophrenie</TO>
<SO>Treatment guidelines for schizophrenia</SO>
<YR>2006</YR>
<PB>Steinkopf</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldman-1992" MODIFIED="2009-07-24 15:14:05 +0100" MODIFIED_BY="[Empty name]" NAME="Goldman 1992" TYPE="JOURNAL_ARTICLE">
<AU>Goldman HH, Skodol AE, Lave TR</AU>
<TI>Revising axis V for DSM-IV: a review of mesures of social functioning</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>149</VL>
<PG>1148-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2009-07-24 15:14:26 +0100" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="OTHER">
<AU>Guy U</AU>
<TI>ECDEU assessment manual for psychopharmacology</TI>
<SO>National Institute of Mental Health</SO>
<YR>1976</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heres-2006" NAME="Heres 2006" TYPE="JOURNAL_ARTICLE">
<AU>Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S</AU>
<TI>Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<PG>185-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-07-24 15:17:33 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]</TI>
<SO>The Cochrane Collaboration</SO>
<YR>2008. Available from www.cochrane-handbook.org</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2006-a" MODIFIED="2012-07-30 10:35:01 +0100" MODIFIED_BY="[Empty name]" NAME="Jones 2006 a" TYPE="JOURNAL_ARTICLE">
<AU>Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW</AU>
<TI>Randomized controlled trial of the effect on quality of life</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<PG>1079-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1988" MODIFIED="2009-02-05 17:22:30 +0000" MODIFIED_BY="[Empty name]" NAME="Kane 1988" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group</AU>
<TI>Clozapine for the treatment of treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<PG>789-96</PG>
<IDENTIFIERS MODIFIED="2009-02-05 17:22:30 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1993" NAME="Kane 1993" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM</AU>
<TI>Treatment programme and long term outcome in chronic schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>46</VL>
<PG>585-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and negative syndrome scale (PANSS) manual</SO>
<YR>1986</YR>
<PB>Multi-Health Systems</PB>
<CY>North Tonawanda (NY)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2002" MODIFIED="2009-07-24 15:18:49 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2002" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Pitschel-Walz G, Engel RR, Kissling W</AU>
<TI>Amisulpride, an unusual "atypical" antipsychotic: A meta-analysis of randomized controlled trials</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<PG>180-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<PG>231-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005b" MODIFIED="2009-07-24 15:20:10 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liebermann-2005" NAME="Liebermann 2005" TYPE="JOURNAL_ARTICLE">
<AU>Liebermann JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<PG>1209-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marvaha-2004" MODIFIED="2009-07-16 08:43:22 +0100" MODIFIED_BY="[Empty name]" NAME="Marvaha 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marvaha S, Johnson S</AU>
<TI>Schizophrenia and employment - a review</TI>
<SO>Social Psychiatry and Psychiatric Epidemiology</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>337-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2009-07-24 15:21:07 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>1987-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mota-Neto-2002" MODIFIED="2012-07-26 12:50:43 +0100" MODIFIED_BY="[Empty name]" NAME="Mota Neto 2002" TYPE="COCHRANE_REVIEW">
<AU>Mota Neto JIS, Lima MS, Soares BGO</AU>
<TI>Amisulpride for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-07-26 12:50:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-26 12:50:43 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001357"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-M_x00f6_ller-2000" NAME="Möller 2000" TYPE="JOURNAL_ARTICLE">
<AU>Möller HJ</AU>
<TI>New assessment of atypical antipsychotics</TI>
<TO>Aktuelle Bewertung neuer/atypischer Neuroleptika</TO>
<SO>Nervenarzt</SO>
<YR>2000</YR>
<VL>71</VL>
<PG>329-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rein-1997" NAME="Rein 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rein W, Turjanski S</AU>
<TI>Clinical update on amisulpride in deficit schizophrenia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>12</VL>
<PG>19-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rust-1989" MODIFIED="2009-08-20 15:54:01 +0100" MODIFIED_BY="[Empty name]" NAME="Rust 1989" TYPE="BOOK">
<AU>Rust J, Golombok S</AU>
<SO>Modern Psychometrics</SO>
<YR>1989</YR>
<PB>Routledge</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson EN, Angus JWF</AU>
<TI>A rating scale for extrapyramidal side-effects</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tandon-2008" MODIFIED="2009-07-24 15:26:37 +0100" MODIFIED_BY="[Empty name]" NAME="Tandon 2008" TYPE="JOURNAL_ARTICLE">
<AU>Tandon R, Keshavan MS, Nasralllah HA</AU>
<TI>Schizophrenia, "Just the facts" What we know in 2008. 2. Epidemiology and etiology</TI>
<SO>Schizophrenia research</SO>
<YR>2008</YR>
<VL>102</VL>
<PG>1-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsuang-1978" MODIFIED="2009-07-16 08:43:22 +0100" MODIFIED_BY="[Empty name]" NAME="Tsuang 1978" TYPE="JOURNAL_ARTICLE">
<AU>Tsuang MT</AU>
<TI>Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1978</YR>
<VL>35</VL>
<PG>153-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2009-02-05 17:23:07 +0000" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>iii-92</PG>
<IDENTIFIERS MODIFIED="2009-02-05 17:23:07 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2001" MODIFIED="2009-07-24 21:35:12 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2001" TYPE="OTHER">
<AU>WHO</AU>
<TI>Mental Health: New Understanding, New Hope</TI>
<SO>The World Health report</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2007" MODIFIED="2009-08-20 15:55:38 +0100" MODIFIED_BY="[Empty name]" NAME="Xia 2007" TYPE="CONFERENCE_PROC">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al</AU>
<TI>The Leeds Outcomes Stakeholders Survey (LOSS) Study</TI>
<SO>Proceedings of the 15th Cochrane Colloquium, Sao Paulo, 23-27 October 2007</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-07-24 15:33:36 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Leucht-2008" MODIFIED="2009-07-24 15:33:36 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2008" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Komossa K, Rumel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM</AU>
<TI>A Meta-analysis of head-to-head comparisons of second generation antipsychotics in the treatment of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>166</VL>
<NO>2</NO>
<PG>152-63</PG>
<IDENTIFIERS MODIFIED="2009-07-24 15:33:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-24 15:33:36 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1176/appi.ajp.2008.08030368 "/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2009-08-20 16:00:21 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-07-30 10:04:51 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-11-09 20:21:53 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-07-21 14:51:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bai-2005">
<CHAR_METHODS MODIFIED="2009-07-16 11:44:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, no further details.<BR/>Duration: 24 weeks.<BR/>Design: parallel.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-21 14:51:03 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic schizophrenia.<BR/>N=80.<BR/>Age: mean=50.2 years, range not described.<BR/>Sex: 39M, 41F.<BR/>Setting: not described.<BR/>History: duration illness not described, age of onset not described.<BR/>Excluded:<B> </B>not described.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-14 16:02:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: dose range not described, mean dose not described, fixed/flexible dose not described. N=40.</P>
<P>2. Olanzapine: dose range not described, mean dose not described, fixed/flexible dose not described. N=40.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-16 11:55:35 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Cognitive functioning: Wisconsin card sorting test.<BR/>
</P>
<P>Unable to use -<BR/>Mental state: BPRS change (no data).<BR/>Adverse effects: BAS, SAS, UKU (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-16 11:54:35 +0100" MODIFIED_BY="[Empty name]">
<P>There are control groups without further details provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-28 08:02:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hwang-2003">
<CHAR_METHODS MODIFIED="2009-07-16 11:56:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-21 14:51:29 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV) - disorganised (n=9), paranoid (n=22) or undifferentiated (n=16)*. <BR/>N=48.<BR/>Age: 18-65 years (amisulpride mean=36.3 years, risperidone mean=34.1 years).<BR/>Sex: 20M, 27F*.<BR/>Location: multicentre.<BR/>Setting: not described.<BR/>History: mean duration illness: amisulpride group=13.3 years, risperidone group=13.4 years.<BR/>Excluded: neurological diseases, severe medical diseases, pregnancy, hypersensitivity to study medication and benzodiazepines, abuse of psychoactive drugs, placebo responders.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-16 11:59:42 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: flexible dose. Allowed dose range: 400-800 mg/day. Mean dose: 630 mg/day. N=23.</P>
<P>2. Risperidone: flexible dose. Allowed dose range: 4-8 mg/day. Mean dose: 6.88 mg/day. N=25.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-28 08:02:56 +0000" MODIFIED_BY="[Empty name]">
<P>Global State: CGI.<BR/>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, PANSS negative subscore.<BR/>General Functioning: SOFAS total score.<BR/>Adverse effects: open interviews, cardiac effects (QTc interval of &gt;500 ms), EPS (akathisia, rigor, tremor, use of antiparkinson medication), weight, laboratory (hematology, blood chemistry, urinanalysis).<BR/>
</P>
<P>Unable to use-<BR/>Adverse effects: ESRS (no data), leukopenia (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-21 12:16:30 +0100" MODIFIED_BY="[Empty name]">
<P>*of intent-to-treat population</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-28 08:02:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lecrubier-2006">
<CHAR_METHODS MODIFIED="2009-08-20 13:49:02 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 26 weeks.<BR/>Design: parallel.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-21 14:52:32 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV) - catatonic (n=11), disorganised (n=102) or residual (n=131)*.<BR/>N=245.<BR/>Age: amisulpride mean=37.8 years, olanzapine (5mg/day) mean=38.1 years, olanzapine (20 mg/day) mean=36.4 years, placebo mean=38.2 years.<BR/>Sex: 167M, 78F.<BR/>Location: multicentre.<BR/>Setting: inpatient and outpatient.<BR/>History: SANS severity score of 10 or more (excluding the item attention), mean duration illness: amisulpride group=12.33 years, olanzapine (5 mg/day) group=10.08 years, olanzapine (20 mg/day)group=11.08 years, placebo group=15.42 years.<BR/>Excluded: suicidal, pregnancy, substance abuse, treatment resistance to amisulpride or olanzapine, history of drug allergic reactions.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-21 12:34:50 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: fixed dose: 150 mg/day. N=70.</P>
<P>2. Olanzapine: fixed dose: 5 mg/day. N=70.</P>
<P>3. Olanzapine: fixed dose: 20 mg/day. N=70.**</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-28 08:02:33 +0000" MODIFIED_BY="[Empty name]">
<P>Global State: CGI, relapse, Participants´ global impression.<BR/>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, PANSS negative subscore, SANS total score, Psychotic depression Scale.<BR/>Quality of life: Carpenters QLS total score.<BR/>Adverse effects: EPS (akathisia, akinesia, parkinsonism, tremor), prolactin associated side effects, sedation, seizures, weight, laboratory (leukopenia).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-20 14:37:52 +0100" MODIFIED_BY="[Empty name]">
<P>* of intent-to-treat population<BR/>**There is also a placebo group (n=35), which is not relevant for this review, comparing atypical antipsychotics head to head.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-28 08:03:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mortimer-2004">
<CHAR_METHODS MODIFIED="2009-07-16 12:07:42 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, computer-generated randomisation.<BR/>Blindness: double, identical capsules.<BR/>Duration: 24 weeks.<BR/>Design: parallel.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-21 14:53:03 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis:schizophrenia (DSM-IV) - disorganised (n=33), paranoid (n=260), undifferentiated (n=76), schizophreniform disorder (n=8).<BR/>N=377.<BR/>Age: 18-65 years (amisulpride mean=38.2 years, olanzapine mean=37.4 years).<BR/>Sex: 245M, 132F.<BR/>Location: multicentre.<BR/>Setting: inpatient and outpatient.<BR/>History: dominant positive symptoms, BPRS score &gt; 36, PANSS positive score higher than PANSS negative score, mean duration illness: amisulpride group=9.56 years, olanzapine group=8.12 years.<BR/>Excluded:<B> </B>pregnancy.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-16 13:03:09 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: flexible dose. Allowed dose range: 200-800 mg/day. Mean dose: 504 mg/day. N=189.</P>
<P>2. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 13 mg/day. N=188.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-28 08:03:54 +0000" MODIFIED_BY="[Empty name]">
<P>Global State: CGI.<BR/>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, PANSS negative subscore, depression MADRS.<BR/>General Functioning: SOFAS total score.<BR/>Quality of life: QLS total score.<BR/>Adverse effects: open interviews, cardiac effects (ECG), death (natural causes, suicide) EPS (akathisia, dystonia, parkinsonism, use of antiparkinson medication, AIMS, Simpson-Angus), glucose, sedation, weight.</P>
<P>Unable to use-<BR/>Adverse effects: amenorrhoea (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-08 11:29:16 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-21 14:30:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-M_x00f6_ller-2005">
<CHAR_METHODS MODIFIED="2009-07-16 13:04:16 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-21 12:56:58 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV), schizophreniform disorder, schizoaffective disorder, delusional disorder or shared psychotic disorder. <BR/>N=36.<BR/>Age: 65 years or more.<BR/>Sex: not described.<BR/>Location: not described.<BR/>Setting: not described.<BR/>History: not described.<BR/>Excluded:<B> </B>not described.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-21 14:30:01 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: flexible dose. Allowed dose range: 100-400 mg/day. N=24.</P>
<P>2. Risperidone: flexible dose. Allowed dose range: 1-4 mg/day. N=12.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-21 12:57:57 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: adverse events.<BR/>Cognitive functioning: MMSE.<BR/>Adverse effects: open interviews.<BR/>
</P>
<P>Unable to use-<BR/>Mental State: PANSS total score, BPRS total score (no usable data).<BR/>Cardiac effects: (QTc), laboratory tests (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-28 08:05:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Olie-2006">
<CHAR_METHODS MODIFIED="2009-10-28 08:04:55 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-21 14:53:25 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic schizophrenia (DSM-III-R).<BR/>N=123.<BR/>Age: 18-64 years, mean= 9 years.<BR/>Sex: 79M, 44F.<BR/>History: PANSS negative subscore at least 6 points higher than PANSS positive subscore.<BR/>Location: multicentre.<BR/>Setting: outpatient.<BR/>Excluded: acute exacerbation.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-16 13:14:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: flexible dose. Allowed dose range: 100-200 mg/day. Mean dose: 144.7 mg/day. N=63.</P>
<P>2. Ziprasidone: flexible dose. Allowed dose range: 80-160 mg/day. Mean dose: 118.0 mg/day. N=60.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-28 08:05:21 +0000" MODIFIED_BY="[Empty name]">
<P>Global State: CGI.<BR/>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, BPRS total score, PANSS negative subscore.<BR/>Adverse effects: open interviews, cardiac effects (QTc prolongation), EPS (akathisia, parkinsonism, use of antiparkinson medication, movement disorder burden score), sedation, weight gain.<BR/>
</P>
<P>Unable to use:<BR/>Global state: GAF (no data).<BR/>Adverse effects: laboratory (blood chemistry, urinanalysis) (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-28 08:06:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peuskens-1999">
<CHAR_METHODS MODIFIED="2009-07-16 13:18:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-21 14:53:45 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV) - disorganised, paranoid or undifferentiated.<BR/>N=228.<BR/>Age: 18-65 years (amisulpride mean=36 years, risperidone mean=37 years).<BR/>Sex: 137M, 91F.<BR/>Location: multicentre.<BR/>Setting: inpatient and outpatient.<BR/>History: BPRS score &gt; 36, mean duration illness: amisulpride group=7.9 years, risperidone group=10.2 years.<BR/>Excluded: treatment possibly interfering with study drug (depot antipsychotic treatment within the last dosing interval, lithium based therapy within 10 days of the start of the trial, drug abuse within the last three months).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-16 13:20:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: fixed dose: 800 mg/day. N=115.</P>
<P>2. Risperidone: fixed dose: 8 mg/day. N=113.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-28 08:06:16 +0000" MODIFIED_BY="[Empty name]">
<P>Global State: CGI.<BR/>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: BPRS total score, PANSS positive subscore, BPRS positive subscore, PANSS negative subscore.<BR/>General functioning: SOFAS.<BR/>Adverse effects: open interviews, cardiac effects (arrhythmia, ECG, QTc interval of &gt;500 ms), EPS<BR/>(akathisia, extrapyramidal symptoms, hyperkinesia, parkinsonism, rigor, tremor, use of antiparkinson medication, AIMS, SAS), prolactin associated side effects, weight.</P>
<P>Unable to use-<BR/>General Functioning: SOFAS (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Individual BPRS factors are also available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-28 08:07:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sechter-2002">
<CHAR_METHODS MODIFIED="2009-07-16 13:23:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 26 weeks.<BR/>Design: parallel.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-21 14:54:11 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV) - disorganised (n=37), paranoid (n=227), residual (n=19) or undifferentiated (n=27).<BR/>N=310.<BR/>Age: 18-65 years, mean=38.4 years.<BR/>Sex: 170M, 140F.<BR/>Location: multicentre.<BR/>Setting: inpatient and outpatient.<BR/>History: PANSS score between 60 and 120, chronically ill with recent worsening of symptoms, mean duration illness=11.8 years.<BR/>Excluded: predominant negative symptoms, aberrant medical condition.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-16 13:25:21 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: flexible dose. Allowed dose range: 400-1000 mg/day. Mean dose: 683 mg/day. N=152.</P>
<P>2. Risperidone: flexible dose. Allowed dose range: 4-10 mg/day. Mean dose: 6.92 mg/day. N=158.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-28 08:07:01 +0000" MODIFIED_BY="[Empty name]">
<P>Global State: CGI, relapse.<BR/>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, PANSS negative subscore, SANS total score.<BR/>General Functioning: SOFAS total score.<BR/>Adverse effects: open interviews, death (natural causes, suicide), EPS (akathisia, hyperkinesia, parkinsonism, tremor, use of antiparkinson medication, AIMS, SAS), prolactin associated side effects (amenorrhoea, galactorrhoea, sexual dysfunction), sedation, seizures, weight.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-28 08:07:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vanelle-2006">
<CHAR_METHODS MODIFIED="2009-07-16 13:35:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-21 14:34:36 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia and comorbid depression (DSM-IV) - disorganised (n=26), paranoid (n=32), residual (n=4), undifferentiated (n=23).<BR/>N=85.<BR/>Age: 18-65 years, mean=34 years.<BR/>Sex: 54M, 31F.<BR/>Location: multicentre.<BR/>Setting: inpatient and outpatient.<BR/>History: not described.<BR/>Excluded: severe somatic disease, bradycardia, pregnancy, treatment possibly interfering with study drug (psychotropic medication, antidepressants, depot antipsychotic treatment within the last dosing interval, lithium based therapy within 10 days, drug abuse).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-16 13:29:14 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: flexible dose. Allowed dose range: 200-600 mg/day. Mean dose: 471 mg/day. N=45.</P>
<P>2. Olanzapine: flexible dose. Allowed dose range: 5-15 mg/day. Mean dose: 11.4 mg/day. N=40.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-28 08:07:52 +0000" MODIFIED_BY="[Empty name]">
<P>Global State: CGI.<BR/>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, PANSS negative subscore, depression Calgary Depression scale.<BR/>Adverse effects: open interviews, cardiac effects (QTc abnormalities in ms), weight gain, laboratory (glucose, cholesterol).</P>
<P>Unable to use-<BR/>Adverse effects: EPS, SAS, BAS, AIMS, tremor (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-28 08:08:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wagner-2005">
<CHAR_METHODS MODIFIED="2009-07-16 13:34:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, medication containers according to a pseudo-random computer algorithm.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-28 08:08:14 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV and ICD-10).<BR/>N=52.<BR/>Age: 18-65 years (amisulpride mean=38.3 years, olanzapine mean=34.3 years).<BR/>Sex: 23M, 13F*.<BR/>Location: single centre.<BR/>Setting: inpatient.<BR/>History: CGI score &gt; 4, PANSS score &gt; 61, mean duration illness=8.4 years, age at onset 27.9 years*<BR/>Excluded: risk of suicide or aggressive behaviour, previous CNS trauma, epilepsy, instable somatic condition, drug dependence, lack of sufficient contraception, drug resistance.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-16 13:34:02 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: flexible dose. Allowed dose range: 400-800 mg/day. Mean dose: 511.1 mg/day. N=26.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 10-20 mg/day. Mean dose: 15.0 mg/day. N=26.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-28 08:08:34 +0000" MODIFIED_BY="[Empty name]">
<P>Global State: CGI.<BR/>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore, SANS total score.<BR/>Cognitive Functioning: Global Cognitive Index total score, trail making test A &amp; B, continuous performance test, self ordered pointing task, Rey auditory verbal learning test.<BR/>Adverse effects: EPS, SAS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-21 14:39:03 +0100" MODIFIED_BY="[Empty name]">
<P>* data only available for 36 participants.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Diagnostic tool<BR/>DSM III-R and DSM-IV - Diagnostic Statistical Manual version 3 Revised and version 4.<BR/>ICD 10 - The International Statistical Classification of Diseases and Related Health Problems.<BR/>
</P>
<P>Rating Scales:</P>
<P>Global rating scales:<BR/>CGI - Clinical Global Impressions.<BR/>CGI-S - Clinical Global Impression-Severity.<BR/>CGI-I - Clinical Global Impression-Improvement.</P>
<P>Mental state:<BR/>BPRS - Brief Psychiatric Rating Scale.<BR/>MADRS - Montgomery-Asberg Depression Rating Scale.<BR/>MMSE - Wiing Mini Mental State Examination.<BR/>PANSS - Positive and Negative Syndrome Scale.<BR/>SANS - Scale for the Assessment of Negative Symptoms.<BR/>SAPS- Scale for the Assessment of Positive Symptoms.<BR/>
</P>
<P>General functioning:<BR/>GAF - Global assessment of functioning.</P>
<P>Side effects:<BR/>AIMS - Abnormal Involuntary Movement Scale.<BR/>BAS - Barnes Akathisia Scale.<BR/>ESRS - Extrapyramidal Syndrome Rating Scale.<BR/>SAS - Simpson-Angus Index - for neurological side effects.<BR/>UKU - Udvalg for kliniske undersogelser side effect ratings.</P>
<P>Quality of Life:<BR/>QLS - Quality of Life Scale.<BR/>SWN -Subjective Well-being List.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-08-20 14:28:48 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-08-20 13:51:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baloescu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-20 13:51:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled - trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-20 13:49:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beuzen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-20 13:49:29 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-20 13:49:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fleischhacker-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-20 13:49:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Giudicelli-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: inappropriate intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-20 13:51:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kelemen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-20 13:51:43 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled - trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-20 13:52:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moritz-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-20 13:52:16 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-20 13:49:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-M_x00f6_ller-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-20 13:49:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-20 14:00:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oliveira_x002d_Castro-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-20 14:00:00 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled trial.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-20 14:02:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oli_x00e9_-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-20 14:02:46 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-20 13:56:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rettenbacher-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-20 13:56:40 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-20 13:54:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ryu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-20 13:54:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-20 14:24:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yagdiran-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-20 14:24:29 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-07-30 10:04:51 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2012-07-27 14:19:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anon-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:19:59 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Assion-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:00 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beuzen-2005a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:02 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beuzen-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:07 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bhowmick-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:09 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Birchwood-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:10 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dazzan-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:15 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DRKS00003603">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:16 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eufest-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:18 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fleischhacker-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:22 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Genc-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:24 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goder-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:30 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haro-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:32 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN68824876">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:34 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jones-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:39 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Joyce-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:41 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:42 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2007a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:47 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lecrubier-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:48 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lewis-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:50 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mahmoud-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:09 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martins-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:10 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCue-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:15 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moore-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:17 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mortimer-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:54 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:20:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00419653">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:20:57 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00761670">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:00 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00926965">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:24 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00956189">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:25 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01029769">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:27 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01246232">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:32 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01446328">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:33 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01448499">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:35 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01609153">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:40 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nicholls-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:42 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pfizer-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rettenbacher-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:52 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Riedel-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:57 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:21:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ruiz_x002d_Doblado-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:21:58 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:22:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schimmelmann-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:22:05 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:22:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmechtig-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:22:06 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:22:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmechtig-2010a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:22:08 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:22:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmechtig-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:22:13 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:22:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sechter-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:22:15 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:22:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shim-2012">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:22:19 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:22:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Somers-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:22:21 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-07-27 14:22:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vanelle-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-27 14:22:22 +0100" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-10-28 08:08:44 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-07-21 13:04:15 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-18 10:01:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bai-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-18 10:02:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hwang-2003">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-18 10:02:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lecrubier-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-18 10:03:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mortimer-2004">
<DESCRIPTION>
<P>Random, computer-generated randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-18 10:04:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-M_x00f6_ller-2005">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-21 13:04:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olie-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-18 10:05:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peuskens-1999">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-18 10:05:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sechter-2002">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-18 10:06:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vanelle-2006">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 11:54:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wagner-2005">
<DESCRIPTION>
<P>Random, medication containers according to a pseudo-random computer algorithm.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-07-21 13:02:30 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-18 10:02:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bai-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-18 10:02:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hwang-2003">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-18 10:03:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lecrubier-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-21 12:55:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mortimer-2004">
<DESCRIPTION>
<P>The computer generated randomisation list was prepared and kept outside the study centre. The participant numbers were assigned in strict chronological order in each centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-18 10:03:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-M_x00f6_ller-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-21 13:02:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olie-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-18 10:05:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peuskens-1999">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-18 10:05:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sechter-2002">
<DESCRIPTION>
<P>No further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-18 10:06:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vanelle-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-18 10:06:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wagner-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-10-28 08:08:44 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-05 17:34:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bai-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-10-28 08:00:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bai-2005">
<DESCRIPTION>
<P>Single, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-08 11:19:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hwang-2003">
<DESCRIPTION>
<P>Double, identical capsules. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-10-28 08:01:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hwang-2003">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-08 11:24:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lecrubier-2006">
<DESCRIPTION>
<P>Double, no further details. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-10-28 08:03:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lecrubier-2006">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-08 11:27:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mortimer-2004">
<DESCRIPTION>
<P>Double, identical capsules. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-10-28 08:04:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mortimer-2004">
<DESCRIPTION>
<P>Double, identical capsules ("to permit dose adjustment whilst maintaining the double-blind, blister packs corresponding to a low and a high dosage were provided"). Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-08 11:29:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-M_x00f6_ller-2005">
<DESCRIPTION>
<P>Double, no further details. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-10-28 08:04:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-M_x00f6_ller-2005">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-05 17:35:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olie-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-10-28 08:05:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olie-2006">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-05 17:35:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peuskens-1999">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-10-28 08:06:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peuskens-1999">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds in side effects. This may be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-08 11:37:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sechter-2002">
<DESCRIPTION>
<P>Double, no further details. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-10-28 08:07:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sechter-2002">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-08 11:40:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanelle-2006">
<DESCRIPTION>
<P>Double, no further details. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-10-28 08:07:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vanelle-2006">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-08 11:46:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wagner-2005">
<DESCRIPTION>
<P>Double, no further details. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-10-28 08:08:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wagner-2005">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-07-21 14:42:24 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME/>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-07-21 12:12:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bai-2005">
<DESCRIPTION>
<P>The rate of leaving the study early was only 5% and data on reasons for leaving early were provided. All data were analysed on an intent to treat basis with the last-observation-carried-forward method. This method is not perfect, but due to the very low attrition the risk of bias was low.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-07-21 12:17:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hwang-2003">
<DESCRIPTION>
<P>The rate of participants leaving the study early was below 10% and data on reasons for leaving early were available. The data were analysed on an intent to treat basis with the last-observation-carried-forward method. This method is not perfect, but due to the very low attrition the risk of bias was low.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-07-21 12:47:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lecrubier-2006">
<DESCRIPTION>
<P>The rate of leaving the study early was high (57.6%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if they had remained in the study. This assumption can often be wrong and poses a problem given the high attrition.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-07-21 12:55:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mortimer-2004">
<DESCRIPTION>
<P>The rate of leaving the study early was 35.8%. The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can often be wrong. It is unclear whether this led to bias .</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-02-08 11:31:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-M_x00f6_ller-2005">
<DESCRIPTION>
<P>Numbers of participants leaving the study early were only reported for the category 'due to adverse effects'. The statistical method used to account for incomplete data was not described.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-02-08 11:36:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olie-2006">
<DESCRIPTION>
<P>The rate of leaving the study early was about 25%, the analysis was based on the 'least squares mean change' (last-observation-carried-forward). It is unclear whether the degree of attrition and the method used to account for it led to bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-07-21 14:17:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Peuskens-1999">
<DESCRIPTION>
<P>The rate of leaving the study early was 30.3%. Statistical analysis was based on an intent to treat basis. The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can often be wrong.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-07-21 14:24:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sechter-2002">
<DESCRIPTION>
<P>The rate of participants leaving the study early was considerable (40%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can often be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-02-11 18:46:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanelle-2006">
<DESCRIPTION>
<P>The rate of participants leaving the study early was 16.5% and reasons for leaving the study early were provided. The analysis was based on the last-observation carried forward method with two people being excluded due to no exploitable outcome data. In addition there was a per protocol population which excluded subjects with a major protocol deviation. As two different methods with similar results were applied and as the overall attrition was low we do not think that there was a bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-07-21 14:42:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wagner-2005">
<DESCRIPTION>
<P>The rate of participants leaving the study early was high (50%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can often be wrong and lead to bias in cases of high attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-07-21 14:24:35 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-21 15:47:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bai-2005">
<DESCRIPTION>
<P>The study is only available as an abstract. Data on BPRS and EPS scales were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-21 12:17:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hwang-2003">
<DESCRIPTION>
<P>Data on the extrapyramidal symptom scale have not been presented. Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-21 12:36:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lecrubier-2006">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-21 12:56:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mortimer-2004">
<DESCRIPTION>
<P>Only treatment emergent adverse events occurring in 5% of the participants are presented, therefore important side effects may have been missed by this procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-08 11:32:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-M_x00f6_ller-2005">
<DESCRIPTION>
<P>The study is only available as an abstract. The data for primary outcomes were either not available or only available in percentage change without a standard deviation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-21 13:03:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Olie-2006">
<DESCRIPTION>
<P>Predefined laboratory data and data on the Global Assessment of Functioning Scale have not been presented. Treatment emergent adverse events had to occur with an incidence of 5% for reporting, therefore important side effects may have been missed by this procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-21 14:18:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Peuskens-1999">
<DESCRIPTION>
<P>Data on general functioning (a secondary outcome) were not available. Adverse effects had to occur with an incidence of at least 5% to be reported. Rare but important side effects may have been missed by this procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-21 14:24:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sechter-2002">
<DESCRIPTION>
<P>Adverse effects had to occur with an incidence of at least 5% to be reported. Rare but important side effects may have been missed by this procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-22 09:02:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vanelle-2006">
<DESCRIPTION>
<P>Data on extrapyramidal symptoms were not provided. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-08 11:47:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wagner-2005">
<DESCRIPTION>
<P>Additional treatment with biperiden up to 4mg/day was permitted, but data on use of antiparkinson medication was not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-07-21 14:36:17 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-22 11:01:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bai-2005">
<DESCRIPTION>
<P>Insufficient data to judge on baseline imbalance or industry sponsoring.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-05 17:06:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hwang-2003">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of amisulpride.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 12:40:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lecrubier-2006">
<DESCRIPTION>
<P>The study was industry sponsored by the manufacturers of olanzapine and one of the authors is an employee of that company.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-05 17:06:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mortimer-2004">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of amisulpride.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-08 11:33:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-M_x00f6_ller-2005">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of amisulpride. Whether there was baseline imbalance could not be judged due to insufficient data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-21 13:03:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Olie-2006">
<DESCRIPTION>
<P>The study was sponsored by the manufacturers of ziprasidone.<BR/>The dose of ziprasidone could be increased to the maximum daily dose, whereas amisulpride could only be increased up to 200 mg which might lead to a bias in terms of efficacy and side effects occurrence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-05 17:05:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Peuskens-1999">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of amisulpride.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-05 17:04:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sechter-2002">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of amisulpride.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-21 14:36:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vanelle-2006">
<DESCRIPTION>
<P>The study was sponsored by the manufacturers of amisulpride. There was a relatively high number of participants (18) with major protocol deviations.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-05 17:04:36 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wagner-2005">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-09-11 13:26:50 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-09-11 13:26:50 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-12-12 15:10:21 +0000" MODIFIED_BY="[Empty name]">Suggested design of future study</TITLE>
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Methods</P>
</TH>
<TD>
<P>Allocation: randomised - clearly described generation of sequence and concealment of allocation.<BR/>Blindness: double - described and tested.<BR/>Duration: 6 months minimum.</P>
</TD>
</TR>
<TR>
<TH>
<P>Participants</P>
</TH>
<TD>
<P>Diagnosis: schizophrenia (operational criteria).<BR/>N=2700.*<BR/>Age: any.<BR/>Sex: both.<BR/>History: any.</P>
</TD>
</TR>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TD>
<P>1. Amisulpride: dose ~ 400-800 mg/day. N=300.<BR/>2. Aripiprazole: dose ~ 10-30 mg/day. N=300.<BR/>3. Clozapine: dose ~ 300-800 mg/day. N=300.<BR/>4. Olanzapine: dose ~ 10-20 mg/day. N=300.<BR/>5. Quetiapine: dose ~300-800 mg/day. N=300.<BR/>6. Risperidone: dose ~ 4-8 mg/day. N=300.<BR/>7. Sertindole: dose ~ 12-24 mg/day. N=300.<BR/>8. Ziprasidone: dose ~ 120-160 mg/day. N=300.<BR/>9. Zotepine: dose ~ 100-300 mg/day. N=300.</P>
</TD>
</TR>
<TR>
<TH>
<P>Outcomes</P>
</TH>
<TD>
<P>Leaving study early (any reason, adverse events, inefficacy).<BR/>Service outcomes: hospitalised, time in hospital, attending out patient clinics.<BR/>Global impression: CGI**, relapse.<BR/>Mental state: PANSS.<BR/>Adverse events: UKU.<BR/>Employment, family satisfaction, patient satisfaction.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<BR/>
<BR/>** Primary outcome<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-08-20 16:24:10 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-08-20 09:18:12 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>AMISULPRIDE versus OLANZAPINE</NAME>
<DICH_OUTCOME CHI2="2.9716852764756907" CI_END="1.2218555951770986" CI_START="0.8743306785357942" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.033588811667362" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="167" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.0870198819101888" LOG_CI_START="-0.058324282809071266" LOG_EFFECT_SIZE="0.014347799550558796" METHOD="MH" MODIFIED="2009-08-19 14:44:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3960115615849785" P_Q="1.0" P_Z="0.6987860113900178" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="330" TOTAL_2="394" WEIGHT="100.0" Z="0.386959743871558">
<NAME>Global state: 1a. No clinically significant response (as defined by original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5965936325978598" CI_START="0.8027057401796025" EFFECT_SIZE="1.1320754716981132" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="53" LOG_CI_END="0.20319439292129843" LOG_CI_START="-0.0954436313555893" LOG_EFFECT_SIZE="0.05387538078285457" ORDER="14" O_E="0.0" SE="0.17542145374230542" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" VAR="0.030772686433063797" WEIGHT="23.6867236554782"/>
<DICH_DATA CI_END="1.3615557688209834" CI_START="0.8754149714788954" EFFECT_SIZE="1.0917537746806039" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="82" LOG_CI_END="0.13403543458173847" LOG_CI_START="-0.0577860302896508" LOG_EFFECT_SIZE="0.03812470214604386" ORDER="15" O_E="0.0" SE="0.11267687799701906" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="0.012696078835155118" WEIGHT="57.411751229706326"/>
<DICH_DATA CI_END="1.5354520059570869" CI_START="0.5145868797752614" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.18623624612994785" LOG_CI_START="-0.28854129102471043" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="16" O_E="0.0" SE="0.27888667551135854" STUDY_ID="STD-Vanelle-2006" TOTAL_1="45" TOTAL_2="40" VAR="0.07777777777777778" WEIGHT="9.37162439584284"/>
<DICH_DATA CI_END="1.1821753363629721" CI_START="0.39981907544624734" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.0726818944535737" LOG_CI_START="-0.39813648944897323" LOG_EFFECT_SIZE="-0.16272729749769974" ORDER="17" O_E="0.0" SE="0.2765610492929436" STUDY_ID="STD-Wagner-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.07648601398601398" WEIGHT="9.52990071897263"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.023826100262691" CI_END="1.1879406255820364" CI_START="0.6993028360824838" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9114440457686462" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="112" I2="33.85863030197893" I2_Q="59.87870257819615" ID="CMP-001.02" LOG_CI_END="0.07479473473062828" LOG_CI_START="-0.15533471043775984" LOG_EFFECT_SIZE="-0.040269987853565774" METHOD="MH" MODIFIED="2009-08-19 15:34:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.22048784430265045" P_Q="0.11439439159253129" P_Z="0.4927496888550448" Q="2.492441830798203" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.019714070605730584" TOTALS="YES" TOTAL_1="260" TOTAL_2="254" WEIGHT="100.0" Z="0.6859419992352752">
<NAME>Global State: 1b. No clinically important change (as defined by original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.49791050443382795" CI_END="1.0618701303555977" CI_START="0.5490915183211448" DF="1" EFFECT_SIZE="0.763586198236209" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="36" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.026071404580827" LOG_CI_START="-0.260355264676661" LOG_EFFECT_SIZE="-0.11714193004791701" MODIFIED="2009-08-19 15:34:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.48041972115293485" P_Z="0.10889921936471608" STUDIES="2" TAU2="0.0" TOTAL_1="71" TOTAL_2="66" WEIGHT="47.198108403412384" Z="1.603160519714248">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.5354520059570869" CI_START="0.5145868797752614" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.18623624612994785" LOG_CI_START="-0.28854129102471043" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="18" O_E="0.0" SE="0.27888667551135854" STUDY_ID="STD-Vanelle-2006" TOTAL_1="45" TOTAL_2="40" VAR="0.07777777777777778" WEIGHT="18.743525458320946"/>
<DICH_DATA CI_END="1.0584498539222107" CI_START="0.46294115699883853" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="0.02467028731456555" LOG_CI_START="-0.33447420728605204" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="19" O_E="0.0" SE="0.21096325392232293" STUDY_ID="STD-Wagner-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.0445054945054945" WEIGHT="28.45458294509144"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.346625751003853" CI_START="0.8346185410219359" DF="0" EFFECT_SIZE="1.0601503759398496" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="76" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.12924691505688363" LOG_CI_START="-0.07851197168029539" LOG_EFFECT_SIZE="0.02536747168829411" MODIFIED="2009-08-19 15:34:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6322052102555139" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="188" WEIGHT="52.80189159658761" Z="0.4786253109913159">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.346625751003853" CI_START="0.8346185410219359" EFFECT_SIZE="1.0601503759398496" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="76" LOG_CI_END="0.12924691505688363" LOG_CI_START="-0.07851197168029539" LOG_EFFECT_SIZE="0.02536747168829411" ORDER="20" O_E="0.0" SE="0.12203859849249449" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="0.014893419522012279" WEIGHT="52.80189159658761"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.183747608847751" CI_START="0.3989064979770033" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.3392024424490088" LOG_CI_START="-0.3991288892038952" LOG_EFFECT_SIZE="-0.02996322337744321" METHOD="MH" MODIFIED="2009-08-19 14:45:16 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8736059209284648" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="140" WEIGHT="100.0" Z="0.1590799040020295">
<NAME>Global State: 1c. Relapse - medium term (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.183747608847751" CI_START="0.3989064979770033" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.3392024424490088" LOG_CI_START="-0.3991288892038952" LOG_EFFECT_SIZE="-0.02996322337744321" MODIFIED="2009-08-19 14:45:16 +0100" MODIFIED_BY="[Empty name]" ORDER="603" O_E="0.0" SE="0.4336994790119514" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" VAR="0.18809523809523807" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.396228547194495" CI_END="1.2674047915722588" CI_START="0.9341369556928028" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0880853154186858" ESTIMABLE="YES" EVENTS_1="218" EVENTS_2="259" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.1029153446934799" LOG_CI_START="-0.029589446316736222" LOG_EFFECT_SIZE="0.03666294918837183" METHOD="MH" MODIFIED="2009-08-19 16:24:16 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5812427652948895" P_Q="0.8551955278419928" P_Z="0.27809411115493" Q="0.3128503389339058" RANDOM="YES" SCALE="8.326893624304766" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1030" TOTAL_2="1222" WEIGHT="300.0" Z="1.0846107439343926">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.167372324744638" CI_END="1.2621682795468636" CI_START="0.89929812090097" DF="4" EFFECT_SIZE="1.0653945569868961" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="163" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.10111726141087961" LOG_CI_START="-0.046096314051448865" LOG_EFFECT_SIZE="0.027510473679715354" MODIFIED="2009-08-19 16:24:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5302170598965461" P_Z="0.4638421819664684" STUDIES="5" TAU2="0.0" TOTAL_1="370" TOTAL_2="434" WEIGHT="100.00000000000001" Z="0.7325348554376647">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="5.296053860021452" CI_START="0.0472049579947035" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7239523931595834" LOG_CI_START="-1.3260123844875458" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1" O_E="0.0" SE="1.2041594578792296" STUDY_ID="STD-Bai-2005" TOTAL_1="40" TOTAL_2="40" VAR="1.4500000000000002" WEIGHT="0.515706877687075"/>
<DICH_DATA CI_END="1.3078757845924165" CI_START="0.8033064090466469" EFFECT_SIZE="1.025" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="80" LOG_CI_END="0.11656649885999033" LOG_CI_START="-0.09511876807644416" LOG_EFFECT_SIZE="0.010723865391773066" ORDER="2" O_E="0.0" SE="0.12434497365743259" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" VAR="0.015461672473867604" WEIGHT="48.36313625903688"/>
<DICH_DATA CI_END="1.4910274735624722" CI_START="0.8667429909053086" EFFECT_SIZE="1.1368102796674224" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="63" LOG_CI_END="0.17348564580487497" LOG_CI_START="-0.06210966166863013" LOG_EFFECT_SIZE="0.05568799206812243" ORDER="3" O_E="0.0" SE="0.13838984982551739" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="0.019151750534729256" WEIGHT="39.044732296938825"/>
<DICH_DATA CI_END="6.533760868898246" CI_START="0.7558084392780947" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.815163235554417" LOG_CI_START="-0.1215882631051045" LOG_EFFECT_SIZE="0.3467874862246563" ORDER="4" O_E="0.0" SE="0.5502524673073059" STUDY_ID="STD-Vanelle-2006" TOTAL_1="45" TOTAL_2="40" VAR="0.30277777777777776" WEIGHT="2.469715505987644"/>
<DICH_DATA CI_END="1.4809320338004415" CI_START="0.49610236039368555" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.17053512737822982" LOG_CI_START="-0.30442870663945626" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="5" O_E="0.0" SE="0.27899610721088536" STUDY_ID="STD-Wagner-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.07783882783882784" WEIGHT="9.606709060349583"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9488359640064454" CI_END="1.9215866312535679" CI_START="0.7377479130421905" DF="3" EFFECT_SIZE="1.1906496239184274" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="35" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.2836599686220064" LOG_CI_START="-0.13209201036821652" LOG_EFFECT_SIZE="0.07578397912689488" MODIFIED="2009-08-19 16:24:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5830938925749886" P_Z="0.47489880707224175" STUDIES="4" TAU2="0.0" TOTAL_1="330" TOTAL_2="394" WEIGHT="99.99999999999999" Z="0.7145311493386409">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="1.8129160745216562" CI_START="0.4558657141422258" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="22" LOG_CI_END="0.25837769972938807" LOG_CI_START="-0.3411630700458382" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="6" O_E="0.0" SE="0.35217321594064194" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" VAR="0.12402597402597401" WEIGHT="48.08739022719709"/>
<DICH_DATA CI_END="3.4162937967577287" CI_START="0.7414414187212763" EFFECT_SIZE="1.5915343915343916" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.5335552123752971" LOG_CI_START="-0.12992315688257614" LOG_EFFECT_SIZE="0.2018160277463605" ORDER="7" O_E="0.0" SE="0.3897304783729706" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="0.1518898457728245" WEIGHT="39.265859945736366"/>
<DICH_DATA CI_END="90.14412987144205" CI_START="0.22032034742213485" EFFECT_SIZE="4.456521739130435" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9549374509980162" LOG_CI_START="-0.6569453922496556" LOG_EFFECT_SIZE="0.6489960293741802" ORDER="8" O_E="0.0" SE="1.534232911152273" STUDY_ID="STD-Vanelle-2006" TOTAL_1="45" TOTAL_2="40" VAR="2.353870625662778" WEIGHT="2.533735434000719"/>
<DICH_DATA CI_END="4.504828095259613" CI_START="0.22198405329879073" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6536782229056234" LOG_CI_START="-0.6536782229056235" LOG_EFFECT_SIZE="0.0" ORDER="9" O_E="0.0" SE="0.7679476477883045" STUDY_ID="STD-Wagner-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.5897435897435898" WEIGHT="10.113014393065814"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.651053419133051" CI_END="1.9890370640285635" CI_START="0.712281435701198" DF="3" EFFECT_SIZE="1.1902748319733392" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="61" I2="35.49848325416148" ID="CMP-001.04.03" LOG_CI_END="0.29864287591131694" LOG_CI_START="-0.14734837459070332" LOG_EFFECT_SIZE="0.07564725066030681" MODIFIED="2009-08-19 16:24:16 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.19920603258961733" P_Z="0.5061256595866924" STUDIES="4" TAU2="0.09087946465678484" TOTAL_1="330" TOTAL_2="394" WEIGHT="100.0" Z="0.6648824911106795">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="2.333281889438907" CI_START="1.002493679228468" EFFECT_SIZE="1.5294117647058822" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="34" LOG_CI_END="0.36796721013212164" LOG_CI_START="0.0010816430529664266" LOG_EFFECT_SIZE="0.184524426592544" ORDER="10" O_E="0.0" SE="0.21551039821514273" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" VAR="0.046444731738849394" WEIGHT="49.97822355081018"/>
<DICH_DATA CI_END="1.3823636752734074" CI_START="0.4580888815195044" EFFECT_SIZE="0.7957671957671958" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.14062231321671614" LOG_CI_START="-0.33905024905195746" LOG_EFFECT_SIZE="-0.09921396791762069" ORDER="11" O_E="0.0" SE="0.28176203749409623" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="0.0793898457728245" WEIGHT="40.308023619051866"/>
<DICH_DATA CI_END="117.21085637060243" CI_START="0.3321087294094186" EFFECT_SIZE="6.239130434782608" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.068967839015588" LOG_CI_START="-0.47871970891075133" LOG_EFFECT_SIZE="0.7951240650524183" ORDER="12" O_E="0.0" SE="1.4965242769086855" STUDY_ID="STD-Vanelle-2006" TOTAL_1="45" TOTAL_2="40" VAR="2.239584911377064" WEIGHT="2.945000771939148"/>
<DICH_DATA CI_END="6.57367138033803" CI_START="0.15212199426199158" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8178079897862158" LOG_CI_START="-0.8178079897862158" LOG_EFFECT_SIZE="0.0" ORDER="13" O_E="0.0" SE="0.9607689228305228" STUDY_ID="STD-Wagner-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.9230769230769231" WEIGHT="6.768752058198813"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1821753363629721" CI_START="0.39981907544624734" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.0726818944535737" LOG_CI_START="-0.39813648944897323" LOG_EFFECT_SIZE="-0.16272729749769974" METHOD="MH" MODIFIED="2009-08-19 15:53:24 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.17547144605011544" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="1.3548308787493848">
<NAME>Mental state: 1a. General - no clinically important change - short term (less than 50% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1821753363629721" CI_START="0.39981907544624734" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.0726818944535737" LOG_CI_START="-0.39813648944897323" LOG_EFFECT_SIZE="-0.16272729749769974" MODIFIED="2009-08-19 14:46:09 +0100" MODIFIED_BY="[Empty name]" ORDER="604" O_E="0.0" SE="0.2765610492929436" STUDY_ID="STD-Wagner-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.07648601398601398" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.778519181484886" CI_END="6.091254350686615" CI_START="-2.9413460600931174" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="1.574954145296749" ESTIMABLE="YES" I2="37.219044518562036" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2009-08-19 15:53:19 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.18875234214658365" P_Q="0.4833570815111804" P_Z="0.494296240116589" Q="0.49127965471234114" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="7.729543578864256" TOTALS="YES" TOTAL_1="318" TOTAL_2="383" UNITS="" WEIGHT="100.00000000000001" Z="0.6834916329077866">
<NAME>Mental state: 1b. General - average score at endpoint (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.3062872844123175" CI_END="11.358259707713092" CI_START="-17.080960949869986" DF="1" EFFECT_SIZE="-2.8613506210784463" ESTIMABLE="YES" I2="69.75459438402228" ID="CMP-001.06.01" MODIFIED="2009-08-19 15:35:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06901532012540612" P_Z="0.6932893863688379" STUDIES="2" TAU2="77.22335831390843" TOTAL_1="62" TOTAL_2="57" WEIGHT="39.9060213632939" Z="0.39439506672695734">
<NAME>short term</NAME>
<CONT_DATA CI_END="8.79417127617175" CI_START="-2.9341712761717513" EFFECT_SIZE="2.9299999999999997" ESTIMABLE="YES" MEAN_1="-14.89" MEAN_2="-17.82" ORDER="23" SD_1="14.78" SD_2="12.47" SE="2.9919790988138484" STUDY_ID="STD-Vanelle-2006" TOTAL_1="44" TOTAL_2="39" WEIGHT="31.829863665979445"/>
<CONT_DATA CI_END="2.9786668271231527" CI_START="-26.87866682712316" EFFECT_SIZE="-11.950000000000003" ESTIMABLE="YES" MEAN_1="-45.28" MEAN_2="-33.33" ORDER="24" SD_1="23.53" SD_2="22.15" SE="7.61680670914291" STUDY_ID="STD-Wagner-2005" TOTAL_1="18" TOTAL_2="18" WEIGHT="8.076157697314454"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.3153687773532365" CI_END="7.541483346775273" CI_START="-2.4808137498182106" DF="1" EFFECT_SIZE="2.530334798478531" ESTIMABLE="YES" I2="23.975692808203675" ID="CMP-001.06.02" MODIFIED="2009-08-19 15:35:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.25142503713377884" P_Z="0.32233724253984175" STUDIES="2" TAU2="3.3041501651305696" TOTAL_1="256" TOTAL_2="326" WEIGHT="60.09397863670611" Z="0.9896663461577075">
<NAME>medium term</NAME>
<CONT_DATA CI_END="12.977748782685433" CI_START="-1.477748782685433" EFFECT_SIZE="5.75" ESTIMABLE="YES" MEAN_1="-13.7" MEAN_2="-19.45" ORDER="25" SD_1="25.4" SD_2="24.77" SE="3.6876946921968936" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" WEIGHT="24.89466841007807"/>
<CONT_DATA CI_END="5.815481416230663" CI_START="-4.815481416230663" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-26.8" MEAN_2="-27.3" ORDER="26" SD_1="26.6" SD_2="25.7" SE="2.712030148593802" STUDY_ID="STD-Mortimer-2004" TOTAL_1="186" TOTAL_2="186" WEIGHT="35.19931022662804"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3615557688209834" CI_START="0.8754149714788954" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0917537746806039" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="82" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.13403543458173847" LOG_CI_START="-0.0577860302896508" LOG_EFFECT_SIZE="0.03812470214604386" METHOD="MH" MODIFIED="2009-08-19 15:53:14 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.4359270105084544" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="189" TOTAL_2="188" WEIGHT="100.0" Z="0.7790894848776438">
<NAME>Mental state: 1c. General - no clinically important change - medium term (less than 50% BPRS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3615557688209834" CI_START="0.8754149714788954" EFFECT_SIZE="1.0917537746806039" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="82" LOG_CI_END="0.13403543458173847" LOG_CI_START="-0.0577860302896508" LOG_EFFECT_SIZE="0.03812470214604386" MODIFIED="2009-08-19 14:52:33 +0100" MODIFIED_BY="[Empty name]" ORDER="605" O_E="0.0" SE="0.11267687799701906" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="0.012696078835155118" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.7233247571016033" CI_END="3.3395234535138636" CI_START="-0.8184842724255936" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="1.260519590544135" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2009-08-19 15:53:11 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.4224595444398126" P_Q="0.9973765759579991" P_Z="0.23469769714583566" Q="1.081081487615576E-5" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="300" TOTAL_2="365" UNITS="" WEIGHT="100.00000000000001" Z="1.188344592945883">
<NAME>Mental state: 1d. General - average score at endpoint (BPRS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.975196812404689" CI_START="-2.175196812404688" DF="0" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" MODIFIED="2009-08-19 15:35:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.44278662280198144" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="39" WEIGHT="33.815100592572534" Z="0.7674960910782664">
<NAME>short term</NAME>
<CONT_DATA CI_END="4.975196812404689" CI_START="-2.175196812404688" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" MEAN_1="-10.09" MEAN_2="-11.49" ORDER="28" SD_1="9.07" SD_2="7.54" SE="1.8241135248429994" STUDY_ID="STD-Vanelle-2006" TOTAL_1="44" TOTAL_2="39" WEIGHT="33.815100592572534"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.714490627073932" CI_END="4.826017305710815" CI_START="-2.0426503880759763" DF="1" EFFECT_SIZE="1.3916834588174196" ESTIMABLE="YES" I2="41.67363856012039" ID="CMP-001.08.02" MODIFIED="2009-08-19 15:35:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.19040386399306497" P_Z="0.42706181036649804" STUDIES="2" TAU2="2.6259601497695866" TOTAL_1="256" TOTAL_2="326" WEIGHT="66.18489940742748" Z="0.7942295591413255">
<NAME>medium term</NAME>
<CONT_DATA CI_END="7.690532153715408" CI_START="-0.7905321537154091" EFFECT_SIZE="3.4499999999999993" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="-9.45" ORDER="29" SD_1="15.0" SD_2="14.33" SE="2.163576569347286" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" WEIGHT="24.03642483536754"/>
<CONT_DATA CI_END="3.1023173298185487" CI_START="-3.3023173298185515" EFFECT_SIZE="-0.10000000000000142" ESTIMABLE="YES" MEAN_1="-18.3" MEAN_2="-18.2" ORDER="30" SD_1="16.2" SD_2="15.3" SE="1.6338653950164495" STUDY_ID="STD-Mortimer-2004" TOTAL_1="186" TOTAL_2="186" WEIGHT="42.14847457205993"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3305555317305497" CI_START="0.3602179160497175" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.12403300487077343" LOG_CI_START="-0.4434346906057972" LOG_EFFECT_SIZE="-0.1597008428675119" METHOD="MH" MODIFIED="2009-08-19 15:53:03 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.2699514796360025" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="1.1031743403759522">
<NAME>Mental state: 2a. Positive symptoms - no clinically important change - short term (less than 50% PANSS positive subscore reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3305555317305497" CI_START="0.3602179160497175" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.12403300487077343" LOG_CI_START="-0.4434346906057972" LOG_EFFECT_SIZE="-0.1597008428675119" MODIFIED="2009-08-19 14:57:34 +0100" MODIFIED_BY="[Empty name]" ORDER="606" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Wagner-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.1111111111111111" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.238030997960827" CI_END="1.8845588186692632" CI_START="-0.5578421684565299" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6633583251063667" ESTIMABLE="YES" I2="29.212410163033695" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2009-08-19 15:52:52 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.23688189061292508" P_Q="0.6162167282083947" P_Z="0.2870316465109407" Q="0.25122092803845913" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.45433934030696416" TOTALS="YES" TOTAL_1="318" TOTAL_2="383" UNITS="" WEIGHT="100.0" Z="1.064655994577952">
<NAME>Mental state: 2b. Positive symptoms - average score at endpoint (PANSS positive subscore, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.8142546029779028" CI_END="2.5736115487065074" CI_START="-2.2716247051407157" DF="1" EFFECT_SIZE="0.15099342178289574" ESTIMABLE="YES" I2="44.88094458414998" ID="CMP-001.10.01" MODIFIED="2009-08-19 15:35:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.177998846242716" P_Z="0.9027740572971572" STUDIES="2" TAU2="1.587798057498058" TOTAL_1="62" TOTAL_2="57" WEIGHT="45.81044752585125" Z="0.12215778677952277">
<NAME>short term</NAME>
<CONT_DATA CI_END="2.5628139346745114" CI_START="-0.5828139346745109" EFFECT_SIZE="0.9900000000000002" ESTIMABLE="YES" MEAN_1="-2.32" MEAN_2="-3.31" ORDER="32" SD_1="4.14" SD_2="3.15" SE="0.802470834709549" STUDY_ID="STD-Vanelle-2006" TOTAL_1="44" TOTAL_2="39" WEIGHT="35.34738243847578"/>
<CONT_DATA CI_END="1.8666595329043503" CI_START="-5.20665953290435" EFFECT_SIZE="-1.67" ESTIMABLE="YES" MEAN_1="-12.28" MEAN_2="-10.61" ORDER="33" SD_1="4.78" SD_2="5.98" SE="1.8044512862486604" STUDY_ID="STD-Wagner-2005" TOTAL_1="18" TOTAL_2="18" WEIGHT="10.463065087375467"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.356259735675704" CI_END="3.1207511177202694" CI_START="-1.1646004404405597" DF="1" EFFECT_SIZE="0.9780753386398549" ESTIMABLE="YES" I2="57.55985705399196" ID="CMP-001.10.02" MODIFIED="2009-08-19 15:35:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12478120981811514" P_Z="0.3709623574283425" STUDIES="2" TAU2="1.3929485407066053" TOTAL_1="256" TOTAL_2="326" WEIGHT="54.189552474148755" Z="0.8946721928800914">
<NAME>medium term</NAME>
<CONT_DATA CI_END="4.43064715552728" CI_START="-0.03064715552728048" EFFECT_SIZE="2.2" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="-1.0" ORDER="34" SD_1="8.3" SD_2="6.6" SE="1.13810619640072" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" WEIGHT="22.188746632937576"/>
<CONT_DATA CI_END="1.7073268705074673" CI_START="-1.7073268705074673" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-11.2" MEAN_2="-11.2" ORDER="35" SD_1="8.5" SD_2="8.3" SE="0.8711011447019659" STUDY_ID="STD-Mortimer-2004" TOTAL_1="186" TOTAL_2="186" WEIGHT="32.00080584121118"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5965936325978598" CI_START="0.8027057401796025" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1320754716981132" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.20319439292129843" LOG_CI_START="-0.0954436313555893" LOG_EFFECT_SIZE="0.05387538078285457" METHOD="MH" MODIFIED="2009-08-19 15:52:48 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.47946134304401944" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="140" WEIGHT="100.0" Z="0.7071691975156728">
<NAME>Mental state: 3a. Negative symptoms - no clinically important change - medium term (less than 20% SANS total plus 10% PANSS total reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5965936325978598" CI_START="0.8027057401796025" EFFECT_SIZE="1.1320754716981132" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="53" LOG_CI_END="0.20319439292129843" LOG_CI_START="-0.0954436313555893" LOG_EFFECT_SIZE="0.05387538078285457" MODIFIED="2009-08-19 14:57:42 +0100" MODIFIED_BY="[Empty name]" ORDER="607" O_E="0.0" SE="0.17542145374230542" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" VAR="0.030772686433063797" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.8552737955948793" CI_END="1.1011430598802732" CI_START="-0.68913822338847" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.20600241824590165" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2009-08-19 15:52:42 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.6029814174207928" P_Q="0.5431413368139596" P_Z="0.6519501858053851" Q="0.3697491018498724" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="318" TOTAL_2="383" UNITS="" WEIGHT="100.0" Z="0.4510546183591143">
<NAME>Mental state: 3b. Negative symptoms - average score at endpoint (PANSS negative subscore, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.6047690247663782" CI_END="2.0498775984292474" CI_START="-3.021821757020564" DF="1" EFFECT_SIZE="-0.4859720792956583" ESTIMABLE="YES" I2="37.68573641645534" ID="CMP-001.12.01" MODIFIED="2009-08-19 15:36:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2052287305131657" P_Z="0.7072076550242028" STUDIES="2" TAU2="1.6845712606837626" TOTAL_1="62" TOTAL_2="57" WEIGHT="42.36161804859517" Z="0.37560892559139364">
<NAME>short term</NAME>
<CONT_DATA CI_END="1.708100733141191" CI_START="-1.1881007331411906" EFFECT_SIZE="0.26000000000000023" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-3.56" ORDER="36" SD_1="3.63" SD_2="3.1" SE="0.7388404810310927" STUDY_ID="STD-Vanelle-2006" TOTAL_1="44" TOTAL_2="39" WEIGHT="38.21070093621269"/>
<CONT_DATA CI_END="1.6635871463623646" CI_START="-7.1235871463623655" EFFECT_SIZE="-2.7300000000000004" ESTIMABLE="YES" MEAN_1="-9.56" MEAN_2="-6.83" ORDER="37" SD_1="6.72" SD_2="6.73" SE="2.2416672862452676" STUDY_ID="STD-Wagner-2005" TOTAL_1="18" TOTAL_2="18" WEIGHT="4.150917112382482"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.04926310562462617" CI_END="1.5607046796815034" CI_START="-0.7974124930089075" DF="1" EFFECT_SIZE="0.3816460933362979" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.02" MODIFIED="2009-08-19 15:36:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8243505225098879" P_Z="0.5258099465461684" STUDIES="2" TAU2="0.0" TOTAL_1="256" TOTAL_2="326" WEIGHT="57.63838195140483" Z="0.634415122744844">
<NAME>medium term</NAME>
<CONT_DATA CI_END="2.8601033974029924" CI_START="-1.660103397402993" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" MEAN_1="-7.0" MEAN_2="-7.6" ORDER="38" SD_1="7.8" SD_2="8.03" SE="1.1531351673961359" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" WEIGHT="15.686495708525328"/>
<CONT_DATA CI_END="1.682023823257996" CI_START="-1.0820238232579964" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="-2.7" MEAN_2="-3.0" ORDER="39" SD_1="6.8" SD_2="6.8" SE="0.7051271524166891" STUDY_ID="STD-Mortimer-2004" TOTAL_1="186" TOTAL_2="186" WEIGHT="41.9518862428795"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7893571246411785" CI_END="1.4331805826424755" CI_START="-1.4309418577326751" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0011193624549001328" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2009-08-19 15:52:38 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.37429463486678793" P_Q="0.37429463486678793" P_Z="0.9987776456165687" Q="0.7893571246411785" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="87" TOTAL_2="156" UNITS="" WEIGHT="100.0" Z="0.0015319946286676462">
<NAME>Mental state: 3c. Negative symptoms - average score at endpoint (SANS total score, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.45228387422615" CI_START="-27.692283874226153" DF="0" EFFECT_SIZE="-8.620000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.01" MODIFIED="2009-08-19 15:36:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.37570665501129685" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="16" WEIGHT="0.56379051378431" Z="0.8858346309309414">
<NAME>short term</NAME>
<CONT_DATA CI_END="10.45228387422615" CI_START="-27.692283874226153" EFFECT_SIZE="-8.620000000000001" ESTIMABLE="YES" MEAN_1="-34.68" MEAN_2="-26.06" ORDER="41" SD_1="31.21" SD_2="24.46" SE="9.730935886917257" STUDY_ID="STD-Wagner-2005" TOTAL_1="17" TOTAL_2="16" WEIGHT="0.56379051378431"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4861152832369275" CI_START="-1.386115283236928" DF="0" EFFECT_SIZE="0.04999999999999982" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.02" MODIFIED="2009-08-19 15:36:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9455958649136985" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="140" WEIGHT="99.43620948621569" Z="0.06823839309482148">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.4861152832369275" CI_START="-1.386115283236928" EFFECT_SIZE="0.04999999999999982" ESTIMABLE="YES" MEAN_1="-4.3" MEAN_2="-4.35" ORDER="42" SD_1="4.9" SD_2="5.21" SE="0.7327253432026414" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" WEIGHT="99.43620948621569"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.942983449477028" CI_START="-10.54298344947703" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2009-08-19 16:01:34 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.9708930378838766" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="177" UNITS="" WEIGHT="100.0" Z="0.03648826219936993">
<NAME>General functioning: General - average score at endpoint - medium term (SOFAS total - percent change,high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.942983449477028" CI_START="-10.54298344947703" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="-30.0" MEAN_2="-30.2" MODIFIED="2009-08-19 15:14:18 +0100" MODIFIED_BY="[Empty name]" ORDER="608" SD_1="54.3" SD_2="49.5" SE="5.481214723442018" STUDY_ID="STD-Mortimer-2004" TOTAL_1="182" TOTAL_2="177" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3558602874301315" CI_END="0.22372431063147002" CI_START="-0.21948820318023998" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0021180537256150263" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2009-08-20 09:18:12 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.5508145884007354" P_Q="1.0" P_Z="0.9850542502359078" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="233" TOTAL_2="277" UNITS="" WEIGHT="99.99999999999999" Z="0.018732815027375036">
<NAME>Quality of life: General - average score at endpoint - medium term (QLS total score, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.210456183599572" CI_START="-4.910456183599575" EFFECT_SIZE="2.1499999999999986" ESTIMABLE="YES" MEAN_1="-50.7" MEAN_2="-52.85" MODIFIED="2009-08-20 09:18:12 +0100" MODIFIED_BY="[Empty name]" ORDER="180" SD_1="20.6" SD_2="24.61" SE="3.602339756899387" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="58" TOTAL_2="107" WEIGHT="0.09851412677279199"/>
<CONT_DATA CI_END="0.22171549435765792" CI_START="-0.22171549435765792" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.6" MODIFIED="2009-08-20 09:18:12 +0100" MODIFIED_BY="[Empty name]" ORDER="179" SD_1="1.1" SD_2="1.0" SE="0.11312222882997924" STUDY_ID="STD-Mortimer-2004" TOTAL_1="175" TOTAL_2="170" WEIGHT="99.90148587322719"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3468114404098084" CI_START="0.7424944353722742" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.12930679682040805" LOG_CI_START="-0.12930679682040805" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2009-08-19 15:18:16 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="0.0">
<NAME>Cognitive functioning: 1a. No clinically important change - short term (less than 50% Global Cognitive Index reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3468114404098084" CI_START="0.7424944353722742" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.12930679682040805" LOG_CI_START="-0.12930679682040805" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-19 15:17:24 +0100" MODIFIED_BY="[Empty name]" ORDER="610" O_E="0.0" SE="0.15191090506255" STUDY_ID="STD-Wagner-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.023076923076923078" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.08947124031163123" CI_START="-0.34947124031163124" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.13" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.17" MODIFIED="2009-08-19 15:52:19 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.24566191714618024" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="1.1609508272173545">
<NAME>Cognitive functioning: 1b. General - average score at endpoint - short term (Global Cognitive Index, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.08947124031163123" CI_START="-0.34947124031163124" EFFECT_SIZE="-0.13" ESTIMABLE="YES" MEAN_1="-0.25" MEAN_2="-0.12" MODIFIED="2009-08-19 15:17:04 +0100" MODIFIED_BY="[Empty name]" ORDER="609" SD_1="0.24" SD_2="0.41" SE="0.11197718021493883" STUDY_ID="STD-Wagner-2005" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.1895016357005539" CI_END="1.213030967082728" CI_START="0.8733089837703822" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.029247706407462" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="124" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.083871887974143" LOG_CI_START="-0.05883207221088938" LOG_EFFECT_SIZE="0.012519907881626841" METHOD="MH" MODIFIED="2009-08-19 15:19:58 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.6633317333382693" P_Q="1.0" P_Z="0.7309149302815579" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="228" WEIGHT="99.99999999999999" Z="0.34390872553124047">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2112924468858988" CI_START="0.8482659574203688" EFFECT_SIZE="1.0136558327034517" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="105" LOG_CI_END="0.08324900915093333" LOG_CI_START="-0.07146796173951878" LOG_EFFECT_SIZE="0.005890523705707267" ORDER="48" O_E="0.0" SE="0.09088151456240914" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="0.008259449689157386" WEIGHT="85.0738608901533"/>
<DICH_DATA CI_END="1.7178704154776676" CI_START="0.7338711856768256" EFFECT_SIZE="1.1228070175438596" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" LOG_CI_END="0.23499040049315975" LOG_CI_START="-0.13438016387036825" LOG_EFFECT_SIZE="0.050305118311395745" ORDER="49" O_E="0.0" SE="0.21697009792091823" STUDY_ID="STD-Vanelle-2006" TOTAL_1="45" TOTAL_2="40" VAR="0.04707602339181285" WEIGHT="14.926139109846691"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9701646013337415" CI_END="3.9974051460709017" CI_START="0.16549141073049978" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.813348767064064" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.6017781672208388" LOG_CI_START="-0.781224541883123" LOG_EFFECT_SIZE="-0.08972318733114207" METHOD="MH" MODIFIED="2009-08-19 15:37:05 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.6156465760200107" P_Q="0.6158596364094172" P_Z="0.7992577437666916" Q="0.9694725685272496" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="448" TOTAL_2="516" WEIGHT="300.00000000000006" Z="0.2543078398756191">
<NAME>Adverse effects: 2. Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.7917799326809" CI_START="0.12234228196658924" DF="0" EFFECT_SIZE="2.9842105263157896" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.19.01" LOG_CI_END="1.8620823390460248" LOG_CI_START="-0.9124234231658697" LOG_EFFECT_SIZE="0.47482945794007764" MODIFIED="2009-08-19 15:36:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5023114842884946" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="188" WEIGHT="100.00000000000001" Z="0.6708572380972789">
<NAME>natural causes</NAME>
<DICH_DATA CI_END="72.7917799326809" CI_START="0.12234228196658924" EFFECT_SIZE="2.9842105263157896" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8620823390460248" LOG_CI_START="-0.9124234231658697" LOG_EFFECT_SIZE="0.47482945794007764" ORDER="54" O_E="0.0" SE="1.6297584187482894" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="2.6561125034809248" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.29305407925318" CI_START="0.0706246027520533" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="0.7988614638657641" LOG_CI_START="-1.1510439819771265" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2009-08-19 15:37:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7233394513294845" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="140" WEIGHT="100.00000000000001" Z="0.353999242863037">
<NAME>suicide attempt</NAME>
<DICH_DATA CI_END="6.29305407925318" CI_START="0.0706246027520533" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.7988614638657641" LOG_CI_START="-1.1510439819771265" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="55" O_E="0.0" SE="1.1453841110757395" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" VAR="1.311904761904762" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.087975548075658" CI_START="0.013593586885176579" DF="0" EFFECT_SIZE="0.33157894736842103" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.19.03" LOG_CI_END="0.9078398296067001" LOG_CI_START="-1.8666659326051946" LOG_EFFECT_SIZE="-0.4794130514992473" MODIFIED="2009-08-19 15:37:05 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4981946294954601" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="188" WEIGHT="100.00000000000001" Z="0.6773331145709182">
<NAME>suicide</NAME>
<DICH_DATA CI_END="8.087975548075658" CI_START="0.013593586885176579" EFFECT_SIZE="0.33157894736842103" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9078398296067001" LOG_CI_START="-1.8666659326051946" LOG_EFFECT_SIZE="-0.4794130514992473" ORDER="56" O_E="0.0" SE="1.6297584187482894" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="2.6561125034809248" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-08-19 15:21:44 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="189" TOTAL_2="188" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 3a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="50" O_E="0.0" SE="0.0" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.019667570891277474" CI_END="11.070466767074429" CI_START="-0.5666557201541611" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="5.251905523460134" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.21" MODIFIED="2009-08-19 15:21:49 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.888469494287073" P_Q="1.0" P_Z="0.07687922449581426" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="157" TOTAL_2="146" UNITS="" WEIGHT="100.0" Z="1.7690877942525254">
<NAME>Adverse effects: 3b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.800729496222004" CI_START="-1.8007294962220044" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="-1.9" ORDER="51" SD_1="27.2" SD_2="24.0" SE="3.469823705876889" STUDY_ID="STD-Mortimer-2004" TOTAL_1="112" TOTAL_2="106" WEIGHT="73.20154005743264"/>
<CONT_DATA CI_END="17.179854557495155" CI_START="-5.299854557495155" EFFECT_SIZE="5.94" ESTIMABLE="YES" MEAN_1="-1.71" MEAN_2="-7.65" ORDER="52" SD_1="26.39" SD_2="26.39" SE="5.7347250491099295" STUDY_ID="STD-Vanelle-2006" TOTAL_1="45" TOTAL_2="40" WEIGHT="26.79845994256736"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.9127646721232858" CI_END="2.339893502055208" CI_START="0.6357418321526074" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2196590433553791" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="0.3691960913749778" LOG_CI_START="-0.1967192108201082" LOG_EFFECT_SIZE="0.08623844027743476" METHOD="MH" MODIFIED="2009-08-19 16:29:45 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.33938206533601867" P_Q="1.0" P_Z="0.5502749486606958" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="259" TOTAL_2="328" WEIGHT="100.0" Z="0.5973481769129242">
<NAME>Adverse effects: 4a. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.679725721719282" CI_START="0.5988269828196549" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.8247586301418107" LOG_CI_START="-0.22269863881384844" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="76" O_E="0.0" SE="0.6152815847816581" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" VAR="0.3785714285714286" WEIGHT="29.189741214124776"/>
<DICH_DATA CI_END="2.157518889136815" CI_START="0.45860362527386195" EFFECT_SIZE="0.9947089947089947" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.33395460666394516" LOG_CI_START="-0.3385625164830738" LOG_EFFECT_SIZE="-0.002303954909564312" ORDER="77" O_E="0.0" SE="0.3950398871500081" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="0.15605651243949115" WEIGHT="70.81025878587522"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.04410899353727" CI_START="0.027312623293406925" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6619718309859155" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="1.205315603641884" LOG_CI_START="-1.5636365852085994" LOG_EFFECT_SIZE="-0.17916049078335783" METHOD="MH" MODIFIED="2009-08-19 15:24:14 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.7997794995143178" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="140" WEIGHT="100.0" Z="0.25363248293115453">
<NAME>Adverse effects: 4b. Central nervous system - seizures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.04410899353727" CI_START="0.027312623293406925" EFFECT_SIZE="0.6619718309859155" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.205315603641884" LOG_CI_START="-1.5636365852085994" LOG_EFFECT_SIZE="-0.17916049078335783" ORDER="78" O_E="0.0" SE="1.6264962222651649" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" VAR="2.645489961042853" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.218692222726792" CI_END="1.5062618300605388" CI_START="0.8091510010283207" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1039897044828975" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="92" I2="28.690440550694273" I2_Q="13.47436700662614" ID="CMP-001.24" LOG_CI_END="0.17790047084663613" LOG_CI_START="-0.09197042425432471" LOG_EFFECT_SIZE="0.04296502329615571" METHOD="MH" MODIFIED="2009-08-19 15:25:38 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.18961316371089554" P_Q="0.3269603074094596" P_Z="0.532578048580576" Q="6.934361289745757" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.10551985061606141" TOTALS="SUB" TOTAL_1="1106" TOTAL_2="1452" WEIGHT="700.0" Z="0.6240754359515949">
<NAME>Adverse effects: 5a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4283818637659131" CI_END="1.2140874389862892" CI_START="0.3558127155906424" DF="1" EFFECT_SIZE="0.6572577490073435" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="33" I2="0.0" ID="CMP-001.24.01" LOG_CI_END="0.08424996590048751" LOG_CI_START="-0.4487785357007328" LOG_EFFECT_SIZE="-0.18226428490012256" MODIFIED="2009-08-19 15:25:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5127840328610186" P_Z="0.18012053900462097" STUDIES="2" TAU2="0.0" TOTAL_1="259" TOTAL_2="328" WEIGHT="100.0" Z="1.340383986969038">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="1.3855768119178506" CI_START="0.3682250433496015" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="28" LOG_CI_END="0.14163060667356797" LOG_CI_START="-0.43388667803004394" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="57" O_E="0.0" SE="0.33806170189140666" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" VAR="0.1142857142857143" WEIGHT="85.77962053774662"/>
<DICH_DATA CI_END="2.0253703683368105" CI_START="0.07816415206804789" EFFECT_SIZE="0.3978835978835979" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3065044518555135" LOG_CI_START="-1.1069923790187173" LOG_EFFECT_SIZE="-0.40024396358160186" ORDER="58" O_E="0.0" SE="0.8302950353776809" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="0.6893898457728244" WEIGHT="14.220379462253383"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.04410899353727" CI_START="0.027312623293406925" DF="0" EFFECT_SIZE="0.6619718309859155" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.24.02" LOG_CI_END="1.205315603641884" LOG_CI_START="-1.5636365852085994" LOG_EFFECT_SIZE="-0.17916049078335783" MODIFIED="2009-08-19 15:25:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7997794995143178" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="140" WEIGHT="100.0" Z="0.25363248293115453">
<NAME>dyskinesia</NAME>
<DICH_DATA CI_END="16.04410899353727" CI_START="0.027312623293406925" EFFECT_SIZE="0.6619718309859155" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.205315603641884" LOG_CI_START="-1.5636365852085994" LOG_EFFECT_SIZE="-0.17916049078335783" ORDER="59" O_E="0.0" SE="1.6264962222651649" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" VAR="2.645489961042853" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="102.90851000155884" CI_START="0.2403837605428753" DF="0" EFFECT_SIZE="4.973684210526317" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.24.03" LOG_CI_END="2.012451290155048" LOG_CI_START="-0.6190948750421794" LOG_EFFECT_SIZE="0.6966782075564341" MODIFIED="2009-08-19 15:25:15 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.29937915636241974" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="188" WEIGHT="100.0" Z="1.0377657163557257">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="102.90851000155875" CI_START="0.24038376054287525" EFFECT_SIZE="4.973684210526316" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0124512901550475" LOG_CI_START="-0.6190948750421795" LOG_EFFECT_SIZE="0.696678207556434" ORDER="60" O_E="0.0" SE="1.5457832438004555" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="2.389445836814258" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9964796097478983" CI_START="0.7212695751908196" DF="0" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="30" I2="0.0" ID="CMP-001.24.04" LOG_CI_END="0.3002648790586846" LOG_CI_START="-0.141902386963435" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2009-08-19 15:25:23 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.48270263742540387" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="140" WEIGHT="100.0" Z="0.7019623677732199">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="1.9964796097478983" CI_START="0.7212695751908196" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="30" LOG_CI_END="0.3002648790586846" LOG_CI_START="-0.141902386963435" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="61" O_E="0.0" SE="0.2597312408246598" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" VAR="0.06746031746031744" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.56586180861472" CI_END="31.124096440530938" CI_START="0.41724971515004106" DF="1" EFFECT_SIZE="3.6036815028681355" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" I2="61.02673976273536" ID="CMP-001.24.05" LOG_CI_END="1.4930967523419472" LOG_CI_START="-0.37960395113477335" LOG_EFFECT_SIZE="0.5567464006035869" MODIFIED="2009-08-19 15:25:29 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.1091933956331258" P_Z="0.24386569583866757" STUDIES="2" TAU2="1.4814647528681981" TOTAL_1="259" TOTAL_2="328" WEIGHT="100.0" Z="1.1653788474362095">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="7.796870822716734" CI_START="0.22801170087339354" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.8919203389601847" LOG_CI_START="-0.6420428657435848" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="62" O_E="0.0" SE="0.9010575796833197" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" VAR="0.8119047619047619" WEIGHT="52.76402483188485"/>
<DICH_DATA CI_END="83.90845776995002" CI_START="1.4268283229682792" EFFECT_SIZE="10.941798941798941" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.9238057388702892" LOG_CI_START="0.15437172162703242" LOG_EFFECT_SIZE="1.0390887302486607" ORDER="63" O_E="0.0" SE="1.039374300568335" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="1.0802989366819153" WEIGHT="47.23597516811514"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.678985941491934" CI_START="0.12188589988010622" DF="0" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-001.24.06" LOG_CI_END="0.42797043456808315" LOG_CI_START="-0.914046531940672" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2009-08-19 15:25:33 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.47776902065067883" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="140" WEIGHT="100.0" Z="0.7098953801414877">
<NAME>tremor</NAME>
<DICH_DATA CI_END="2.678985941491934" CI_START="0.12188589988010622" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.42797043456808315" LOG_CI_START="-0.914046531940672" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="64" O_E="0.0" SE="0.7883074092183654" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" VAR="0.6214285714285714" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.709064487795397" CI_START="0.8543220194027956" DF="0" EFFECT_SIZE="1.5213196389666979" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="17" I2="0.0" ID="CMP-001.24.07" LOG_CI_END="0.43281934329833854" LOG_CI_START="-0.06837839993237904" LOG_EFFECT_SIZE="0.18222047168297978" MODIFIED="2009-08-19 15:25:38 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.15410856433847508" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="188" WEIGHT="100.0" Z="1.4251682756685338">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="2.709064487795397" CI_START="0.8543220194027956" EFFECT_SIZE="1.5213196389666979" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="17" LOG_CI_END="0.43281934329833854" LOG_CI_START="-0.06837839993237904" LOG_EFFECT_SIZE="0.18222047168297978" ORDER="65" O_E="0.0" SE="0.29440603534256504" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="0.08667491364612767" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.4057148810426274" CI_END="0.07648242577249145" CI_START="-0.08526414584316602" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.004390860035337286" ESTIMABLE="YES" I2="0.0" I2_Q="12.960892314904198" ID="CMP-001.25" MODIFIED="2009-08-19 15:26:43 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.49516842760172486" P_Q="0.2837777298557653" P_Z="0.9152550856021704" Q="1.1489088371838119" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="385" TOTAL_2="377" UNITS="" WEIGHT="200.0" Z="0.10641248768928188">
<NAME>Adverse effects: 5b. Extrapyramidal effects - scale measured</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3278952290562799" CI_START="-1.1278952290562798" DF="0" EFFECT_SIZE="-0.4" ESTIMABLE="YES" I2="0.0" ID="CMP-001.25.01" MODIFIED="2009-08-19 15:26:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2814542399164566" STUDIES="1" TAU2="0.0" TOTAL_1="181" TOTAL_2="175" WEIGHT="100.0" Z="1.0770582942719151">
<NAME>abnormal involuntary movement: AIMS (high=poor)</NAME>
<CONT_DATA CI_END="0.3278952290562799" CI_START="-1.1278952290562798" EFFECT_SIZE="-0.4" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.5" ORDER="66" SD_1="3.4" SD_2="3.6" SE="0.37138194109576733" STUDY_ID="STD-Mortimer-2004" TOTAL_1="181" TOTAL_2="175" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2568060438588157" CI_END="0.08193088794192156" CI_START="-0.0808233605688135" DF="1" EFFECT_SIZE="5.537636865540288E-4" ESTIMABLE="YES" I2="0.0" ID="CMP-001.25.02" MODIFIED="2009-08-19 15:26:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6123230248459987" P_Z="0.9893586332400979" STUDIES="2" TAU2="0.0" TOTAL_1="204" TOTAL_2="202" WEIGHT="99.99999999999999" Z="0.013337370809345541">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</NAME>
<CONT_DATA CI_END="0.08140530369587114" CI_START="-0.08140530369587114" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.1" ORDER="67" SD_1="0.4" SD_2="0.4" SE="0.04153408141067172" STUDY_ID="STD-Mortimer-2004" TOTAL_1="186" TOTAL_2="185" WEIGHT="99.93077953918073"/>
<CONT_DATA CI_END="3.893036858756264" CI_START="-2.293036858756264" EFFECT_SIZE="0.8" ESTIMABLE="YES" MEAN_1="0.56" MEAN_2="-0.24" ORDER="68" SD_1="6.46" SD_2="1.71" SE="1.5781090281014059" STUDY_ID="STD-Wagner-2005" TOTAL_1="18" TOTAL_2="17" WEIGHT="0.0692204608192536"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.162738391212326" CI_START="0.019326163138661458" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3971830985915493" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.26" LOG_CI_END="0.9118358779555612" LOG_CI_START="-1.7138543587549895" LOG_EFFECT_SIZE="-0.40100924039971414" METHOD="MH" MODIFIED="2009-08-19 15:30:06 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.5493916071967773" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="140" WEIGHT="100.0" Z="0.5986720426213374">
<NAME>Adverse effects: 6. Haematological - white blood cell count - leukopenia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.162738391212326" CI_START="0.019326163138661458" EFFECT_SIZE="0.3971830985915493" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.9118358779555612" LOG_CI_START="-1.7138543587549895" LOG_EFFECT_SIZE="-0.40100924039971414" ORDER="85" O_E="0.0" SE="1.5423434424200682" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" VAR="2.3788232943761862" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2253463438553576" CI_END="6.506324231877577" CI_START="0.5327741783230774" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8618274749670292" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.8133357018303509" LOG_CI_START="-0.2734568320426224" LOG_EFFECT_SIZE="0.26993943489386424" METHOD="MH" MODIFIED="2009-08-19 15:30:34 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.7469319254946829" P_Q="0.6844370115736736" P_Z="0.3302360352889777" Q="0.7583177882840398" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="279" TOTAL_2="374" WEIGHT="300.0" Z="0.9736385812545669">
<NAME>Adverse effects: 7. Prolactin associated side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.481540822276944" CI_START="0.2772033007181748" DF="0" EFFECT_SIZE="1.5333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.27.01" LOG_CI_END="0.9284747567172605" LOG_CI_START="-0.5572016027934372" LOG_EFFECT_SIZE="0.18563657696191166" MODIFIED="2009-08-19 15:30:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6242765141433084" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="46" WEIGHT="100.00000000000001" Z="0.4897984715573917">
<NAME>amenorrhea</NAME>
<DICH_DATA CI_END="8.481540822276944" CI_START="0.2772033007181748" EFFECT_SIZE="1.5333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.9284747567172605" LOG_CI_START="-0.5572016027934372" LOG_EFFECT_SIZE="0.18563657696191166" ORDER="72" O_E="0.0" SE="0.8726936477931707" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="20" TOTAL_2="46" VAR="0.7615942028985506" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="158.10026899209382" CI_START="0.28514583144267525" DF="0" EFFECT_SIZE="6.7142857142857135" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.27.02" LOG_CI_END="2.1989326088422825" LOG_CI_START="-0.5449329729993616" LOG_EFFECT_SIZE="0.8269998179214606" MODIFIED="2009-08-19 15:30:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.23741827782028124" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="46" WEIGHT="100.0" Z="1.1814644777601142">
<NAME>galactorrhea</NAME>
<DICH_DATA CI_END="158.10026899209382" CI_START="0.28514583144267525" EFFECT_SIZE="6.714285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.1989326088422825" LOG_CI_START="-0.5449329729993616" LOG_EFFECT_SIZE="0.8269998179214606" ORDER="73" O_E="0.0" SE="1.6117602251274654" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="20" TOTAL_2="46" VAR="2.597771023302938" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4659834722380525" CI_END="12.93568514690999" CI_START="0.14241308868938948" DF="1" EFFECT_SIZE="1.357280691708576" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.27.03" LOG_CI_END="1.1117894363492034" LOG_CI_START="-0.8464500943764446" LOG_EFFECT_SIZE="0.13266967098637936" MODIFIED="2009-08-19 15:30:34 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4948408193342725" P_Z="0.7905680794540323" STUDIES="2" TAU2="0.0" TOTAL_1="239" TOTAL_2="282" WEIGHT="100.0" Z="0.2655730036026041">
<NAME>sexual dysfunction</NAME>
<DICH_DATA CI_END="14.967952953088924" CI_START="0.025757395083749128" EFFECT_SIZE="0.6209150326797386" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.1751624094300894" LOG_CI_START="-1.5890980604875913" LOG_EFFECT_SIZE="-0.20696782552875104" ORDER="74" O_E="0.0" SE="1.6237402833396535" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="50" TOTAL_2="94" VAR="2.636532507739938" WEIGHT="50.18497363510565"/>
<DICH_DATA CI_END="72.7917799326809" CI_START="0.12234228196658924" EFFECT_SIZE="2.9842105263157896" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8620823390460248" LOG_CI_START="-0.9124234231658697" LOG_EFFECT_SIZE="0.47482945794007764" ORDER="75" O_E="0.0" SE="1.6297584187482894" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="2.6561125034809248" WEIGHT="49.815026364894344"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.566635634169851E-33" CI_END="5.478948543195413" CI_START="-12.318948543195413" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.4200000000000004" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-001.28" MODIFIED="2009-08-19 15:31:26 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.0" P_Q="1.0" P_Z="0.4513034964136825" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="40" UNITS="" WEIGHT="100.0" Z="0.7532436888010211">
<NAME>Adverse effects: 8a. Metabolic - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.478948543195413" CI_START="-12.318948543195413" EFFECT_SIZE="-3.42" ESTIMABLE="YES" MEAN_1="-0.54" MEAN_2="2.88" ORDER="53" SD_1="19.6" SD_2="21.98" SE="4.5403632992183445" STUDY_ID="STD-Vanelle-2006" TOTAL_1="45" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.087975548075658" CI_START="0.013593586885176579" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.33157894736842103" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.29" LOG_CI_END="0.9078398296067001" LOG_CI_START="-1.8666659326051946" LOG_EFFECT_SIZE="-0.4794130514992473" METHOD="MH" MODIFIED="2009-08-19 15:31:53 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.4981946294954601" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="189" TOTAL_2="188" WEIGHT="100.00000000000001" Z="0.6773331145709182">
<NAME>Adverse effects: 8b. Metabolic - glucose - diabetes mellitus</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.087975548075658" CI_START="0.013593586885176579" EFFECT_SIZE="0.33157894736842103" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9078398296067001" LOG_CI_START="-1.8666659326051946" LOG_EFFECT_SIZE="-0.4794130514992473" ORDER="69" O_E="0.0" SE="1.6297584187482894" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="2.6561125034809248" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.41534573143319004" CI_END="-6.988428474736233" CI_START="-7.616226080017226" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.30232727737673" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.30" MODIFIED="2009-08-19 15:32:15 +0100" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.5192686341207726" P_Q="1.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="208" TOTAL_2="198" UNITS="" WEIGHT="100.00000000000001" Z="45.59526301657949">
<NAME>Adverse effects: 8c. Metabolic - glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-6.98602141481497" CI_START="-7.6139785851850315" EFFECT_SIZE="-7.300000000000001" ESTIMABLE="YES" MEAN_1="-2.82" MEAN_2="4.48" ORDER="70" SD_1="1.08" SD_2="1.71" SE="0.16019609934756635" STUDY_ID="STD-Mortimer-2004" TOTAL_1="163" TOTAL_2="158" WEIGHT="99.94918608347757"/>
<CONT_DATA CI_END="2.0451000499339997" CI_START="-25.805100049933998" EFFECT_SIZE="-11.879999999999999" ESTIMABLE="YES" MEAN_1="-9.54" MEAN_2="2.34" ORDER="71" SD_1="27.5" SD_2="36.7" SE="7.1047734344984965" STUDY_ID="STD-Vanelle-2006" TOTAL_1="45" TOTAL_2="40" WEIGHT="0.050813916522445435"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.1677300192406324" CI_END="0.7462499779081406" CI_START="0.40009311182636237" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5464151131343479" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="100" I2="0.0" I2_Q="8.113616323106429" ID="CMP-001.31" LOG_CI_END="-0.12711566871935542" LOG_CI_START="-0.3978389255556504" LOG_EFFECT_SIZE="-0.2624772971375029" METHOD="MH" MODIFIED="2009-08-19 16:12:52 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.5577387302549252" P_Q="0.2968485237019435" P_Z="1.4438642112638505E-4" Q="1.0883005293976624" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="304" TOTAL_2="368" WEIGHT="100.0" Z="3.8005308827974607">
<NAME>Adverse effects: 8d. Metabolic - weight - gain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8262217645629351" CI_START="0.41815452620417976" DF="0" EFFECT_SIZE="0.5877825877825877" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="66" I2="0.0" ID="CMP-001.31.01" LOG_CI_END="-0.0829033689030226" LOG_CI_START="-0.37866319794684494" LOG_EFFECT_SIZE="-0.2307832834249338" MODIFIED="2009-08-19 15:32:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0022226638039664548" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="188" WEIGHT="83.78625110107393" Z="3.058744828255559">
<NAME>weight gain of 7% or more of total body weight</NAME>
<DICH_DATA CI_END="0.8262217645629351" CI_START="0.41815452620417976" EFFECT_SIZE="0.5877825877825877" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="66" LOG_CI_END="-0.0829033689030226" LOG_CI_START="-0.37866319794684494" LOG_EFFECT_SIZE="-0.2307832834249338" ORDER="79" O_E="0.0" SE="0.17373078761510663" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" VAR="0.030182386565365288" WEIGHT="83.78625110107393"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.048825523207140904" CI_END="0.812655735833469" CI_START="0.17281224353818078" DF="1" EFFECT_SIZE="0.37474906395287094" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="34" I2="0.0" ID="CMP-001.31.02" LOG_CI_END="-0.09009339498668441" LOG_CI_START="-0.7624254915289759" LOG_EFFECT_SIZE="-0.4262594432578301" MODIFIED="2009-08-19 15:33:03 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8251197005030346" P_Z="0.012946428513808502" STUDIES="2" TAU2="0.0" TOTAL_1="115" TOTAL_2="180" WEIGHT="16.213748898926063" Z="2.4852395450166935">
<NAME>as "weight gain" reported adverse event</NAME>
<DICH_DATA CI_END="0.8839613109833477" CI_START="0.16951410738141887" EFFECT_SIZE="0.3870967741935484" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="31" LOG_CI_END="-0.05356674267260492" LOG_CI_START="-0.7707941529006908" LOG_EFFECT_SIZE="-0.41218044778664786" ORDER="80" O_E="0.0" SE="0.42130293110091727" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="140" VAR="0.17749615975422425" WEIGHT="14.247457652588405"/>
<DICH_DATA CI_END="2.7355646673181084" CI_START="0.0320926411456292" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4370469857292651" LOG_CI_START="-1.4935945400633526" LOG_EFFECT_SIZE="-0.5282737771670437" ORDER="81" O_E="0.0" SE="1.1340683890802667" STUDY_ID="STD-Vanelle-2006" TOTAL_1="45" TOTAL_2="40" VAR="1.2861111111111112" WEIGHT="1.9662912463376576"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.0956040737675345" CI_END="-1.2891470935721192" CI_START="-2.936687664007056" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.1129173787895876" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.32" MODIFIED="2009-08-19 16:13:00 +0100" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.5782194432211348" P_Q="1.0" P_Z="4.977436498819699E-7" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="304" TOTAL_2="367" UNITS="" WEIGHT="100.0" Z="5.027180561196273">
<NAME>Adverse effects: 8e. Metabolic - weight - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.5258668028267746" CI_START="-3.914133197173226" EFFECT_SIZE="-2.22" ESTIMABLE="YES" MEAN_1="0.21" MEAN_2="2.43" ORDER="82" SD_1="5.99" SD_2="5.71" SE="0.8643695550205678" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="70" TOTAL_2="139" WEIGHT="23.64379248071511"/>
<CONT_DATA CI_END="-1.269476488619035" CI_START="-3.3305235113809646" EFFECT_SIZE="-2.3" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="3.9" ORDER="83" SD_1="4.9" SD_2="5.3" SE="0.5257869631838149" STUDY_ID="STD-Mortimer-2004" TOTAL_1="189" TOTAL_2="188" WEIGHT="63.89934920625971"/>
<CONT_DATA CI_END="1.3840054177746672" CI_START="-3.284005417774667" EFFECT_SIZE="-0.95" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="1.45" ORDER="84" SD_1="5.48" SD_2="5.48" SE="1.190840972683684" STUDY_ID="STD-Vanelle-2006" TOTAL_1="45" TOTAL_2="40" WEIGHT="12.45685831302518"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-08-20 16:24:10 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>AMISULPRIDE versus RISPERIDONE</NAME>
<DICH_OUTCOME CHI2="4.348867369406825" CI_END="1.2000052101658754" CI_START="0.6665114319173646" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8943249917876364" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="152" I2="54.01101413049543" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.07918313166543924" LOG_CI_START="-0.17619239722378918" LOG_EFFECT_SIZE="-0.04850463277917492" METHOD="MH" MODIFIED="2009-08-20 16:24:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11367259034651489" P_Q="1.0" P_Z="0.45655608429056727" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.035940423660893575" TOTALS="YES" TOTAL_1="290" TOTAL_2="296" WEIGHT="100.00000000000001" Z="0.7445297029361041">
<NAME>Global state: 1a. No clinically significant response (as def. by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.089880526764992" CI_START="0.5552224673796501" EFFECT_SIZE="0.7778985507246376" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="48" LOG_CI_END="0.037378892976852485" LOG_CI_START="-0.25553296823479055" LOG_EFFECT_SIZE="-0.10907703762896905" ORDER="97" O_E="0.0" SE="0.1720578772128164" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" VAR="0.029603913110980602" WEIGHT="34.3319592908164"/>
<DICH_DATA CI_END="0.995421355460892" CI_START="0.6546513342201984" EFFECT_SIZE="0.8072508398656215" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="94" LOG_CI_END="-0.001993046272991799" LOG_CI_START="-0.18398994266619353" LOG_EFFECT_SIZE="-0.09299149446959268" ORDER="98" O_E="0.0" SE="0.10690587784053336" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.011428866716855043" WEIGHT="47.50473321113104"/>
<DICH_DATA CI_END="2.7212979387727483" CI_START="0.8509505512434773" EFFECT_SIZE="1.5217391304347827" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.4347760927100943" LOG_CI_START="-0.07009567604472874" LOG_EFFECT_SIZE="0.18234020833268277" MODIFIED="2009-08-20 16:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.29656417612214425" STUDY_ID="STD-Hwang-2003" TOTAL_1="23" TOTAL_2="25" VAR="0.0879503105590062" WEIGHT="18.16330749805258"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.478284851222844" CI_END="1.2253743585163865" CI_START="0.6514864300548051" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8934846200749835" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="136" I2="55.34004498499289" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.08826878829285643" LOG_CI_START="-0.18609462586650682" LOG_EFFECT_SIZE="-0.04891291878682516" METHOD="MH" MODIFIED="2009-08-19 16:30:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10654995383271182" P_Q="0.4316287335699177" P_Z="0.4846543332382548" Q="0.6184374442305482" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04227546567585506" TOTALS="YES" TOTAL_1="290" TOTAL_2="296" WEIGHT="100.0" Z="0.6988363189359169">
<NAME>Global State: 1b. No clinically important change (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.852675870956527" CI_END="2.0039779506242823" CI_START="0.5417853600955763" DF="1" EFFECT_SIZE="1.0419817251768726" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="58" I2="74.04401425153567" ID="CMP-002.02.01" LOG_CI_END="0.3018929387646271" LOG_CI_START="-0.26617273447377726" LOG_EFFECT_SIZE="0.01786010214542487" MODIFIED="2009-08-19 16:30:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.049666743462345786" P_Z="0.9019144025948918" STUDIES="2" TAU2="0.167672048696199" TOTAL_1="138" TOTAL_2="138" WEIGHT="56.07944698524127" Z="0.12324334531845056">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.7212979387727483" CI_START="0.8509505512434773" EFFECT_SIZE="1.5217391304347827" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.4347760927100943" LOG_CI_START="-0.07009567604472874" LOG_EFFECT_SIZE="0.18234020833268277" ORDER="99" O_E="0.0" SE="0.29656417612214425" STUDY_ID="STD-Hwang-2003" TOTAL_1="23" TOTAL_2="25" VAR="0.0879503105590062" WEIGHT="19.944844116300175"/>
<DICH_DATA CI_END="1.089880526764992" CI_START="0.5552224673796501" EFFECT_SIZE="0.7778985507246376" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="48" LOG_CI_END="0.037378892976852485" LOG_CI_START="-0.25553296823479055" LOG_EFFECT_SIZE="-0.10907703762896905" MODIFIED="2009-08-19 10:34:18 +0100" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.1720578772128164" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" VAR="0.029603913110980602" WEIGHT="36.134602868941094"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0141479906248703" CI_START="0.6095937159840911" DF="0" EFFECT_SIZE="0.7862685560053981" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="78" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.006101334506273849" LOG_CI_START="-0.21495951858364615" LOG_EFFECT_SIZE="-0.10442909203868612" MODIFIED="2009-08-19 16:30:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.06405842660611524" STUDIES="1" TAU2="0.0" TOTAL_1="152" TOTAL_2="158" WEIGHT="43.92055301475873" Z="1.8517729980060071">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.0141479906248703" CI_START="0.6095937159840911" EFFECT_SIZE="0.7862685560053981" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="78" LOG_CI_END="0.006101334506273849" LOG_CI_START="-0.21495951858364615" LOG_EFFECT_SIZE="-0.10442909203868612" ORDER="101" O_E="0.0" SE="0.12985223937388995" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.016861604070414017" WEIGHT="43.92055301475873"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0652397973471746" CI_START="0.4187900604576398" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6679160419790104" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.027447383307090983" LOG_CI_START="-0.3780036343944019" LOG_EFFECT_SIZE="-0.1752781255436554" METHOD="MH" MODIFIED="2009-08-19 15:39:42 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.09015117159826876" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="92" TOTAL_2="81" WEIGHT="100.0" Z="1.6946008190620943">
<NAME>Global State: 1c. Relapse - medium term (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0652397973471746" CI_START="0.4187900604576398" EFFECT_SIZE="0.6679160419790104" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" LOG_CI_END="0.027447383307090983" LOG_CI_START="-0.3780036343944019" LOG_EFFECT_SIZE="-0.1752781255436554" MODIFIED="2009-08-19 15:39:42 +0100" MODIFIED_BY="[Empty name]" ORDER="611" O_E="0.0" SE="0.23816393481276324" STUDY_ID="STD-Sechter-2002" TOTAL_1="92" TOTAL_2="81" VAR="0.056722059845498135" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.352968351575502" CI_END="1.2200966871144128" CI_START="0.7252341052029934" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.940667703889401" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="164" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.08639424790133136" LOG_CI_START="-0.1395217807580131" LOG_EFFECT_SIZE="-0.02656376642834083" METHOD="MH" MODIFIED="2009-08-19 16:24:45 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6077584781421395" P_Q="0.44976079714680106" P_Z="0.6448597033362874" Q="1.5980795936902812" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="894" TOTAL_2="900" WEIGHT="300.0" Z="0.46091484346857786">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.937102955633514" CI_END="1.4696385601948918" CI_START="0.6541958352550614" DF="2" EFFECT_SIZE="0.9805260962410655" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="101" I2="49.20122682750158" ID="CMP-002.04.01" LOG_CI_END="0.16721053841218078" LOG_CI_START="-0.18429222501003245" LOG_EFFECT_SIZE="-0.008540843298925823" MODIFIED="2009-08-19 16:24:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13965918262670762" P_Z="0.9241188496100194" STUDIES="3" TAU2="0.05769021251628025" TOTAL_1="290" TOTAL_2="296" WEIGHT="99.99999999999999" Z="0.09524673490767235">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="139.3150128529981" CI_START="0.41278354189382616" EFFECT_SIZE="7.583333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1439979193521634" LOG_CI_START="-0.3842776268052258" LOG_EFFECT_SIZE="0.8798601462734688" ORDER="86" O_E="0.0" SE="1.4851215709786458" STUDY_ID="STD-Hwang-2003" TOTAL_1="23" TOTAL_2="25" VAR="2.2055860805860807" WEIGHT="1.8836279107436347"/>
<DICH_DATA CI_END="1.687418900000711" CI_START="0.7649653938596017" EFFECT_SIZE="1.1361413043478261" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="32" LOG_CI_END="0.22722290913058546" LOG_CI_START="-0.11635821137679128" LOG_EFFECT_SIZE="0.055432348876897075" ORDER="87" O_E="0.0" SE="0.20182125094000902" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" VAR="0.04073181733099009" WEIGHT="43.31520495998217"/>
<DICH_DATA CI_END="1.0741042949212924" CI_START="0.6161264922656947" EFFECT_SIZE="0.8135011441647597" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="69" LOG_CI_END="0.03104645316026988" LOG_CI_START="-0.21033011696954335" LOG_EFFECT_SIZE="-0.08964183190463673" ORDER="88" O_E="0.0" SE="0.14178579212754444" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.02010321084923524" WEIGHT="54.801167129274184"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7928365025351388" CI_END="1.6504241649968336" CI_START="0.7019052247544462" DF="3" EFFECT_SIZE="1.0763091305346582" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="35" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.2175955738162521" LOG_CI_START="-0.1537215248287327" LOG_EFFECT_SIZE="0.031937024493759736" MODIFIED="2009-08-19 16:24:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8511797179541631" P_Z="0.7360012377532059" STUDIES="4" TAU2="0.0" TOTAL_1="314" TOTAL_2="308" WEIGHT="100.0" Z="0.33715343575378903">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="76.00582420414608" CI_START="0.13896961332370927" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8808468728440408" LOG_CI_START="-0.857080150886292" LOG_EFFECT_SIZE="0.5118833609788743" ORDER="89" O_E="0.0" SE="1.6082718866965442" STUDY_ID="STD-Hwang-2003" TOTAL_1="23" TOTAL_2="25" VAR="2.5865384615384617" WEIGHT="1.8392728494846913"/>
<DICH_DATA CI_END="7.320246739710027" CI_START="0.03415185428707326" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.8645257198409816" LOG_CI_START="-1.466585711168944" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="90" O_E="0.0" SE="1.3693063937629153" STUDY_ID="STD-M_x00f6_ller-2005" TOTAL_1="24" TOTAL_2="12" VAR="1.875" WEIGHT="2.5372533154429844"/>
<DICH_DATA CI_END="2.079139765855722" CI_START="0.5330942131058776" EFFECT_SIZE="1.0527950310559007" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.31788368485799756" LOG_CI_START="-0.2731960318434951" LOG_EFFECT_SIZE="0.022343826507251273" ORDER="91" O_E="0.0" SE="0.3472031514822427" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" VAR="0.12055002839920116" WEIGHT="39.46369842984725"/>
<DICH_DATA CI_END="1.9308400551185794" CI_START="0.6169632512414819" EFFECT_SIZE="1.0914473684210526" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.28574629964351234" LOG_CI_START="-0.20974070348433613" LOG_EFFECT_SIZE="0.03800279807958814" ORDER="92" O_E="0.0" SE="0.2910515183375203" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.08471098632657592" WEIGHT="56.159775405225076"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1331397610162478" CI_END="1.207270037739149" CI_START="0.39495427223435575" DF="1" EFFECT_SIZE="0.6905189781212453" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="28" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="0.08180442236173877" LOG_CI_START="-0.40345318403404484" LOG_EFFECT_SIZE="-0.16082438083615302" MODIFIED="2009-08-19 16:24:45 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7151986754937413" P_Z="0.19389417553582178" STUDIES="3" TAU2="0.0" TOTAL_1="290" TOTAL_2="296" WEIGHT="100.0" Z="1.2991449907030348">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="93" O_E="0.0" SE="0.0" STUDY_ID="STD-Hwang-2003" TOTAL_1="23" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.919415969556312" CI_START="0.32193787746615987" EFFECT_SIZE="0.7860869565217391" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.2831691038163664" LOG_CI_START="-0.49222792357286327" LOG_EFFECT_SIZE="-0.1045294098782484" ORDER="94" O_E="0.0" SE="0.455472052165622" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" VAR="0.20745479030396308" WEIGHT="39.164847502725124"/>
<DICH_DATA CI_END="1.3001954447676491" CI_START="0.31035497960323494" EFFECT_SIZE="0.6352339181286549" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.1140086401562079" LOG_CI_START="-0.5081412820270698" LOG_EFFECT_SIZE="-0.19706632093543097" ORDER="95" O_E="0.0" SE="0.3654539439822408" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.13355658517217478" WEIGHT="60.835152497274876"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.995421355460892" CI_START="0.6546513342201984" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8072508398656215" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="94" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-0.001993046272991799" LOG_CI_START="-0.18398994266619353" LOG_EFFECT_SIZE="-0.09299149446959268" METHOD="MH" MODIFIED="2009-08-19 15:51:46 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.04518898092338836" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="158" WEIGHT="100.00000000000001" Z="2.002891078265282">
<NAME>Mental state: 1a. General - no clinically important change -medium term (less than 50% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.995421355460892" CI_START="0.6546513342201984" EFFECT_SIZE="0.8072508398656215" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="94" LOG_CI_END="-0.001993046272991799" LOG_CI_START="-0.18398994266619353" LOG_EFFECT_SIZE="-0.09299149446959268" MODIFIED="2009-08-19 15:43:03 +0100" MODIFIED_BY="[Empty name]" ORDER="612" O_E="0.0" SE="0.10690587784053336" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.011428866716855043" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.5443313871947337" CI_START="0.5926079833880404" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4492753623188406" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.5495343206929342" LOG_CI_START="-0.22723250216744467" LOG_EFFECT_SIZE="0.1611509092627447" METHOD="MH" MODIFIED="2009-08-19 15:51:35 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.41607892373320965" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0" Z="0.8132427105158035">
<NAME>Mental state: 1b. General - no clinically important change - short term (less than 20% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.5443313871947337" CI_START="0.5926079833880404" EFFECT_SIZE="1.4492753623188406" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5495343206929342" LOG_CI_START="-0.22723250216744467" LOG_EFFECT_SIZE="0.1611509092627447" MODIFIED="2009-08-19 15:43:23 +0100" MODIFIED_BY="[Empty name]" ORDER="613" O_E="0.0" SE="0.456276676805972" STUDY_ID="STD-Hwang-2003" TOTAL_1="23" TOTAL_2="25" VAR="0.2081884057971014" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.7246945687566685" CI_END="5.332376864814948" CI_START="-4.571830764932009" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3802730499414693" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2009-08-19 15:51:29 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.39460833516818805" P_Q="0.39460833516818805" P_Z="0.8803653942226284" Q="0.7246945687566685" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="143" TOTAL_2="148" UNITS="" WEIGHT="100.0" Z="0.15050602936431445">
<NAME>Mental state: 1c. General - average score at endpoint (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="14.593986237406119" CI_START="-5.993986237406125" DF="0" EFFECT_SIZE="4.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" MODIFIED="2009-08-19 15:44:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.41294881183983856" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="23.14260882238183" Z="0.8187154071468699">
<NAME>short term</NAME>
<CONT_DATA CI_END="14.593986237406119" CI_START="-5.993986237406125" EFFECT_SIZE="4.299999999999997" ESTIMABLE="YES" MEAN_1="-24.1" MEAN_2="-28.4" ORDER="105" SD_1="17.2" SD_2="18.8" SE="5.252130303721788" STUDY_ID="STD-Hwang-2003" TOTAL_1="22" TOTAL_2="25" WEIGHT="23.14260882238183"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.848679332467784" CI_START="-6.448679332467792" DF="0" EFFECT_SIZE="-0.8000000000000043" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.02" MODIFIED="2009-08-19 15:44:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7813333220870281" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="123" WEIGHT="76.85739117761817" Z="0.27758190814967687">
<NAME>medium term</NAME>
<CONT_DATA CI_END="4.848679332467784" CI_START="-6.448679332467792" EFFECT_SIZE="-0.8000000000000043" ESTIMABLE="YES" MEAN_1="-32.2" MEAN_2="-31.4" ORDER="106" SD_1="23.9" SD_2="21.0" SE="2.8820322092772366" STUDY_ID="STD-Sechter-2002" TOTAL_1="121" TOTAL_2="123" WEIGHT="76.85739117761817"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9790797453263582" CI_START="0.6160233013557624" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7766182698124622" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="87" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-0.0091819337895667" LOG_CI_START="-0.21040286014265905" LOG_EFFECT_SIZE="-0.10979239696611288" METHOD="MH" MODIFIED="2009-08-19 15:51:23 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.03244906291669766" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="158" WEIGHT="99.99999999999999" Z="2.1388346404121297">
<NAME>Mental state: 1d. General - no clinically important change - medium term (less than 50% BPRS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9790797453263582" CI_START="0.6160233013557624" EFFECT_SIZE="0.7766182698124622" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="87" LOG_CI_END="-0.0091819337895667" LOG_CI_START="-0.21040286014265905" LOG_EFFECT_SIZE="-0.10979239696611288" MODIFIED="2009-08-19 15:44:54 +0100" MODIFIED_BY="[Empty name]" ORDER="614" O_E="0.0" SE="0.11819816819945612" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.01397080696570692" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.089880526764992" CI_START="0.5552224673796501" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7778985507246376" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.037378892976852485" LOG_CI_START="-0.25553296823479055" LOG_EFFECT_SIZE="-0.10907703762896905" METHOD="MH" MODIFIED="2009-08-19 15:51:19 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.14436251060826044" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="115" TOTAL_2="113" WEIGHT="100.0" Z="1.4597364846118543">
<NAME>Mental state: 1e. General - no clinically important change - short term (less than 40% BPRS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.089880526764992" CI_START="0.5552224673796501" EFFECT_SIZE="0.7778985507246376" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="48" LOG_CI_END="0.037378892976852485" LOG_CI_START="-0.25553296823479055" LOG_EFFECT_SIZE="-0.10907703762896905" MODIFIED="2009-08-19 15:45:23 +0100" MODIFIED_BY="[Empty name]" ORDER="615" O_E="0.0" SE="0.1720578772128164" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" VAR="0.029603913110980602" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.1367011695090135" CI_END="1.7867673486150508" CI_START="-3.1439307857566456" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6785817185707975" ESTIMABLE="YES" I2="6.397767336853455" I2_Q="0.0" ID="CMP-002.10" MODIFIED="2009-08-19 15:52:00 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.34357495068042654" P_Q="0.9243475367313421" P_Z="0.5895587137949574" Q="0.009017177432438744" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.3271436014036689" TOTALS="YES" TOTAL_1="258" TOTAL_2="261" UNITS="" WEIGHT="100.00000000000001" Z="0.5394756250417002">
<NAME>Mental state: 1f. General - average score at endpoint (BPRS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.9873449978137379" CI_END="4.5403501186989494" CI_START="-5.533509771738746" DF="1" EFFECT_SIZE="-0.49657982651989846" ESTIMABLE="YES" I2="49.681610334386235" ID="CMP-002.10.01" MODIFIED="2009-08-19 15:51:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.15861909962329912" P_Z="0.8467799951604105" STUDIES="2" TAU2="6.977782171464546" TOTAL_1="137" TOTAL_2="138" WEIGHT="54.500295648994395" Z="0.1932285312707206">
<NAME>short term</NAME>
<CONT_DATA CI_END="9.149221849005851" CI_START="-3.5492218490058542" EFFECT_SIZE="2.799999999999999" ESTIMABLE="YES" MEAN_1="-14.9" MEAN_2="-17.7" ORDER="109" SD_1="10.7" SD_2="11.5" SE="3.2394584283628194" STUDY_ID="STD-Hwang-2003" TOTAL_1="22" TOTAL_2="25" WEIGHT="14.621227950114593"/>
<CONT_DATA CI_END="1.2395500320887907" CI_START="-6.239550032088791" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="-17.7" MEAN_2="-15.2" ORDER="110" SD_1="14.9" SD_2="13.9" SE="1.9079687492147224" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" WEIGHT="39.8790676988798"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.278721209453306" CI_START="-3.6787212094533044" DF="0" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-002.10.02" MODIFIED="2009-08-19 15:52:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9102818669443643" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="123" WEIGHT="45.49970435100562" Z="0.11268301577107775">
<NAME>medium term</NAME>
<CONT_DATA CI_END="3.278721209453306" CI_START="-3.6787212094533044" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="-19.8" MEAN_2="-19.6" ORDER="111" SD_1="15.0" SD_2="12.6" SE="1.7748903739522839" STUDY_ID="STD-Sechter-2002" TOTAL_1="121" TOTAL_2="123" WEIGHT="45.49970435100562"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.7224343951287495" CI_END="1.2394024252719762" CI_START="-1.2949231479493928" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.02776036133870829" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.11" MODIFIED="2009-08-19 15:50:55 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.4226476557023281" P_Q="0.7630967352582585" P_Z="0.9657510371368454" Q="0.0908520608794647" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="258" TOTAL_2="261" UNITS="" WEIGHT="100.0" Z="0.04293789953161146">
<NAME>Mental state: 2a. Positive symptoms - average score at endpoint (PANSS positive subscore, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.4748823027723406" CI_END="2.1671692143027252" CI_START="-2.4719296130574895" DF="1" EFFECT_SIZE="-0.1523801993773823" ESTIMABLE="YES" I2="32.197979586554325" ID="CMP-002.11.01" MODIFIED="2009-08-19 15:50:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2245772796582285" P_Z="0.8975494267697337" STUDIES="2" TAU2="1.0061868620798236" TOTAL_1="137" TOTAL_2="138" WEIGHT="50.93690542251359" Z="0.12875763757188521">
<NAME>short term</NAME>
<CONT_DATA CI_END="4.964628527489397" CI_START="-1.9646285274893955" EFFECT_SIZE="1.5000000000000009" ESTIMABLE="YES" MEAN_1="-6.8" MEAN_2="-8.3" ORDER="112" SD_1="6.0" SD_2="6.1" SE="1.7677000979701383" STUDY_ID="STD-Hwang-2003" TOTAL_1="22" TOTAL_2="25" WEIGHT="13.37677636615875"/>
<CONT_DATA CI_END="1.0676111826547081" CI_START="-3.067611182654708" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-9.6" MEAN_2="-8.6" ORDER="113" SD_1="8.5" SD_2="7.4" SE="1.0549230490783306" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" WEIGHT="37.56012905635484"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.1090682086866526" CI_START="-1.5090682086866545" DF="0" EFFECT_SIZE="0.29999999999999893" ESTIMABLE="YES" I2="0.0" ID="CMP-002.11.02" MODIFIED="2009-08-19 15:50:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7451634896919006" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="123" WEIGHT="49.06309457748641" Z="0.32502323159439206">
<NAME>medium term</NAME>
<CONT_DATA CI_END="2.1090682086866526" CI_START="-1.5090682086866545" EFFECT_SIZE="0.29999999999999893" ESTIMABLE="YES" MEAN_1="-11.8" MEAN_2="-12.1" ORDER="114" SD_1="7.5" SD_2="6.9" SE="0.9230109445665087" STUDY_ID="STD-Sechter-2002" TOTAL_1="121" TOTAL_2="123" WEIGHT="49.06309457748641"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8888793368806971" CI_START="-1.888879336880697" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.12" MODIFIED="2009-08-19 15:51:00 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.4804419759947307" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="115" TOTAL_2="113" UNITS="" WEIGHT="100.0" Z="0.7055918871044492">
<NAME>Mental state: 2b. Positive symptoms - average score at endpoint - short term (BPRS positive subscore, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8888793368806971" CI_START="-1.888879336880697" DF="0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-002.12.01" MODIFIED="2009-08-19 15:51:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4804419759947307" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="113" WEIGHT="100.0" Z="0.7055918871044492">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.8888793368806971" CI_START="-1.888879336880697" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-7.2" MEAN_2="-6.7" ORDER="115" SD_1="5.4" SD_2="5.3" SE="0.7086249277211214" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.245300491845032" CI_END="0.11131794552892638" CI_START="-2.1133406090333064" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.00101133175219" ESTIMABLE="YES" I2="10.925062936385018" I2_Q="0.0" ID="CMP-002.13" MODIFIED="2009-08-19 15:54:41 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.3254165350437169" P_Q="0.6655608672172557" P_Z="0.07776266275057028" Q="0.18683870950808046" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.11441183936315624" TOTALS="YES" TOTAL_1="258" TOTAL_2="261" UNITS="" WEIGHT="100.0" Z="1.763817781679166">
<NAME>Mental state: 3a. Negative symptoms - average score at endpoint (PANSS negative subscore, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.120241465867493" CI_END="1.7169958341901652" CI_START="-2.9200947446102563" DF="1" EFFECT_SIZE="-0.6015494552100457" ESTIMABLE="YES" I2="52.83556066144326" ID="CMP-002.13.01" MODIFIED="2009-08-19 15:54:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1453636836796356" P_Z="0.6110921610222178" STUDIES="2" TAU2="1.5216641470495669" TOTAL_1="137" TOTAL_2="138" WEIGHT="49.02837336928738" Z="0.5085150902686838">
<NAME>short term</NAME>
<CONT_DATA CI_END="3.460108396632753" CI_START="-1.8601083966327514" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" MEAN_1="-5.6" MEAN_2="-6.4" ORDER="116" SD_1="4.5" SD_2="4.8" SE="1.3572231008402948" STUDY_ID="STD-Hwang-2003" TOTAL_1="22" TOTAL_2="25" WEIGHT="16.46259007187331"/>
<CONT_DATA CI_END="0.23297730638624792" CI_START="-3.432977306386249" EFFECT_SIZE="-1.6000000000000005" ESTIMABLE="YES" MEAN_1="-6.9" MEAN_2="-5.3" ORDER="117" SD_1="7.5" SD_2="6.6" SE="0.9352096879557683" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" WEIGHT="32.565783297414065"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2099199552360156" CI_START="-2.6099199552360153" DF="0" EFFECT_SIZE="-1.1999999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-002.13.02" MODIFIED="2009-08-19 15:54:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.09528612140585256" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="123" WEIGHT="50.97162663071263" Z="1.6681491546478293">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.2099199552360156" CI_START="-2.6099199552360153" EFFECT_SIZE="-1.1999999999999997" ESTIMABLE="YES" MEAN_1="-5.1" MEAN_2="-3.9" ORDER="118" SD_1="5.1" SD_2="6.1" SE="0.7193601343480207" STUDY_ID="STD-Sechter-2002" TOTAL_1="121" TOTAL_2="123" WEIGHT="50.97162663071263"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.3338623603488866" CI_START="-7.733862360348889" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.700000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.14" MODIFIED="2009-08-19 15:55:41 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.29313878749752686" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="121" TOTAL_2="123" UNITS="" WEIGHT="100.0" Z="1.0512609164568767">
<NAME>Mental state: 3b. Negative symptoms - average score at endpoint - medium term (SANS total score, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.3338623603488866" CI_START="-7.733862360348889" EFFECT_SIZE="-2.700000000000001" ESTIMABLE="YES" MEAN_1="-14.8" MEAN_2="-12.1" MODIFIED="2009-08-19 15:55:41 +0100" MODIFIED_BY="[Empty name]" ORDER="616" SD_1="20.5" SD_2="19.6" SE="2.568344316556504" STUDY_ID="STD-Sechter-2002" TOTAL_1="121" TOTAL_2="123" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0081280411970106" CI_START="0.7974906478741579" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.896645239051828" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="131" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.003515694861332247" LOG_CI_START="-0.09827440118672123" LOG_EFFECT_SIZE="-0.04737935316269447" METHOD="MH" MODIFIED="2009-08-19 16:02:03 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.06806520800818965" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="158" WEIGHT="100.0" Z="1.824574873489587">
<NAME>General functioning: 1a. No clinically important change - medium term (less than 50% SOFAS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0081280411970108" CI_START="0.7974906478741579" EFFECT_SIZE="0.896645239051828" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="131" LOG_CI_END="0.0035156948613323425" LOG_CI_START="-0.09827440118672123" LOG_EFFECT_SIZE="-0.04737935316269447" MODIFIED="2009-08-19 15:56:33 +0100" MODIFIED_BY="[Empty name]" ORDER="617" O_E="0.0" SE="0.05979200628772838" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.0035750840159117494" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.10535216229557741" CI_END="1.2811905451120356" CI_START="-5.896181353903323" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.3074954043956435" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.16" MODIFIED="2009-08-19 16:02:11 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.7454990148219796" P_Q="0.7454990148219796" P_Z="0.20758259022081205" Q="0.10535216229557741" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="143" TOTAL_2="148" UNITS="" WEIGHT="100.0" Z="1.2602406426027868">
<NAME>General functioning: 1b. General - average score at endpoint (SOFAS total score, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.026709525752775" CI_START="-9.226709525752774" DF="0" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-002.16.01" MODIFIED="2009-08-19 16:00:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7907836400038515" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="19.50030637362374" Z="0.265293151694671">
<NAME>short term</NAME>
<CONT_DATA CI_END="7.026709525752775" CI_START="-9.226709525752774" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" MEAN_1="-11.1" MEAN_2="-10.0" ORDER="121" SD_1="13.9" SD_2="14.5" SE="4.146356560556838" STUDY_ID="STD-Hwang-2003" TOTAL_1="22" TOTAL_2="25" WEIGHT="19.50030637362374"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.399800594266679" CI_START="-6.599800594266679" DF="0" EFFECT_SIZE="-2.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-002.16.02" MODIFIED="2009-08-19 16:00:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.20264922964941323" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="123" WEIGHT="80.49969362637626" Z="1.2740401026762738">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.399800594266679" CI_START="-6.599800594266679" EFFECT_SIZE="-2.5999999999999996" ESTIMABLE="YES" MEAN_1="-14.5" MEAN_2="-11.9" ORDER="122" SD_1="17.4" SD_2="14.3" SE="2.040752088210087" STUDY_ID="STD-Sechter-2002" TOTAL_1="121" TOTAL_2="123" WEIGHT="80.49969362637626"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.9284145454048107" CI_END="1.1073932320883577" CI_START="0.911324560920242" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0045868061043657" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="220" I2="0.0" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="0.044301864962746795" LOG_CI_START="-0.040326924987787734" LOG_EFFECT_SIZE="0.001987469987479557" METHOD="MH" MODIFIED="2009-08-19 16:04:24 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.40279459502662696" P_Q="1.0" P_Z="0.9266521264006162" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="314" TOTAL_2="308" WEIGHT="99.99999999999999" Z="0.09205778785425116">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.549267717065527" CI_START="0.6702555622776822" EFFECT_SIZE="1.0190217391304348" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.19012647134086946" LOG_CI_START="-0.1737595732324671" LOG_EFFECT_SIZE="0.008183449054201205" ORDER="123" O_E="0.0" SE="0.21374846384734894" STUDY_ID="STD-Hwang-2003" TOTAL_1="23" TOTAL_2="25" VAR="0.045688405797101435" WEIGHT="5.408856530897169"/>
<DICH_DATA CI_END="2.2702994966838874" CI_START="0.4404705200616261" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.3560831528659938" LOG_CI_START="-0.3560831528659938" LOG_EFFECT_SIZE="0.0" ORDER="124" O_E="0.0" SE="0.41833001326703784" STUDY_ID="STD-M_x00f6_ller-2005" TOTAL_1="24" TOTAL_2="12" VAR="0.17500000000000004" WEIGHT="1.4121258976110407"/>
<DICH_DATA CI_END="1.3269202286744184" CI_START="0.9535154009315222" EFFECT_SIZE="1.1248283752860413" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="76" LOG_CI_END="0.12284481488564224" LOG_CI_START="-0.020672287950371796" LOG_EFFECT_SIZE="0.05108626346763525" ORDER="125" O_E="0.0" SE="0.08430265662699123" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" VAR="0.007106937914368387" WEIGHT="34.771941877009425"/>
<DICH_DATA CI_END="1.065611573830082" CI_START="0.8257789421201979" EFFECT_SIZE="0.9380616174582799" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="123" LOG_CI_END="0.02759892881500431" LOG_CI_START="-0.08313619610118511" LOG_EFFECT_SIZE="-0.027768633643090408" ORDER="126" O_E="0.0" SE="0.06504636052347842" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.004231029017350333" WEIGHT="58.40707569448235"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.039729501925016036" CI_END="16.29374652077097" CI_START="0.35486599519911727" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4045990465388494" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.18" LOG_CI_END="1.212020955776838" LOG_CI_START="-0.44993561464206794" LOG_EFFECT_SIZE="0.381042670567385" METHOD="MH" MODIFIED="2009-08-19 16:05:32 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.8420104891469854" P_Q="0.8421605337790867" P_Z="0.3687934281112105" Q="0.039653069332229236" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="304" TOTAL_2="316" WEIGHT="200.0" Z="0.8987357722552188">
<NAME>Adverse effects: 2. Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="75.94280279611384" CI_START="0.12798741718139994" DF="0" EFFECT_SIZE="3.1176470588235294" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.18.01" LOG_CI_END="1.8804866214635592" LOG_CI_START="-0.8928327250185286" LOG_EFFECT_SIZE="0.4938269482225151" MODIFIED="2009-08-19 16:05:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4851796428367121" STUDIES="1" TAU2="0.0" TOTAL_1="152" TOTAL_2="158" WEIGHT="100.0" Z="0.6979960921840468">
<NAME>natural causes</NAME>
<DICH_DATA CI_END="75.94280279611384" CI_START="0.12798741718139994" EFFECT_SIZE="3.1176470588235294" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8804866214635592" LOG_CI_START="-0.8928327250185286" LOG_EFFECT_SIZE="0.4938269482225151" ORDER="129" O_E="0.0" SE="1.6290615122757481" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="2.6538414107781474" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.690964474414667" CI_START="0.19047326813887278" DF="0" EFFECT_SIZE="2.0789473684210527" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.18.02" LOG_CI_END="1.3558529558679329" LOG_CI_START="-0.7201659665206702" LOG_EFFECT_SIZE="0.31784349467363127" MODIFIED="2009-08-19 16:05:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5484060034886087" STUDIES="1" TAU2="0.0" TOTAL_1="152" TOTAL_2="158" WEIGHT="100.0" Z="0.6001504086137186">
<NAME>suicide</NAME>
<DICH_DATA CI_END="22.690964474414667" CI_START="0.19047326813887278" EFFECT_SIZE="2.0789473684210527" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3558529558679329" LOG_CI_START="-0.7201659665206702" LOG_EFFECT_SIZE="0.31784349467363127" ORDER="130" O_E="0.0" SE="1.2194637914704678" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="1.4870919387075283" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.19" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-08-19 16:06:38 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="138" TOTAL_2="138" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 3. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="127" O_E="0.0" SE="0.0" STUDY_ID="STD-Hwang-2003" TOTAL_1="23" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="128" O_E="0.0" SE="0.0" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4191302337487547E-31" CI_END="1.648209132342378" CI_START="0.29136149963920815" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6929824561403509" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="100.0" I2_Q="0.0" ID="CMP-002.20" LOG_CI_END="0.21701231613530245" LOG_CI_START="-0.5355678362273648" LOG_EFFECT_SIZE="-0.15927776004603114" METHOD="MH" MODIFIED="2009-08-19 16:06:29 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.0" P_Q="1.0" P_Z="0.4067523202871539" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="158" WEIGHT="99.99999999999999" Z="0.8296223923747471">
<NAME>Adverse effects: 4a. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.648209132342378" CI_START="0.29136149963920815" EFFECT_SIZE="0.6929824561403509" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.21701231613530245" LOG_CI_START="-0.5355678362273648" LOG_EFFECT_SIZE="-0.15927776004603114" ORDER="156" O_E="0.0" SE="0.4420693068296663" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.19542527204086163" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.21" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-08-19 16:07:35 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="152" TOTAL_2="158" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 4b. Central nervous system - seizures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="157" O_E="0.0" SE="0.0" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.366084337164136" CI_END="1.1476579850463864" CI_START="0.813986602168572" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9665289564723542" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="277" I2="0.0" I2_Q="0.0" ID="CMP-002.22" LOG_CI_END="0.059812482715732154" LOG_CI_START="-0.08938274333210604" LOG_EFFECT_SIZE="-0.014785130308186938" METHOD="MH" MODIFIED="2009-08-19 16:08:52 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.5740444656938073" P_Q="0.5378140113613314" P_Z="0.697674320048841" Q="5.04688550573431" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1657" TOTAL_2="1681" WEIGHT="700.0" Z="0.3884617983887272">
<NAME>Adverse effects: 5a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8772218360608268" CI_END="1.1077428990929459" CI_START="0.5758890261510775" DF="2" EFFECT_SIZE="0.7987095713614605" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="64" I2="0.0" ID="CMP-002.22.01" LOG_CI_END="0.04443897477710084" LOG_CI_START="-0.23966119708641612" LOG_EFFECT_SIZE="-0.09761111115465765" MODIFIED="2009-08-19 16:08:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6449316851268717" P_Z="0.1780419182881875" STUDIES="3" TAU2="0.0" TOTAL_1="290" TOTAL_2="296" WEIGHT="100.0" Z="1.3468084943360983">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="2.6922152425791412" CI_START="0.10971211193160178" EFFECT_SIZE="0.5434782608695652" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.43010977877908746" LOG_CI_START="-0.9597454247981604" LOG_EFFECT_SIZE="-0.2648178230095365" ORDER="131" O_E="0.0" SE="0.8164078264754906" STUDY_ID="STD-Hwang-2003" TOTAL_1="23" TOTAL_2="25" VAR="0.6665217391304348" WEIGHT="4.178340977290348"/>
<DICH_DATA CI_END="2.2320415464245795" CI_START="0.5076719222952721" EFFECT_SIZE="1.0644927536231885" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.34870227414323385" LOG_CI_START="-0.29441685536519385" LOG_EFFECT_SIZE="0.027142709389020026" ORDER="132" O_E="0.0" SE="0.37777136016428414" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" VAR="0.14271120056037329" WEIGHT="19.514621725050667"/>
<DICH_DATA CI_END="1.102185725844034" CI_START="0.5212257101150889" EFFECT_SIZE="0.7579495614035088" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="48" LOG_CI_END="0.04225478227708411" LOG_CI_START="-0.28297417030840716" LOG_EFFECT_SIZE="-0.1203596940156615" ORDER="133" O_E="0.0" SE="0.19104109665799718" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.03649670061229022" WEIGHT="76.307037297659"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6668927551657877" CI_START="0.7680559549755352" DF="0" EFFECT_SIZE="1.1314888010540185" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="33" I2="0.0" ID="CMP-002.22.02" LOG_CI_END="0.22190765901337958" LOG_CI_START="-0.11460713927591815" LOG_EFFECT_SIZE="0.05365025986873074" MODIFIED="2009-08-19 16:08:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5320034276880945" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="113" WEIGHT="100.0" Z="0.6249506864986571">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="1.6668927551657877" CI_START="0.7680559549755352" EFFECT_SIZE="1.1314888010540185" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="33" LOG_CI_END="0.22190765901337958" LOG_CI_START="-0.11460713927591815" LOG_EFFECT_SIZE="0.05365025986873074" ORDER="134" O_E="0.0" SE="0.1976704582902503" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" VAR="0.03907361008067758" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.039426705349161636" CI_END="2.0250526149482186" CI_START="0.8750502939967937" DF="1" EFFECT_SIZE="1.3311734996120583" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="33" I2="0.0" ID="CMP-002.22.03" LOG_CI_END="0.3064363115431935" LOG_CI_START="-0.05796698494618252" LOG_EFFECT_SIZE="0.1242346632985055" MODIFIED="2009-08-19 16:08:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8426057924326485" P_Z="0.1814164453071704" STUDIES="2" TAU2="0.0" TOTAL_1="267" TOTAL_2="271" WEIGHT="100.0" Z="1.3364064927092658">
<NAME>hyperkinesia</NAME>
<DICH_DATA CI_END="2.636402953994015" CI_START="0.5932259188916666" EFFECT_SIZE="1.2505928853754942" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.4210117895796438" LOG_CI_START="-0.22677988228000173" LOG_EFFECT_SIZE="0.09711595364982106" ORDER="135" O_E="0.0" SE="0.3805160346708472" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" VAR="0.14479245264162538" WEIGHT="31.6441819845078"/>
<DICH_DATA CI_END="2.275961700319298" CI_START="0.8249216136846869" EFFECT_SIZE="1.3702153110047848" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="22" LOG_CI_END="0.357164949515679" LOG_CI_START="-0.08358731734287914" LOG_EFFECT_SIZE="0.13678881608639995" ORDER="136" O_E="0.0" SE="0.25890006331162496" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.06702924278276343" WEIGHT="68.3558180154922"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.538372026375133" CI_END="1.513477703067419" CI_START="0.5133294213947869" DF="1" EFFECT_SIZE="0.8814264765761857" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="40" I2="34.996217894295654" ID="CMP-002.22.04" LOG_CI_END="0.17997602720464173" LOG_CI_START="-0.2896038435061821" LOG_EFFECT_SIZE="-0.05481390815077019" MODIFIED="2009-08-19 16:08:30 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.2148607424079375" P_Z="0.6472600093709912" STUDIES="2" TAU2="0.054257778468049876" TOTAL_1="267" TOTAL_2="271" WEIGHT="100.0" Z="0.4575719383574496">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="2.3972884656388613" CI_START="0.6100903717345137" EFFECT_SIZE="1.2093645484949833" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.37972029581816064" LOG_CI_START="-0.21460582886036847" LOG_EFFECT_SIZE="0.08255723347889607" ORDER="137" O_E="0.0" SE="0.3491101075979325" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" VAR="0.12187786722703998" WEIGHT="43.19633415024914"/>
<DICH_DATA CI_END="1.2050449039569435" CI_START="0.39851185872113526" EFFECT_SIZE="0.6929824561403509" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="27" LOG_CI_END="0.0810032304605683" LOG_CI_START="-0.3995587505526305" LOG_EFFECT_SIZE="-0.15927776004603114" ORDER="138" O_E="0.0" SE="0.2822844864673241" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.0796845313001209" WEIGHT="56.80366584975086"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2746959000783238" CI_END="3.7698707481622735" CI_START="0.22925173829868348" DF="1" EFFECT_SIZE="0.9296501611776119" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="21.54991634172865" ID="CMP-002.22.05" LOG_CI_END="0.5763264604651644" LOG_CI_START="-0.6396873626125149" LOG_EFFECT_SIZE="-0.03168045107367522" MODIFIED="2009-08-19 16:08:36 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2588876805226886" P_Z="0.9186576700635734" STUDIES="2" TAU2="0.35627965555597657" TOTAL_1="138" TOTAL_2="138" WEIGHT="100.0" Z="0.1021247323673232">
<NAME>rigor</NAME>
<DICH_DATA CI_END="4.288129005807293" CI_START="0.010947535482460746" EFFECT_SIZE="0.21666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6322678423720901" LOG_CI_START="-1.9606836385257036" LOG_EFFECT_SIZE="-0.6642078980768068" ORDER="139" O_E="0.0" SE="1.5231125351961998" STUDY_ID="STD-Hwang-2003" TOTAL_1="23" TOTAL_2="25" VAR="2.319871794871795" WEIGHT="19.065207660372046"/>
<DICH_DATA CI_END="3.6557762635346944" CI_START="0.4695253777618463" EFFECT_SIZE="1.3101449275362318" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5629796087014034" LOG_CI_START="-0.32834092922518743" LOG_EFFECT_SIZE="0.11731933973810796" ORDER="140" O_E="0.0" SE="0.5235660960858998" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" VAR="0.2741214569706297" WEIGHT="80.93479233962795"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6705428758432244" CI_END="1.506886256573528" CI_START="0.31153240773772445" DF="2" EFFECT_SIZE="0.6851597650893093" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" I2="0.0" ID="CMP-002.22.06" LOG_CI_END="0.17808047195181267" LOG_CI_START="-0.5064967683641175" LOG_EFFECT_SIZE="-0.16420814820615243" MODIFIED="2009-08-19 16:08:43 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7151440133277757" P_Z="0.34708158869727823" STUDIES="3" TAU2="0.0" TOTAL_1="290" TOTAL_2="296" WEIGHT="100.0" Z="0.9402651373672465">
<NAME>tremor</NAME>
<DICH_DATA CI_END="3.9555952519996516" CI_START="0.13274860937570665" EFFECT_SIZE="0.7246376811594203" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5972118469251526" LOG_CI_START="-0.8769700197276257" LOG_EFFECT_SIZE="-0.1398790864012365" ORDER="141" O_E="0.0" SE="0.8659417257897716" STUDY_ID="STD-Hwang-2003" TOTAL_1="23" TOTAL_2="25" VAR="0.749855072463768" WEIGHT="21.564668334782205"/>
<DICH_DATA CI_END="1.5858529910558599" CI_START="0.15220828384105517" EFFECT_SIZE="0.49130434782608695" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.2002629256471775" LOG_CI_START="-0.8175617107155237" LOG_EFFECT_SIZE="-0.3086493925341732" ORDER="142" O_E="0.0" SE="0.5978752297126576" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" VAR="0.35745479030396304" WEIGHT="45.23754157297681"/>
<DICH_DATA CI_END="4.0821019186320555" CI_START="0.2646934255204218" EFFECT_SIZE="1.0394736842105263" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6108838436301601" LOG_CI_START="-0.57725684561086" LOG_EFFECT_SIZE="0.016813499009650082" ORDER="143" O_E="0.0" SE="0.6979197222514408" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.4870919387075283" WEIGHT="33.197790092240986"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.7466097365824744" CI_END="1.3824758208946717" CI_START="0.636964066847724" DF="2" EFFECT_SIZE="0.9383961962815683" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="84" I2="46.61840595587813" ID="CMP-002.22.07" LOG_CI_END="0.140657544357315" LOG_CI_START="-0.1958850668952968" LOG_EFFECT_SIZE="-0.02761376126899091" MODIFIED="2009-08-19 16:08:52 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.15361524365849133" P_Z="0.7477290630668615" STUDIES="3" TAU2="0.054261149068448936" TOTAL_1="290" TOTAL_2="296" WEIGHT="100.0" Z="0.3216352150086864">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="1.4787772760949636" CI_START="0.3235432075783483" EFFECT_SIZE="0.691699604743083" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.16990276828571207" LOG_CI_START="-0.490067713264759" LOG_EFFECT_SIZE="-0.16008247248952348" ORDER="144" O_E="0.0" SE="0.3876699277693184" STUDY_ID="STD-Hwang-2003" TOTAL_1="23" TOTAL_2="25" VAR="0.15028797289666854" WEIGHT="19.10546906456018"/>
<DICH_DATA CI_END="2.045654410494145" CI_START="0.8552997251013131" EFFECT_SIZE="1.3227424749163879" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="26" LOG_CI_END="0.31083226657435226" LOG_CI_START="-0.06788166755582084" LOG_EFFECT_SIZE="0.12147529950926568" ORDER="145" O_E="0.0" SE="0.2224584395722718" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" VAR="0.049487757336930095" WEIGHT="37.6679336418035"/>
<DICH_DATA CI_END="1.1557133803635962" CI_START="0.5485120114447833" EFFECT_SIZE="0.7961926091825308" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="47" LOG_CI_END="0.0628501413850688" LOG_CI_START="-0.2608138577026291" LOG_EFFECT_SIZE="-0.09898185815878013" ORDER="146" O_E="0.0" SE="0.1901218352267486" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.036146312229986946" WEIGHT="43.226597293636324"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.43473560959096785" CI_END="0.06382381638125967" CI_START="-0.12165735445258949" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.028916769035664903" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.23" MODIFIED="2009-08-19 16:32:14 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.9329770728442052" P_Q="0.7279822536854463" P_Z="0.5411187209722037" Q="0.12097243080027208" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="534" TOTAL_2="542" UNITS="" WEIGHT="200.0" Z="0.6111221489963041">
<NAME>Adverse effects: 5b. Extrapyramidal effects - scale measured</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.29681460617494604" CI_END="0.7153645076523355" CI_START="-0.550911258129709" DF="1" EFFECT_SIZE="0.08222662476131323" ESTIMABLE="YES" I2="0.0" ID="CMP-002.23.01" MODIFIED="2009-08-19 16:09:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5858863873339073" P_Z="0.7990755922627116" STUDIES="2" TAU2="0.0" TOTAL_1="267" TOTAL_2="271" WEIGHT="100.0" Z="0.25454364279479225">
<NAME>abnormal involuntary movement: AIMS (high=poor)</NAME>
<CONT_DATA CI_END="1.3073006128888918" CI_START="-0.7073006128888917" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="1.7" ORDER="147" SD_1="3.88" SD_2="3.88" SE="0.513938327864364" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" WEIGHT="39.50739576703145"/>
<CONT_DATA CI_END="0.7540426491390377" CI_START="-0.8740426491390378" EFFECT_SIZE="-0.06" ESTIMABLE="YES" MEAN_1="-0.16" MEAN_2="-0.1" ORDER="148" SD_1="3.17" SD_2="4.1" SE="0.4153355141013316" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" WEIGHT="60.49260423296855"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.01694857261574963" CI_END="0.06239807805824446" CI_START="-0.12510551185088395" DF="1" EFFECT_SIZE="-0.031353716896319744" ESTIMABLE="YES" I2="0.0" ID="CMP-002.23.02" MODIFIED="2009-08-19 16:09:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8964187345596554" P_Z="0.5121606213331449" STUDIES="2" TAU2="0.0" TOTAL_1="267" TOTAL_2="271" WEIGHT="100.0" Z="0.6554771130305697">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</NAME>
<CONT_DATA CI_END="0.3813430520389473" CI_START="-0.5013430520389472" EFFECT_SIZE="-0.06" ESTIMABLE="YES" MEAN_1="0.29" MEAN_2="0.35" ORDER="149" SD_1="1.7" SD_2="1.7" SE="0.22517916427046872" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" WEIGHT="4.512389654399158"/>
<CONT_DATA CI_END="0.06594140606230124" CI_START="-0.12594140606230125" EFFECT_SIZE="-0.03" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.07" ORDER="150" SD_1="0.45" SD_2="0.41" SE="0.048950596449258664" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" WEIGHT="95.48761034560084"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.1689795571738815" CI_END="1.7266759527846656" CI_START="0.1937937577804904" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5784626360961864" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" I2="44.204053476519334" I2_Q="63.78897759262245" ID="CMP-002.24" LOG_CI_END="0.2372108406813393" LOG_CI_START="-0.7126602159599091" LOG_EFFECT_SIZE="-0.2377246876392849" METHOD="MH" MODIFIED="2009-08-19 16:10:06 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.12722341562211825" P_Q="0.06319125100151646" P_Z="0.3265719127792869" Q="5.523180145260204" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.3405019693030875" TOTALS="SUB" TOTAL_1="336" TOTAL_2="342" WEIGHT="300.0" Z="0.9810422641080806">
<NAME>Adverse effects: 6. Prolactin associated side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.127197065699992" CI_START="0.06565376300727468" DF="0" EFFECT_SIZE="1.0289855072463767" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.24.01" LOG_CI_END="1.2075588928274108" LOG_CI_START="-1.182740376863771" LOG_EFFECT_SIZE="0.01240925798181993" MODIFIED="2009-08-19 16:09:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9837639003756424" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="71" WEIGHT="100.0" Z="0.02035033774024082">
<NAME>amenorrhea</NAME>
<DICH_DATA CI_END="16.127197065699992" CI_START="0.06565376300727468" EFFECT_SIZE="1.0289855072463767" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2075588928274108" LOG_CI_START="-1.182740376863771" LOG_EFFECT_SIZE="0.01240925798181993" ORDER="151" O_E="0.0" SE="1.404073623188812" STUDY_ID="STD-Sechter-2002" TOTAL_1="69" TOTAL_2="71" VAR="1.971422739334558" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.008642987698255" CI_END="6.319705309156274" CI_START="0.33057302748759854" DF="1" EFFECT_SIZE="1.4453802672228644" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.8568926571311901" ID="CMP-002.24.02" LOG_CI_END="0.8006968273977021" LOG_CI_START="-0.4807325847971725" LOG_EFFECT_SIZE="0.15998212130026473" MODIFIED="2009-08-19 16:10:03 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.315228426210313" P_Z="0.6245658085053425" STUDIES="2" TAU2="0.014453185163258938" TOTAL_1="113" TOTAL_2="118" WEIGHT="100.0" Z="0.48938972827502475">
<NAME>galactorrhea</NAME>
<DICH_DATA CI_END="11.088815364213795" CI_START="0.4115903671284957" EFFECT_SIZE="2.1363636363636362" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0448851522568756" LOG_CI_START="-0.385534798029853" LOG_EFFECT_SIZE="0.3296751771135112" ORDER="152" O_E="0.0" SE="0.8402357594913742" STUDY_ID="STD-Peuskens-1999" TOTAL_1="44" TOTAL_2="47" VAR="0.7059961315280464" WEIGHT="78.64319448154217"/>
<DICH_DATA CI_END="8.274789659697781" CI_START="0.014205922475672525" EFFECT_SIZE="0.34285714285714286" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9177569630769294" LOG_CI_START="-1.847530559682231" LOG_EFFECT_SIZE="-0.4648867983026508" ORDER="153" O_E="0.0" SE="1.624343579262732" STUDY_ID="STD-Sechter-2002" TOTAL_1="69" TOTAL_2="71" VAR="2.6384920634920634" WEIGHT="21.356805518457836"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0032993496960563038" CI_END="0.5734196087452972" CI_START="0.010058179553653783" DF="1" EFFECT_SIZE="0.07594443616451506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="12" I2="0.0" ID="CMP-002.24.03" LOG_CI_END="-0.24152745993457922" LOG_CI_START="-1.997480615835293" LOG_EFFECT_SIZE="-1.119504037884936" MODIFIED="2009-08-19 16:10:06 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9541947604817921" P_Z="0.012449463348162014" STUDIES="2" TAU2="0.0" TOTAL_1="154" TOTAL_2="153" WEIGHT="100.0" Z="2.499141377921479">
<NAME>sexual dysfunction</NAME>
<DICH_DATA CI_END="1.246341562326857" CI_START="0.0041111264029660595" EFFECT_SIZE="0.07158119658119658" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.0956370778814795" LOG_CI_START="-2.386039169956037" LOG_EFFECT_SIZE="-1.1452010460372788" ORDER="155" O_E="0.0" SE="1.4577489124753058" STUDY_ID="STD-Peuskens-1999" TOTAL_1="71" TOTAL_2="66" VAR="2.1250318918229367" WEIGHT="50.06515945086982"/>
<DICH_DATA CI_END="1.4083683586265117" CI_START="0.004611092222037393" EFFECT_SIZE="0.08058608058608059" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.1487162593488214" LOG_CI_START="-2.3361961917859206" LOG_EFFECT_SIZE="-1.0937399662185499" ORDER="154" O_E="0.0" SE="1.459649874311561" STUDY_ID="STD-Sechter-2002" TOTAL_1="83" TOTAL_2="87" VAR="2.1305777555777556" WEIGHT="49.93484054913018"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.054590162255507946" CI_END="0.9383681299303308" CI_START="0.34787204909788594" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5713423178507044" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-002.25" LOG_CI_END="-0.02762675071183175" LOG_CI_START="-0.4585804646419188" LOG_EFFECT_SIZE="-0.2431036076768753" METHOD="MH" MODIFIED="2009-08-19 16:32:42 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.8152602984324181" P_Q="0.815501749560939" P_Z="0.02701817136179922" Q="0.0544449425267295" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="267" TOTAL_2="271" WEIGHT="100.0" Z="2.211255177328525">
<NAME>Adverse effects: 7a. Metabolic - weight - gain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9961562168787886" CI_START="0.34319788430313314" DF="0" EFFECT_SIZE="0.584703947368421" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="32" I2="0.0" ID="CMP-002.25.01" LOG_CI_END="-0.0016725503227737635" LOG_CI_START="-0.4644553980911259" LOG_EFFECT_SIZE="-0.23306397420694985" MODIFIED="2009-08-19 16:32:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04836684309255186" STUDIES="1" TAU2="0.0" TOTAL_1="152" TOTAL_2="158" WEIGHT="86.71749962874856" Z="1.9741310540880088">
<NAME>weight gain of 7% or more of total body weight</NAME>
<DICH_DATA CI_END="0.9961562168787886" CI_START="0.34319788430313314" EFFECT_SIZE="0.584703947368421" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="32" LOG_CI_END="-0.0016725503227737635" LOG_CI_START="-0.4644553980911259" LOG_EFFECT_SIZE="-0.23306397420694985" ORDER="158" O_E="0.0" SE="0.2718409355911723" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" VAR="0.07389749426308387" WEIGHT="86.71749962874856"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9168423440356626" CI_START="0.1259258294996877" DF="0" EFFECT_SIZE="0.49130434782608695" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-002.25.02" LOG_CI_END="0.28258639460420293" LOG_CI_START="-0.8998851796725494" LOG_EFFECT_SIZE="-0.3086493925341732" MODIFIED="2009-08-19 16:32:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3062219136621168" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="113" WEIGHT="13.28250037125144" Z="1.0231817937562724">
<NAME>as "weight gain" reported adverse event</NAME>
<DICH_DATA CI_END="1.9168423440356626" CI_START="0.1259258294996877" EFFECT_SIZE="0.49130434782608695" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.28258639460420293" LOG_CI_START="-0.8998851796725494" LOG_EFFECT_SIZE="-0.3086493925341732" ORDER="159" O_E="0.0" SE="0.6945896560588583" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" VAR="0.48245479030396304" WEIGHT="13.28250037125144"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.4537719321162571" CI_END="-0.36592684074728055" CI_START="-1.6116863973251534" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.988806619036217" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.26" MODIFIED="2009-08-19 16:12:28 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.7970118195269869" P_Q="1.0" P_Z="0.0018620534365205292" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="289" TOTAL_2="296" UNITS="" WEIGHT="100.0" Z="3.1113955349611744">
<NAME>Adverse effects: 7b. Metabolic - weight - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.26244251038530897" CI_START="-3.262442510385309" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="1.6" ORDER="160" SD_1="3.3" SD_2="2.8" SE="0.8992218858546537" STUDY_ID="STD-Hwang-2003" TOTAL_1="22" TOTAL_2="25" WEIGHT="12.490463210455559"/>
<CONT_DATA CI_END="-0.12510230272279255" CI_START="-1.8748976972772073" EFFECT_SIZE="-0.9999999999999999" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="1.4" ORDER="161" SD_1="3.37" SD_2="3.37" SE="0.44638457858322333" STUDY_ID="STD-Peuskens-1999" TOTAL_1="115" TOTAL_2="113" WEIGHT="50.686688281514165"/>
<CONT_DATA CI_END="0.22646829859074114" CI_START="-1.8264682985907412" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="2.1" ORDER="162" SD_1="4.2" SD_2="5.0" SE="0.5237179390475499" STUDY_ID="STD-Sechter-2002" TOTAL_1="152" TOTAL_2="158" WEIGHT="36.82284850803027"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-08-19 16:33:45 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>AMISULPRIDE versus ZIPRASIDONE - all data short term</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0750964039058062" CI_START="0.8436726931304279" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.03144740918849073" LOG_CI_START="-0.07382600732836692" LOG_EFFECT_SIZE="-0.021189299069938095" METHOD="MH" MODIFIED="2009-08-19 16:14:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.43011312142355584" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="60" WEIGHT="100.0" Z="0.7889981043424465">
<NAME>Global state: 1a. No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0750964039058062" CI_START="0.8436726931304279" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="55" LOG_CI_END="0.03144740918849073" LOG_CI_START="-0.07382600732836692" LOG_EFFECT_SIZE="-0.021189299069938095" ORDER="166" O_E="0.0" SE="0.06183812597381831" STUDY_ID="STD-Olie-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.0038239538239538233" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2235679444571863" CI_START="0.6612202474411082" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8994708994708994" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.08762809063389145" LOG_CI_START="-0.17965385622383193" LOG_EFFECT_SIZE="-0.04601288279497024" METHOD="MH" MODIFIED="2009-08-19 16:17:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.4997901773416692" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="60" WEIGHT="99.99999999999999" Z="0.6748199357512904">
<NAME>Global State: 1b. No clinically important change (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2235679444571863" CI_START="0.6612202474411082" EFFECT_SIZE="0.8994708994708994" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="36" LOG_CI_END="0.08762809063389145" LOG_CI_START="-0.17965385622383193" LOG_EFFECT_SIZE="-0.04601288279497024" MODIFIED="2009-08-19 16:17:45 +0100" MODIFIED_BY="[Empty name]" ORDER="618" O_E="0.0" SE="0.15700273865120185" STUDY_ID="STD-Olie-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.02464985994397759" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.07460297091826" CI_END="1.0942183314526224" CI_START="0.3772465943268812" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6424874621271175" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="30" I2="34.95095077584341" I2_Q="33.78760469296634" ID="CMP-003.03" LOG_CI_END="0.03910398624297793" LOG_CI_START="-0.42337467221961955" LOG_EFFECT_SIZE="-0.19213534298832083" METHOD="MH" MODIFIED="2009-08-19 16:15:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2149604817708921" P_Q="0.22084572492879573" P_Z="0.10341423221282649" Q="3.02058246152521" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.18861699845516364" TOTALS="SUB" TOTAL_1="189" TOTAL_2="180" WEIGHT="300.0" Z="1.6285220756616368">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2781238317230899" CI_START="0.3701605770732067" DF="0" EFFECT_SIZE="0.6878306878306878" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.1065729327180883" LOG_CI_START="-0.4316098364509031" LOG_EFFECT_SIZE="-0.1625184518664074" MODIFIED="2009-08-19 16:15:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.23652179373849358" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="60" WEIGHT="100.00000000000001" Z="1.183725420913077">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="1.2781238317230899" CI_START="0.3701605770732067" EFFECT_SIZE="0.6878306878306878" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.1065729327180883" LOG_CI_START="-0.4316098364509031" LOG_EFFECT_SIZE="-0.1625184518664074" ORDER="163" O_E="0.0" SE="0.3161312226575381" STUDY_ID="STD-Olie-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.09993894993894994" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.438419360872885" CI_START="0.29650101317918176" DF="0" EFFECT_SIZE="1.2698412698412698" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.7354726933380746" LOG_CI_START="-0.5279738182613509" LOG_EFFECT_SIZE="0.10374943753836186" MODIFIED="2009-08-19 16:15:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7475363149039618" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="60" WEIGHT="100.0" Z="0.3218896235410203">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="5.438419360872885" CI_START="0.29650101317918176" EFFECT_SIZE="1.2698412698412698" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7354726933380746" LOG_CI_START="-0.5279738182613509" LOG_EFFECT_SIZE="0.10374943753836186" ORDER="164" O_E="0.0" SE="0.7421547350746007" STUDY_ID="STD-Olie-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.5507936507936507" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.939842613332127" CI_START="0.047658595756058644" DF="0" EFFECT_SIZE="0.21164021164021163" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="-0.02694486755371845" LOG_CI_START="-1.321858758136845" LOG_EFFECT_SIZE="-0.6744018128452818" MODIFIED="2009-08-19 16:15:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.04119810044743255" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="60" WEIGHT="100.0" Z="2.041530751809356">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="0.939842613332127" CI_START="0.047658595756058644" EFFECT_SIZE="0.21164021164021163" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.02694486755371845" LOG_CI_START="-1.321858758136845" LOG_EFFECT_SIZE="-0.6744018128452818" ORDER="165" O_E="0.0" SE="0.760638829255665" STUDY_ID="STD-Olie-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.5785714285714286" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.887542424834549E-32" CI_END="3.6353403513309064" CI_START="-9.035340351330905" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.6999999999999997" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2009-08-19 16:19:12 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.403549450820061" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="56" UNITS="" WEIGHT="100.0" Z="0.8352988892138118">
<NAME>Mental state: 1a. General - average score at endpoint (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.635340351330907" CI_START="-9.035340351330905" EFFECT_SIZE="-2.6999999999999993" ESTIMABLE="YES" MEAN_1="-14.6" MEAN_2="-11.9" MODIFIED="2009-08-19 16:18:34 +0100" MODIFIED_BY="[Empty name]" ORDER="619" SD_1="17.6" SD_2="17.6" SE="3.232375901446793" STUDY_ID="STD-Olie-2006" TOTAL_1="63" TOTAL_2="56" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.5218619895282717" CI_START="-5.721861989528271" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2009-08-19 16:19:47 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.25578454821994423" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="59" UNITS="" WEIGHT="100.0" Z="1.1364111552108564">
<NAME>Mental state: 1b. General - average score at endpoint (BPRS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.5218619895282712" CI_START="-5.7218619895282705" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="-7.3" MEAN_2="-5.2" MODIFIED="2009-08-19 16:19:47 +0100" MODIFIED_BY="[Empty name]" ORDER="620" SD_1="10.2" SD_2="10.2" SE="1.8479227261812237" STUDY_ID="STD-Olie-2006" TOTAL_1="63" TOTAL_2="59" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0750964039058062" CI_START="0.8436726931304279" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.03144740918849073" LOG_CI_START="-0.07382600732836692" LOG_EFFECT_SIZE="-0.021189299069938095" METHOD="MH" MODIFIED="2009-08-19 16:19:50 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.43011312142355584" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="60" WEIGHT="100.0" Z="0.7889981043424465">
<NAME>Mental state: 2a. Negative symptoms - no clinically important change (less than 50% PANSS negative subscore reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0750964039058062" CI_START="0.8436726931304279" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="55" LOG_CI_END="0.03144740918849073" LOG_CI_START="-0.07382600732836692" LOG_EFFECT_SIZE="-0.021189299069938095" MODIFIED="2009-08-19 16:19:50 +0100" MODIFIED_BY="[Empty name]" ORDER="621" O_E="0.0" SE="0.06183812597381831" STUDY_ID="STD-Olie-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.0038239538239538233" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.4015239544191447" CI_START="-3.001523954419146" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" MODIFIED="2009-08-19 16:20:32 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.4763280538853417" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="59" UNITS="" WEIGHT="100.0" Z="0.7122208161690167">
<NAME>Mental state: 2b. Negative symptoms - average score at endpoint (PANSS negative subscore, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.4015239544191447" CI_START="-3.001523954419146" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" MEAN_1="-6.9" MEAN_2="-6.1" MODIFIED="2009-08-19 16:20:32 +0100" MODIFIED_BY="[Empty name]" ORDER="622" SD_1="6.2" SD_2="6.2" SE="1.1232471472866263" STUDY_ID="STD-Olie-2006" TOTAL_1="63" TOTAL_2="59" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2235679444571863" CI_START="0.6612202474411082" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8994708994708994" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.08762809063389145" LOG_CI_START="-0.17965385622383193" LOG_EFFECT_SIZE="-0.04601288279497024" METHOD="MH" MODIFIED="2009-08-19 16:20:52 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.4997901773416692" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="60" WEIGHT="99.99999999999999" Z="0.6748199357512904">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2235679444571863" CI_START="0.6612202474411082" EFFECT_SIZE="0.8994708994708994" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="36" LOG_CI_END="0.08762809063389145" LOG_CI_START="-0.17965385622383193" LOG_EFFECT_SIZE="-0.04601288279497024" ORDER="172" O_E="0.0" SE="0.15700273865120185" STUDY_ID="STD-Olie-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.02464985994397759" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-08-19 16:33:45 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="63" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 2. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="173" O_E="0.0" SE="0.0" STUDY_ID="STD-Olie-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="13.606973503148872" CI_START="0.5999324761111158" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8571428571428568" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="1.133761539086792" LOG_CI_START="-0.22189762778734323" LOG_EFFECT_SIZE="0.45593195564972433" METHOD="MH" MODIFIED="2009-08-19 16:21:44 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.18738967893672748" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="60" WEIGHT="100.0" Z="1.3183405302895568">
<NAME>Adverse effects: 3. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.606973503148872" CI_START="0.5999324761111158" EFFECT_SIZE="2.857142857142857" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.133761539086792" LOG_CI_START="-0.22189762778734323" LOG_EFFECT_SIZE="0.4559319556497244" ORDER="177" O_E="0.0" SE="0.7963209052429705" STUDY_ID="STD-Olie-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.634126984126984" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.496521081921373" CI_END="0.9355271376987829" CI_START="0.31542100466173617" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.543217184615204" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="-0.028943610000538647" LOG_CI_START="-0.5011093893046925" LOG_EFFECT_SIZE="-0.26502649965261554" METHOD="MH" MODIFIED="2009-08-19 16:22:26 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.4731890336286986" P_Q="0.48726400533891856" P_Z="0.027788857348777198" Q="1.4378986993294036" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="189" TOTAL_2="180" WEIGHT="300.0" Z="2.2002543048899605">
<NAME>Adverse effects: 4. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.668046235191371" CI_START="0.10990161704627208" DF="0" EFFECT_SIZE="0.6349206349206349" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-003.11.01" LOG_CI_END="0.5644348012515088" LOG_CI_START="-0.9589959175027475" LOG_EFFECT_SIZE="-0.19728055812561934" MODIFIED="2009-08-19 16:22:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6117190921331659" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="60" WEIGHT="100.0" Z="0.5076211002130212">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="3.6680462351913707" CI_START="0.10990161704627213" EFFECT_SIZE="0.6349206349206349" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5644348012515088" LOG_CI_START="-0.9589959175027473" LOG_EFFECT_SIZE="-0.19728055812561934" ORDER="174" O_E="0.0" SE="0.8948707452999292" STUDY_ID="STD-Olie-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.8007936507936507" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.279823038032108" CI_START="0.01968652113751783" DF="0" EFFECT_SIZE="0.15873015873015872" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-003.11.02" LOG_CI_END="0.10714992361723047" LOG_CI_START="-1.705831022524394" LOG_EFFECT_SIZE="-0.7993405494535817" MODIFIED="2009-08-19 16:22:18 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0839361919039303" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="60" WEIGHT="100.0" Z="1.7282902963163236">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="1.279823038032108" CI_START="0.01968652113751783" EFFECT_SIZE="0.15873015873015872" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.10714992361723047" LOG_CI_START="-1.705831022524394" LOG_EFFECT_SIZE="-0.7993405494535817" ORDER="175" O_E="0.0" SE="1.0649539821640108" STUDY_ID="STD-Olie-2006" TOTAL_1="63" TOTAL_2="60" VAR="1.1341269841269843" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.068366830887507" CI_START="0.3253487337404708" DF="0" EFFECT_SIZE="0.5895691609977324" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="21" I2="0.0" ID="CMP-003.11.03" LOG_CI_END="0.028720396209932008" LOG_CI_START="-0.4876508792039732" LOG_EFFECT_SIZE="-0.2294652414970206" MODIFIED="2009-08-19 16:22:26 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.08151913398424424" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="60" WEIGHT="100.0" Z="1.741938912761743">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="1.068366830887507" CI_START="0.3253487337404708" EFFECT_SIZE="0.5895691609977324" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="21" LOG_CI_END="0.028720396209932008" LOG_CI_START="-0.4876508792039732" LOG_EFFECT_SIZE="-0.2294652414970206" ORDER="176" O_E="0.0" SE="0.30331904325716513" STUDY_ID="STD-Olie-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.09200244200244201" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.674133638712923" CI_START="0.7736903913903518" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0952380952380953" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="0.7538995602000724" LOG_CI_START="-0.11143279669553605" LOG_EFFECT_SIZE="0.3212333817522682" METHOD="MH" MODIFIED="2009-08-19 16:23:12 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.14562027466994268" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="60" WEIGHT="100.0" Z="1.45517697067326">
<NAME>Adverse effects: 5. Metabolic - weight - gain of 7% or more of total body weight</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.674133638712923" CI_START="0.7736903913903518" EFFECT_SIZE="2.0952380952380953" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7538995602000724" LOG_CI_START="-0.11143279669553605" LOG_EFFECT_SIZE="0.3212333817522682" ORDER="178" O_E="0.0" SE="0.5083005099047299" STUDY_ID="STD-Olie-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.25836940836940836" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-10-28 08:08:45 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-10-28 08:08:45 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-10-28 08:08:45 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-11-03 10:56:30 +0000" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2009-11-03 10:56:30 +0000" MODIFIED_BY="[Empty name]"/>
<EXTENSIONS MODIFIED="2009-11-03 10:56:30 +0000" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>